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ABSTRACT 
 
Introduction: Colorectal cancer is the second most common UK cancer. Biomarkers which predict 
survival may be valuable for targeting adjuvant therapy and can provide insights into tumour 
biology. Small and early cancers are being diagnosed more commonly in the UK population due to 
the introduction of population-based colorectal cancer screening in 2005. Analysis of resected small 
(≤20mm across) tumours in Liverpool has established that flat and depressed morphology can 
predict advanced stage at presentation. Proteomic analysis of small cancers was conducted with 
the aim of generating biomarkers which correspond to morphology, stage and patient survival. 
Patients and Methods: Laser capture microdissection was used to procure enriched matched 
benign and malignant colorectal epithelial cell populations. Laser captured proteins were extracted 
into lysis buffer, normalised against a reference standard, separated using 2D SDS-PAGE and 
visualized with silver staining. Comparison was made between the tumour gels, (n=10) and 
matched normal colonic gels, (n=9) by two different observers and gel analysis software, Progenesis 
SameSpots. Differentially expressed proteins were identified using tandem mass spectrometry and 
included redox proteins peroxiredoxin 2, peroxiredoxin 6 and SH3 binding glutamic acid-rich 
protein-like 3; and cytoskeletal protein cofilin1. Also identified were the anti-apoptotic protein heat 
shock protein 27 and inflammatory protein S100A8, which  had been previously identified in 2D gel 
analysis of undissected colorectal cancer in our Institution (n=12 gels) and previously validated in a 
small cohort of paraffin-embedded colorectal cancers (n=98). In this study, HSP27 was further 
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evaluated in a large cohort of paraffin-embedded colorectal cancer tissue (n=404). S100A8 and 
related proteins S100A9 and Smad4 were similarly evaluated in a large cohort (n=313). 
Results: High HSP27 levels were strongly associated with poor cancer-specific survival in rectal 
cancer (n=205, P=0.0063) but not colon cancer; (n=199, P=0.7385). Multivariate Cox regression 
confirmed nodal metastases (P=0.0001) and HSP27 expression (P=0.0233) as independent markers 
of survival in rectal cancer. HSP27 levels remained unchanged in the majority of cases 65/80 (81%) 
between diagnostic biopsies and matched surgical samples, regardless of whether patients had 
undergone preoperative radiotherapy.  
S100A8 expression co-localised with a subset of S100A9-positive monocytes. S100A9 was co-
expressed with CD14 in tumour-associated monocytes, but not with CD68 in tissue macrophages. 
Smad4 was expressed in the tumour cytoplasm of 262/304 (14%) tumours. Loss of Smad4 
expression correlated with a reduction in the stromal S100A8-positive, but not S100A9-positive cell 
count, (P=0.034, Mann-Whitney U test) and  was associated with a poorer overall survival in 
patients with stage I-II disease, but not stage III disease. Antibodies to cofilin1 and cofilin-
phospho(ser3) were assessed in colorectal cancer cell and tissue lysate and found to be specific on 
1D and 2D western blot.  
Conclusion: Elevated HSP27 is an independent marker of poor prognosis in rectal cancer whose 
expression is not altered by neo-adjuvant radiotherapy. Smad4-negative tumours are associated 
with fewer infiltrating S100A8 positive stromal monocytes. In node-negative tumours, loss of 
Smad4 expression in associated with a poorer prognosis. These findings provide a sound platform 
for further investigation of both S100A8 and HSP27 proteins in colorectal cancer.  
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ABBREVIATIONS 
 
 
2DE   Two-dimensional electrophoresis 
5FU  5-fluorouracil 
µg  Microgram 
µl  Microlitre 
µM  Micromolar 
:C  degrees Celsius 
 
ACG  American College of Gastroenterologists 
ACN  Acetonitrile 
AJCC  American Joint Committee on Cancer 
AMH  Anti-mullerian hormone 
APC  Adenomatous polyposis coli 
APS   ammonium persulphate 
ATM  Ataxia-telangiectasia mutated gene 
AUC  Area under curve 
 
BCA  Bicinchoinic acid 
BCL2  B-cell lymphoma 2 
BMP  Bone morphogenic protein 
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BRCA  Breast cancer associated 
BSG  British Society of Gastroenterologists 
 
C  Cytosine 
CA19-9 Carbohydrate antigen 19-9 
CA242  Carbohydrate antigen 242 
CCD  Charged couple device 
Cdc2  Cell division cycle 2 
CDK   Cyclin dependant kinase 
CEA  Carcinoembryonic antigen 
CHAPS  3-(3-cholamidopropyldimethylammonio-1-propane) sulphate 
CHRPE  Congenital hypertrophy of retinal pigment epithelium 
CI  Confidence interval 
CID  Collision induced decomposition 
CIMP   CpG-island methylator phenotype 
CIN  Chromosomal instability 
CRC  Colorectal cancer 
CRM  Circumferential resection margin 
CT  Computed tomography 
 
DCBE  Double contrast barium enema 
DCC  Deleted in colorectal cancer 
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DIGE  Difference in-gel electrophoresis 
DNA  Deoxyribonucleic acid 
Dpi   dots per inch 
DSH  Dishevelled 
dTMP  Deoxythymidine monophosphate 
DTT   Dithiothreitol 
dUMP  Deoxyuridine monophosphate 
 
EDTA   Ethylendiaminetetraacetic acid 
EGF   Epidermal growth factor 
EGFR   Epidermal growth factor receptor 
EGTM  European Group on Tumour Markers 
EMR  Endoscopic mucosal resection 
ESI   Electrospray ionization 
EVI  Extramural vascular invasion 
 
FA  folinic acid 
FACS  Flourescence activated cell sorting 
FAP   Familial adenomatous polyposis 
FGF2  Fibroblast growth factor 2 
fmol  femtomole (10-15M) 
FOBT  Faecal occult blood test 
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FTICR  Fourier transform ion cyclotron 
G  Guanine 
GDF  Growth and differentiation factors 
GDP   Guanidine diphosphate 
GI  Gastrointestinal 
GRX  Glutaredoxins 
GSK3β  Glycogen synthase kinase 3- beta 
GTP   Guanidine triphosphate 
 
H  Hydrogen 
H&E   Haematoxylin and eosin 
HCl   Hydrochloric acid 
HNPCC  Hereditary Non-polypoid Colorectal Cancer 
HR  Hazard ratio 
HSP27  Heat shock protein 27 
HSE  Heat shock element 
HSF1  Heat shock factor 1 
 
ICAT  Isotope coded affinity tags 
id  Internal diameter 
IEF   Isoelectric focusing 
IFL  irinotecan/fluorouracil/leucovorin chemotherapy 
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IHC   Immunohistochemistry 
IPG  Immobilised pH gradient 
IRA  Ileorectal anastomosis 
iTRAQ  Isobaric tags for relative and absolute quantification 
 
JRSC   Japanese Research Society on Colon Cancer 
 
kDa  KiloDaltons 
 
L  Deuterium 
LC   Liquid chromatography 
LC-MS  Liquid chromatography plus mass spectrometry 
LCM   Laser Capture microdissection 
 
M  Molar 
ml  Mililitre 
MALDI  Matrix assisted laser desorption ionization 
Mdm2  Murine double minute 2 
MGMT  0-6-methylguanine DNA methyltransferase 
min  Minute 
mM  Milimolar 
MMP2  Metalloproteinase 2 
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MMR   Mis-match repair 
ms  Milisecond 
MS   Mass spectrometry 
MSI   Microsatellite instability 
MSI-H  High level microsatellite instability 
MSI-L  Low level microsatellite instability 
MS/MS Tandem mass spectrometry 
mW  Miliwatt 
 
NBS1  Nijmegen breakage syndrome 1 
NCBI  National Center for Biotechnology Information 
NICE   National institute for clinical excellence 
NCI   National cancer institute 
ng  Nanogram 
 
PAGE   Polyacrylamide gel electrophoresis 
PBS  Phosphate buffered saline 
PMF  Peptide mass fingerprinting 
Prx  Peroxiredoxin 
PTEN  Phosphate and tensin homolog gene 
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RAGE  Receptor for advanced glycation end products 
RB  Retinoblastoma 
Rcf  Relative centrifugal force 
RNA  Ribose nucleic acid 
ROC  Receiver operating characteristic 
ROS  Reactive oxygen species 
RR  Relative risk 
 
s  Second 
SDS   Sodium dodecyl sulphate 
SH3BGRPL3 SH3 binding glutamic acid rich protein like-3 
SIL  Stable isotope labelling 
SPARC  Secreted protein, acidic and rich in cysteines 
 
TAM  Tissue associated macrophage 
TCF  T- cell factor 
TEM  Transanal endoscopic microsurgery 
TEMED  N,N,N’,N’ – tetramethylethylenediamine 
TFA  Trifluoroacetic acid 
TGFβ  Transforming Growth Factor-beta 
TIFF  Tagged image file format 
TIMP   Tissue inhibitor of matrix metalloproteinase 
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TIP-B1  Tumour necrosis factor inhibitory protein – B1 
TMA  Tissue microarray 
TNFα  Tumour necrosis factor-alpha 
TNM  Tumour/Nodes/Metastases 
Tof  Time of flight 
TPA  Tissue polypeptide antigen 
TPS  Tissue polypeptide specific antigen 
Tris  tris(hydroxymethyl)aminomethane 
TS   Thymidylate synthase 
 
US  Ultrasound 
 
V  Volt 
VEGF  Vascular endothelial growth factor 
w/v  weight per volume 
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TYPE (5=054-96T, 6=148-01T, 7=108-03T); POLYPOID-TYPE (8=075-00T, 9=233-00T, 10=259-01T). NORMAL 
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1. INTRODUCTION 
 
 
1.1 COLORECTAL ADENOCARCINOMA: INCIDENCE AND SURVIVAL 
 
Colorectal cancer is the second most common cancer in the UK. Worldwide over a million new 
cases of colorectal cancer are diagnosed every year, accounting for more than 9% of all new cancer 
cases. In the UK there are approximately 16,000 deaths from colorectal cancer per year, of which 
5800 (36%) are cancer of the rectum. The incidence of colorectal cancer in the UK is approximately 
59 cases per 100,000 persons. It is strongly related to age with 83% of cases arising in people who 
are 60 years or older. Rectal cancer is more common in men with 58% diagnosed in males 
compared to 42% in females. The incidence of colon cancer is more equal, with 51% diagnosed in 
men and 49% women. The lifetime risk of the disease is estimated at 1 in 18 for men and 1 in 20 for 
women. Females demonstrate an improved five-year survival compared to men. In the early 1970s, 
five-year relative survival for male colon cancer was 22% (23% for women) and this rose to 47% 
(48% for women) in the late 1990s. Over the same time period, the five-year survival rates for male 
rectal cancer rose from 25% to 47% and from 27% to 51% for female rectal cancer.(1) Despite these 
improvements, five-year survival in the UK remains poor in comparison to the rest of Europe, with 
age-standardised rates of 45% compared to France and Germany with 50-55%.(2)  The USA has 
consistently higher five-year survival rates for cancer of the colon and rectum compared to 
European countries. Data from nine areas in the USA in the period 1990-1994 showed 5-year 
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survival rates of 59-66%.(2) These results are attributed to the early detection of colorectal cancer 
through screening programs funded by private health insurance companies across the USA. (3) 
 
1.2 COLORECTAL ADENOCARCINOMA: PROGNOSIS 
 
The association between pathological stage and prognosis was first documented by Cuthbert Dukes 
in his work on rectal cancer in 1950.(4) Other later classification systems, such as the TNM and 
Astler-Coller staging are refinements of the principles established by Dukes, namely that depth of 
tumour invasion and presence of lymph node or distant metastases is inversely correlated with 
patient survival,(5-7) (Figure 1.1). In 2000 the American Joint Committee on Cancer Prognostic 
Factors Consensus Conference listed several histopathological parameters in addition to stage 
which were associated in prognosis in colorectal cancer which should be documented in pathology 
reporting. These were residual tumour at the radial or excision margins, differentiation grade into 
high versus low, tumour border configuration, venous and lymphatic invasion and perineural 
invasion. Insufficient evidence at that time was available for the routine use of DNA content, 
microvessel density and tumour tissue markers such as p53, k-ras, DCC, MSI and p21 for routine 
clinical prognostic grading.(8, 9)  
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1.2.1 STAGING 
Staging of colorectal cancer is based on the three criteria; invasion through the bowel wall (T), 
lymph node metastases (N) and distant metastases (M). The components of the TNM score from 
the 7th edition of the American Joint Committee on Cancer staging for colorectal cancer are listed 
below.(10) 
 
Primary tumour (T) Lymph node metastases (N) Distant Metastases (M) 
TX-Primary tumor cannot be 
assessed 
NX Regional lymph nodes cannot 
be assessed 
M0 No distant metastasis 
 
T0-No evidence of primary tumour N0 No regional lymph node 
metastasis 
M1 Distant metastasis 
Tis-Carcinoma in situ: 
intraepithelial or invasion of 
lamina propria 
N1 Metastasis in 1–3 regional 
lymph nodes 
M1a Metastasis confined to one 
organ (for example, liver, lung, 
ovary, nonregional node) 
T1-Tumour invades submucosa N1a Metastasis in one regional 
lymph node 
M1b Metastases in more than one 
organ or the peritoneum 
T2-Tumour invades muscularis 
propria 
N1b Metastasis in 2–3 regional 
lymph nodes 
 
T3-Tumour invades through the 
muscularis propria into 
pericolorectal tissues 
N1c Tumor deposit(s) in the 
subserosa, mesentery, or 
nonperitonealized pericolic or 
perirectal tissues without regional 
nodal metastasis 
 
T4a-Tumour penetrates to the 
surface of the visceral peritoneum 
N2 Metastasis in 4 or more 
regional lymph nodes 
 
T4b-Tumor directly invades or is 
adherent to other organs or 
structures 
N2a Metastasis in 4–6 regional 
lymph nodes 
 
 N2b Metastasis in 7 or more 
regional lymph nodes 
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Figure 1.1:  Staging of colorectal cancer. Depicts tumour infiltration through bowel wall (T-
stage), Lymph node metastases (N-stage) and distant metastases (M-stage). Images adapted 
from The Carver Colon Cancer Surgical Centre (http://www.carverclinic.com/index.php) and 
Chicago’s Northside Colon & Rectal Clinic (http://cnscrc.com/colon_and_rectal_screening). 
LYMPH 
NODES 
LUNG 
LIVER 
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Colorectal cancer is a curable disease. In the early stages of the disease, adequate resection of a 
tumour with no lymph node metastases can result in a five-year survival of 77% for T3-T4 lesion and 
93.2% for T1-T2 lesions, (Table 1.1). The presence of lymph nodes metastases is the strongest 
prognostic factor for colorectal cancer. Five-year survival for patients with 1-3 positive lymph nodes 
(N1 disease) is 35-60%, whereas  4 positive lymph nodes is associated with a 25-27% survival.(11) 
Currently, 23.6% of patients with colorectal cancer present with nodal metastases and 9.2% present 
with distant metastases in the UK.(1) A further 40-50% of patients will develop distant metastases 
following resection of the primary colorectal cancer. The median survival in this group of patients is 
8 months without treatment and five-year survival is 0-7%. Patients with liver or lung metastases 
amenable to surgical resection have a five-year survival of approximately 25% at five-years.(12)  
 
Table 1.1:  5-year survival by stage1,11,12 
 
 
Dukes’ 
Stage 
Frequency Astler-Coller 
stage 
TNM stage 5-year survival 
A 8.7% I T1-2, N0, M0 80-95% 
B 24.2% IIA T3, N0, M0 72-75% 
  IIB T4, N0, M0 65-66% 
C1 23.6% IIIA T1-2, N1, M0 55-60% 
  IIIB T3-4, N1, M0 35-42% 
C2  IIIC Any T, N2, M0 25-27% 
D 9.2% IV Any T, Any N, M1 0-7% 
Unknown 34.3% - - 35.4% 
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1.2.2 EXCISION MARGINS 
The radial margin of a colorectal resection specimen represents the adventitial soft tissue margin of 
a nonperitonealized surface. A corresponding adventitial margin also exists for the ascending colon, 
descending colon, and rectosigmoid colon, all of which are only partially peritonealized. In those 
segments of the colon that are encased completely by a peritonealized (serosal) surface (the 
cecum, transverse colon, and sigmoid colon), the only radial margin is the mesenteric resection 
margin. The radial margin has been defined fully and studied specifically in rectal cancer, 
multivariate analysis has suggested that tumor involvement of this margin may be the single most 
critical factor in predicting local recurrence of rectal carcinoma. One such meta-analysis of 17,500 
rectal cancer resections demonstrated that involvement of the circumferential resection margin 
(CRM) is a powerful predictor of both development of distant metastases (HR = 2.8; 95% CI, 1.9 to 
4.3) and survival (HR = 1.7; 95% CI, 1.3 to 2.3). After neoadjuvant therapy (both radiotherapy and 
radiochemotherapy), the predictive value of the CRM for local recurrence is significantly higher 
than when no preoperative therapy has been applied (hazard ratio [HR] = 6.3 v 2.0, respectively; P < 
0.05).(13) Involvement of the retroperitoneal resection margin in right-sided colon cancer has also 
been shown as a poor prognostic marker. In this group of patients margin involvement appears to 
correlate with the presence of distant metastases and advancing stage at presentation.(14)  
1.2.3 HISTOLOGICAL GRADE 
Histological grade has been shown repeatedly to be of independent prognostic significance by 
multivariate analysis, as long as the grade assigned is reproducible and reflects the most poorly 
differentiated area of tumour.(15) One multivariate analysis in n=368 showed that differentiation 
Protein expression in colorectal cancer                                     EM Tweedle 
 
  
7 
 
grade was the only other variable apart from Dukes’ stage and tumour site which remained 
independently significant on multivariate analysis with a hazard ratio 0.76 (<0.02) for moderate to 
well differentiated and 0.78 (p<0.01) for poor to moderately differentiated.(16) 
1.2.4 EXTRAMURAL VASCULAR INVASION AND LYMPHATIC INVASION 
Extramural vascular invasion (EVI) by tumour has been demonstrated to have an independent 
adverse impact on outcome by multivariate analysis in many studies. A recent review of 5947 
resected colorectal cancers in the Yorkshire area showed that 17.8% of tumours are EVI+ and that 
the relative five year survival is 0.41(0.37 0.44), P=0.01.(17) Lymphatic invasion was also associated 
with poorer overall survival in a study of 462 patients (colon cancer: 57% vs. 84%, P=0.0001; rectal 
cancer: 38% vs. 71%, P=0.004). Patients with lymphatic vessel invasion also had a significantly 
increased incidence of positive nodes (59% vs. 25%, P=0.0004).(18) 
1.2.5 PERINEURAL INVASION 
Perineural invasion is closely correlated with extramural vascular invasion, however a number of 
studies have suggested that it is independently predictive of survival on multivariate analysis. One 
such study found that overall survival was 25% in the presence of neural invasion and 64% without 
neural invasion (p<.01).(19) 
1.2.6 TUMOUR BORDER CONFIGURATION 
For colorectal carcinoma, the growth pattern of the tumour at the advancing edge (tumour border) 
has been shown to have prognostic significance that is independent of stage and may predict liver 
metastasis. Specifically, an “irregular, infiltrating pattern of growth” as opposed to a “pushing 
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border” has been demonstrated to be an independent adverse prognostic factor by several 
univariate and multivariate analyses.(20) Diagnostic criteria recommended for detection of an 
infiltrative border are as follows; inability to define limits of invasive border of tumour and/or an 
inability to resolve host tissue from malignant tissue, dissection of tumour through the full 
thickness of the muscularis propria without stromal response and/or dissection of mesenteric 
adipose tissue by small glands or irregular clusters or cords of cells.(8) 
 
1.3 MERSEYSIDE AND THE NORTH WEST 
 
The incidence of colorectal cancer in the North West is above the English average in males (56 
versus 51 cases per 100,000 population) and very similar to the UK average in females (34 cases per 
100,000 population). The mortality in the North West region however is proportionally greater than 
the English average in both sexes and is the highest of all the regions in England. In the UK as a 
whole the North West region fares better than Scotland, Ireland and Wales; all of which have a 
higher incidence and mortality rate for colorectal cancer.(21) I retrospectively analysed 662 
patients who underwent surgical resection for colorectal cancer in the Royal Liverpool University 
Hospital between 1999 and 2004. Overall survival data are shown in Figure 1.2. The proportion of 
patients with nodal metastases is high compared to the UK average, (40% versus 23.6%) whereas 
the proportion of patients presenting with distant metastases is less, (8% versus 9.2%).1 The 
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Liverpool group of patients, however only include those who underwent resection of their primary 
tumour.   
A univariate and multivariate analysis was conducted of the data using a stepwise forward selection 
approach. We confirmed that in our Liverpool cohort of n=662 the usual factors, age, T-stage, N-
stage, differentiation grade, resection margin status and vascular invasion remained independently 
significant. In this group, perineural invasion and border configuration did not retain independent 
significance.  
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Figure 1.2: Overall survival according to Dukes’ stage in n=662 patients with resectable colorectal 
cancer operated between 1999 and 2004. 
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Table 1.2: Univariate and multivariate analysis of overall survival in n=662 resected colorectal 
cancers from the Royal Liverpool University Hospital between 1999-2003 
 
 
 
 
Variable Group Cases  Univariate Multivariate 
  n= 662 
(%) 
HR(95%CI) χ
2
 p-
value 
HR(95%CI) χ
2
 p-
value 
Age (years) 71 years (34-
99) 
- 1.029 (1.017-1.041) 23.613 0.001 
 
1.037 (1.025-1.050) 34.964 0.001 
Diff Grade  
 
 
Well 
Moderate 
Poor 
Unrecorded 
9 (1) 
564 (85) 
44 (7) 
45 (7) 
- 
0.973 (0.311-3.04) 
2.313 (0.208-7.560) 
21.259 
0.002 
1.926 
0.001 
0.963 
0.165 
- 
0.657 (0.207-2.082) 
1.123 (0.337-3.738) 
8.098 
0.511 
0.036 
0.017 
0.475 
0.850 
Resection 
margins  
Involved 
Clear 
Unrecorded 
563 (85) 
98 (15) 
1 (0) 
- 
0.449 (0.343-0.588) 
 
33.931 
 
0.001 
- 
0.660 (0.482-0.902) 
- 
6.771 
 
0.009 
Vascular 
invasion 
Yes 
No 
Unrecorded 
189 (17) 
439 (66) 
44 (7) 
 
0.376 (0.297-0.476) 
 
66.328 
 
0.001 
- 
0.518 (0.408-0.668) 
- 
25.626 
 
0.001 
Perineural 
invasion 
Yes 
No 
Unrecorded 
54 (8) 
564 (85) 
44 (7) 
- 
0.479 (0.387-0.679) 
 
16.993 
 
0.001 
- 
0.824 (0.566-1.200) 
- 
1.018 
 
0.313 
Border Pushing 
Infiltrating 
Unrecorded 
69 (11) 
544 (82) 
49 (7) 
- 
1.666 (1.088-2.550) 
 
5.509 
 
0.019 
- 
1.213 (0.784-1.876) 
- 
0.755 
 
0.385 
Infiltrate Sparse 
Dense 
Unrecorded 
584 (88) 
24 (4) 
54 (8) 
- 
0.527 (0.249-1.117) 
 
2.792 
 
0.095 
- 
- 
- 
- 
 
- 
T-stage T1 
T2 
T3 
T4 
25(4) 
78 (12) 
403 (61) 
156 (23) 
- 
1.009 (0.449-12.27) 
1.832 (0.903-3.716) 
12.642 (1.797-7.59) 
51.773 
0.001 
2.817 
12.642 
0.001 
0.982 
0.933 
0.004 
- 
1.073 (0.454-2.536) 
1.433 (0.667-3.078) 
2.157(0.976-4.764) 
11.699 
0.026 
0.852 
3.612 
0.009 
0.872 
0.359 
0.057 
N-stage 
 
N0 
N1 
N2 
 354 (53) 
187 (28) 
121 (19) 
- 
1.848 (1.433-2.384) 
2.914(2.219-3.838) 
62.054 
22.356 
59.082 
0.001 
0.001 
0.001 
- 
1.619 (1.224-2.242) 
2.337 (1.884-3.242) 
27.281 
11.390 
25.812 
0.001 
0.007 
0.001 
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1.4 GENETIC PREDISPOSITION TO COLORECTAL CANCER 
 
Hereditary cancer syndromes account for approximately 10% of colorectal cancer cases. The most 
common condition is Lynch syndrome or hereditary nonpolyposis colorectal cancer (HNPCC) with 4-
5% of the total; 1% is attributed to familial adenomatous polyposis (FAP) and less than 1% of cases 
are due to hamartomatous polyposis syndromes such as Peutz-Jegher, familial juvenile polyposis 
and Cowden’s syndrome. Evidence suggests that the risk of developing colorectal cancer increases 
with presence of a first-degree relative with the disease in the absence of an identifiable cancer 
syndrome.(22) A list of conditions associated with an increased risk of colorectal cancer is shown in 
Table 1.3.(23)   
 
 
Table 1.3: Inherited predisposition to colorectal cancer (23) 
 
 
 
Hereditary condition Genes implicated 
Hereditary Non-polyposis Colorectal Cancer  hMLH1, hMSH2,hMSH6 
Familial Adenomatous Polyposis APC 
Peuz-Jeghers syndrome STK11 
Familial juvenile polyposis PTEN, SMAD4, BMPR1A 
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1.4.1 HEREDITARY NON-POLYPOSIS COLORECTAL CANCER, HNPCCC 
HNPCC sufferers are reported to have a 70% risk of developing colorectal cancer by 70 years.(24) 
The tumours associated with the condition have the following characteristics; 
1. Lower average age of onset of colorectal cancer than in the general population (45 years in Lynch 
syndrome versus 63 years in the general population) 
2. Proximal (right-sided) colonic cancer predilection (70%–85% of colorectal cancers in Lynch 
syndrome are proximal to the splenic flexure) 
3. Accelerated carcinogenesis (tiny adenomas can develop carcinomas within 2–3 years in Lynch 
syndrome versus 8–10 years in the general population) 
4. High risk of additional colorectal cancers (25%–30% of patients who have surgery for a Lynch 
syndrome–associated colorectal cancer have a second primary colorectal cancer within 10 years of 
surgical resection if they received a less than subtotal colectomy) 
5. Increased risk of malignant disease at certain extracolonic sites; endometrium (40%–60% lifetime 
risk for female mutation carriers), ovary (12%–15% lifetime risk for female mutation carriers), 
stomach, small bowel, hepatobiliary tract, pancreas, upper uroepithelial tract (transitional cell 
carcinoma of the ureter and renal pelvis), brain (in the Turcot syndrome variant of Lynch 
syndrome). 
The pathology of colorectal cancer is more often poorly differentiated, with an excess of mucoid 
and signet-cell features, a Crohns-like reaction and an excess of infiltrating lymphocytes within the 
tumour. Survival from this form of colorectal cancer is better than for sporadic cancers of the same 
stage.(25) HNPCC is caused by mutations in the mismatch repair genes, most commonly MLH1, 
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MSH2 or MSH6, that segregates in the patient’s family. Individuals at risk in HNPCC kindred are 
heterozygous for mutations in the mismatch repair genes and so their normal cells do not have an 
elevated mutation rate. The cells lose the ability to correct errors in replication only when a further 
somatic mutation occurs in the functioning copy. Certain areas of the genome are vulnerable to 
replication error once the mismatch repair mechanism is damaged, in particular, poly-oligo tracts 
and base pair repeats known as microsatellites. Microsatellite instability, MSI, is seen in 90% of 
colorectal cancers in HNPCC patients and in 15% of sporadic tumours, described in greater detail in 
section 1.5.2.   
The Revised Bethesda guidelines (2004) are used for detecting those colorectal tumours which 
should be tested for microsatellite instability.(26) Detection of MSI in tumour tissue should prompt 
further investigations in order to establish whether the patient carries a germline mutation 
consistent with HNPCC. Sporadic tumours which display MSI have a more favourable prognosis than 
non-MSI tumours, which can guide patient management and follow up. The criteria are as follows; 
1. Patients aged less than 50 years with a diagnosis of colorectal cancer. 
2. Patients with synchronous or metachronous colorectal or other syndrome-associated tumours, 
regardless of age. 
3. Patients aged less than 60 years with colorectal cancer with histology suggestive of microsatellite 
instability (presence of tumour infiltrating lymphocytes, Crohns disease–like lymphocytic reaction, 
mucinous or signet-ring differentiation, or medullary growth pattern). 
4. Patients with at least one first-degree relative with a diagnosis of colorectal cancer or a 
syndrome-associated tumour under age 50 years. 
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5. Colorectal cancer or syndrome-associated tumour diagnosed at any age in two first- or second-
degree relatives. 
1.4.2 FAMILIAL ADENOMATOUS POLYPOSIS, FAP 
Familial adenomatous polyposis (FAP) has an incidence at birth of about 1 in 8,300. It manifests 
equally in both sexes, and accounts for less than 1% of colorectal cancer (CRC) cases. The disease is 
characterised by multiple polyps (>100) in the colon and rectum which have a 100% lifetime risk of 
malignancy, usually before the age of 40 years.(27) This autosomal dominant condition is caused by 
mutation in the Adenomatous Polyposis Coli (APC) tumour suppressor gene on chromosome 5q21. 
Prophylactic colectomy is recommended before the age of 25 years, British Society of 
gastroenterology (BSG) guidelines.(28) The conventional prophylactic operation has been subtotal 
colectomy and ileorectal anastomosis (IRA). This necessitates surveillance screening of the rectal 
stump with rigid or flexible sigmoidoscopy carried out at least every 12 months. There is a 
cumulative risk of rectal cancer of 4%, 5.6% 7.9% and 25% at 5, 10, 15 and 20 years.(29) 
Approximately 60% of FAP sufferers now undergo proctocolectomy and ileal pouch-anal 
anastomosis.(30) FAP may present with some extraintestinal manifestations such as osteomas, 
dental abnormalities (unerupted teeth, congenital absence of one or more teeth, supernumerary 
teeth, dentigerous cysts and odontomas), congenital hypertrophy of the retinal pigment epithelium 
(CHRPE), desmoid tumors, and extracolonic cancers (thyroid, liver, bile ducts and central nervous 
system).(27) 
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1.4.3 HAMARTOMATOUS POLYPOSIS SYNDROMES 
This spectrum of syndromes include juvenile polyposis, Peutz-Jeghers syndrome, hereditary mixed 
polyposis syndrome, the phosphatase and tensin homolog gene (PTEN) hamartoma tumor 
syndromes (Cowden and Bannayan-Riley-Ruvalcaba syndromes), which are autosomal-dominantly 
inherited and Cronkhite-Canada syndrome, which is acquired.(31) They are characterised by 
multiple hamartomatous polyps in the small bowel, colon and rectum. Peutz-Jegher syndrome is 
also associated with pigmentation of the peri-oral region, hand and feet and is caused by mutations 
in the STK11 gene on chromosome 19p13. Familial Juvenile Polyposis is associated with mutations 
in the PTEN, Smad4 and BMPR1A genes.  
 
1.5 DEVELOPMENT OF SPORADIC COLORECTAL CANCER 
 
The vast majority of colorectal cancers, 90%, develop sporadically following a series of genetic 
mutations in the epithelial cells of bowel mucosa. Two distinct pathways of development have been 
identified, chromosomal instability and microsatellite instability. 
1.5.1 CHROMOSOMAL INSTABILITY: THE ADENOMA-CARCINOMA SEQUENCE 
The adenoma-carcinoma sequence of colorectal cancer development was first proposed by Morson 
et al. who described the similarities in the age and sex of patient, distribution and size of adenomas 
and the subsequent development of colorectal cancer.(32) An estimated 5% of benign adenomas 
undergo malignant transformation; though the risk of transformation increases with increasing size, 
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grade of dysplasia and villous architecture. In 1988 Fearon and Vogelstein published a seminal 
paper that elucidated the sequence of genetic mutations, which underpins the transformation of a 
benign adenoma to a malignant lesion.(33) The candidate genes responsible for the various stages 
were consequently identified as APC, K-ras, Deleted in colorectal cancer gene (DCC) and p53. 
Mutations in these genes were described as occurring sequentially as the phenotype of the lesion 
changed from normal mucosa, through small adenoma to adenocarcinoma (Figure 1.3). Rates of 
mutation of these key genes in benign and malignant lesions are shown in the Table 1.4.  
 
 
 
 
 
 
 
 
(34) 
Normal 
colonic 
epithelium 
Dysplastic 
aberrant 
crypt foci 
Intermediate 
adenoma 
Late 
adenoma   Carcinoma 
APC K-ras DCC p53 
Figure 1.3: The adenoma-carcinoma sequence. The transition from normal colonic epithelium 
through adenoma to carcinoma. The increasing loss of cellular differentiation and capacity to 
metastasise correspond to the accumulation of genetic mutations described by Vogelstein. 
Image adapted from Fearon ER, Vogelstein B. Cell, Vol. 61, 759-767. 
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Table 1.4: Mutation rates of key genes in the adenoma-carcinoma sequence. A number of 
adenomas and carcinomas were tested for mutations in APC, k-ras and p53. Higher rates of p53 
mutation in carcinoma compared to adenoma support the theory that mutation of this gene is a 
late event in the adenoma-carcinoma sequence. 
 
An estimated 60-80% of colorectal cancers are thought to demonstrate chromosomal instability; 
however the conventional sequential model of mutation accumulation has been questioned. 
Studies have demonstrating that only 6.6% of all colorectal tumours were found to contain 
mutations in APC, K-ras and p53, with 38.7% of tumours containing mutations in only one of these 
genes.(35) Further work has indicated that this original model may be an over-simplification of 
colorectal carcinogenesis. As new genetic mutations have been reported it is clear that there may 
be several integrated routes towards the development of colorectal cancer,(36) shown later in 
Figure 1.4. Some of the common genetic pathways are discussed below.(37) 
1.5.1.1 THE WNT PATHWAY 
In the normally functioning colonic epithelial cell, β-catenin is held in a complex in the cytoplasm 
which includes the proteins APC and axin2.35 This complex targets β-catenin for phosphorylation by 
Glycogen synthase kinase 3-beta (GSK3β). Phosphorylated β-catenin becomes multi-ubiquitinated 
 % frequency 
Mutation Adenoma Adenocarcinoma 
APC 59-82 52-60 
K-ras 12-34 (<1cm) 
44-59 (>1cm) 
35-41 
p53 2-26 51-74 
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and subsequently degraded in proteasomes. Wnt proteins bind to cell-surface receptors of the 
Frizzled family, causing the receptors to activate the membrane-bound Dishevelled (DSH) family of 
proteins, inhibiting degradation of β-catenin and ultimately resulting in migration of the protein 
into the nucleus. Activation of DSH inhibits the axin/GSK-3/APC complex preventing proteolytic 
degradation of the β-catenin intracellular signalling molecule. A pool of cytoplasmic β-catenin 
stabilizes, and some β-catenin is able to enter the nucleus and interact with the T-cell factor (TCF) 
family of transcription factors to promote specific target genes promoting cell proliferation. 
Mutations in components of the ‘β-catenin destruction complex’ lead to aberrant stabilization of β-
catenin and thus to constitutive, Wnt-independent activation of TCF/β-catenin signalling.(38)   
The most frequent Wnt pathway mutation is in the APC gene which commonly produces a 
truncated form of the protein which is incapable of complexing with β-catenin.  APC is an enigmatic 
protein which has been implicated in numerous other cellular processes, such as cell migration, 
chromosomal stability, cell cycle regulation and cell adhesion. APC is connected to microtubules, 
and it plays a role in the correct establishment of the mitotic spindle. Disturbance of APC function 
by mutations could lead to chromosomal instability (CIN).(39) Aneuploidy (the abnormal number of 
chromosomes both quantitatively and qualitatively) is a sign of CIN and is a common characteristic 
of colon cancer cells, occurring in 85% of cancers. A role for APC in regulating the cell cycle has also 
been described, both directly and via components of the retinoblastoma, RB pathway.(40)  
β-Catenin is mutated in up to 10% of all sporadic colon carcinomas. These mutations result in 
stabilization of β-catenin and activation of Wnt signalling. Germline mutations of axin2 have also 
been described and sporadic mutations occur in 25% of microsatellite-unstable colorectal tumours. 
Protein expression in colorectal cancer                                     EM Tweedle 
 
  
20 
 
Recent evidence suggests that colorectal cancer cells frequently express Wnt proteins and thus 
stimulate the Wnt pathway by autocrine mechanisms.(38) 
1.5.1.2 RAS/RAF PATHWAY 
K-ras is a member of a group of oncogenes (the others being H- and N-ras) located on chromosome 
12p12. The ras proteins are membrane bound guanine nucleotide binding proteins that transduce 
growth-receptor signals across the cell membrane to effector molecules. In the resting state they 
are bound to GDP. Signalling by the ras proteins is activated by GTP binding and inactivated by 
intrinsic GTPase activity which automatically terminates the signal. Mutated K-ras is unable to 
hydrolyse GTP resulting in abnormal prolongation of growth signal. This results in increased and 
unregulated cell proliferation and growth factor induced differentiation.(41) 
The first identified downstream effectors of ras were the RAF serine/threonine kinases. The RAF 
family is composed of three members, ARAF, BRAF and RAF1, which exhibit a high degree of 
homology within three conserved regions. Each kinase has a ras-binding domain and cysteine-rich 
domain that mediate interaction with GTP-bound ras. On ras association, ras is recruited to the 
plasma membrane and is phosphorylated. Gene disruption studies in mice have shown that BRAF 
interacts with the MEK/ERK pathway causing activation. The higher propensity of BRAF towards 
MEK/ERK activation is thought to be a reason that only BRAF mutations, and not comparable 
mutations in the other RAF proteins, have been observed to be associated with malignancy.(42) 
BRAF mutations have been reported in 4-9% of sporadic colorectal tumours and are associated with 
a significantly higher proportion of MSI tumours.(43, 44) Research into BRAF mutations in MSI 
tumours has identified that the presence of a BRAF mutation indicates the tumour is not related to 
Protein expression in colorectal cancer                                     EM Tweedle 
 
  
21 
 
HNPCC and that germline testing of MLH1 in that individual is not warranted. It has been suggested 
as a rapid and inexpensive method of selecting patients for HNPCC testing.(45)   
1.5.1.3 18Q 
Chromosomal loss within the region of chromosome 18q has been shown to be associated with 
poor prognosis in stage II and III colorectal cancer.(46, 47) This genomic region contains a number 
of genes which have been studied for their possible contribution to colorectal cancer, including, 
DCC (Deleted in Colorectal Carcinoma),(48) Smad2(49, 50) and Smad4.(50, 51) The Smad proteins 
form complexes which migrate into the nucleus causing gene transcription after Transforming 
Growth Factor-Beta (TGF-β) ligand signalling.(52) The TGF-β superfamily of ligands include: Bone 
morphogenetic proteins (BMPs), Growth and differentiation factors (GDFs), Anti-müllerian 
hormone (AMH), Activin, Nodal and TGFβ. Signalling begins with the binding of a TGF-β superfamily 
ligand to a TGF-β type II receptor. The type II receptor is a serine/threonine receptor kinase, which 
catalyses the phosphorylation of the Type I receptor. Receptor-regulated Smad proteins (R-Smad) 
are recruited to the activated membrane-bound receptor-ligand complex and are in turn 
phosphorylated on their c-terminus leading to R-Smad activation. R-Smads include Smad2 and 
Smad3 from the TGF-ß/Activin/Nodal branch, and Smad1, Smad5 and Smad8 from the BMP branch 
of TGF-ß signalling. Cytoplasmic Smad4 forms heteromeric complexes with activated R-Smads 
which migrate into the nucleus and interact with transcriptional activators.  
There is considerable evidence implicating mutation of the Smad4 gene in the development and 
progression of colorectal cancer. Germline mutations of the Smad4 gene are associated with 
human familial juvenile polyposis,(53, 54) an autosomal dominant disorder characterized by a 
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predisposition to Smad4-negative gastrointestinal polyps and cancer at a young age. Consistent 
with a contributory role for Smad4 in this process, Smad4 (+/-) knock-out mice also develop Smad4-
negative gastrointestinal polyps.(55, 56) In human colorectal cancer, the frequency of mutational 
inactivation of Smad4 increases with advancing stage.(57) Smad4 mutations in adenoma or primary 
invasive carcinoma without distant metastasis occur in approximately 10% of cases.(58) In contrast, 
for patients who have primary invasive carcinoma with distant metastasis, the frequency of Smad4 
mutations is 35%, suggesting a strong link between Smad4 loss and disease progression. Our group 
reported a connection between the numbers of S100A8 and S100A9-positive monocytes in the 
stroma of pancreatic adenocarcinomas and the Smad4 expression in the tumour.(59) A similar 
report in colorectal cancer demonstrated a strong relationship between stromal infiltration and 
Smad4-loss and concluded that the combination of these features correlated with poor survival.(60) 
1.5.1.4 P53 
p53 is a tumour suppressor gene with numerous vital functions including prevention of 
inappropriate cell division, repair of DNA damage, induction of apoptosis and inhibition of 
angiogenesis.(61) In unstressed cells, p53 levels are kept low through a continuous degradation of 
p53. The murine double minute 2 protein (Mdm2) binds to p53 preventing its action and transports 
it from the nucleus to the cytosol. Mdm2 acts as ubiquitin ligase and covalently attaches ubiquitin 
to p53 and thus marks p53 for degradation by the proteasome.(62)  
p53 becomes activated in response to a myriad of stress types, which include but are not limited to 
DNA damage (induced by ultraviolet light, irradiation, or chemical agents), oxidative stress, osmotic 
shock, ribonucleotide depletion and deregulated oncogene expression. This activation is marked by 
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two events; firstly the half-life of p53 increases markedly leading to a rapid accumulation of the 
protein in stressed cells. Secondly, phosphorylation of the N-terminal domain of p53 causes a 
conformational change, activating the protein as a transcriptional regulator. Activated p53 directly 
stimulates p21Waf1/Cip1 expression which in turn inhibits cyclin dependent kinases (CDKs).(63) 
CDKs are key regulators of the cell cycle which ensure that DNA replication (S phase) follows on 
from the resting phase G1. Down regulation of CDKs inhibits both the G1 to S and the G2 to mitosis 
transitions in the cycle, effectively causing cell cycle arrest.   
A proportion of cells in which p53 is activated undergo apoptosis rather than cell cycle arrest. There 
are a number of mechanisms by which p53 has this affect. p53 is thought to cause translocation of 
various apoptosis-inducing proteins from the mitochondria including members of the BCL-2 family, 
Bax, Noxa and PUMA.(64) p53 has also been implicated in the membrane death receptor induced 
pathway of apoptosis. DR5/KILLER and FAS are two of the death receptors observed to be up-
regulated by p53. Activation of PIDD, a death domain containing protein, by p53, also induces 
apoptosis and is likely to function through the death receptor pathway.(65)  
p53 participates in DNA damage repair. Ataxia-telangiectasia mutated gene product (ATM) is a 
general sensor to DNA damage and phosphorylates p53, breast cancer protein (BRCA), Nijmegen 
breakage syndrome 1 (NBS1) and Fanconi-Anemia−related tumor suppressor (FA) activate the DNA 
repair process. BRCA and p53 work together in nucleotide excision repair of DNA adducts.(66) p53 
also participates in chromosomal recombination and chromosomal segregation.(67)  
Mutation in p53 prevents the normal function of the gene which is to prevent replication of cells 
with damaged DNA. p53 mutations more often occur late in carcinogenesis, frequently preceding 
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metastasis. It is perhaps unsurprising that these tumours have a worse prognosis than tumours 
with functioning p53.(68) 
1.5.2 MICROSATELLITE  INSTABILITY, MSI  
Microsatellites are short, tandem repeats of nucleotide sequences which make up 3% of DNA and 
are found throughout the genome. Due to their repetitive nature they are prone to errors in 
replication. In normal cells, the mis-match repair (MMR) system is responsible for the correction of 
errors which result from DNA polymerase slippage during DNA replication. MMR is accomplished in 
eukaryotes by a number of highly conserved proteins including heterodimers of MSH2/MSH3 or 
MSH2/MSH6 that are required for the recognition of mismatches or small insertions or deletions, 
and a heterodimeric complex of MLH1/PMS2 which links mismatch recognition to the activation of 
cleavage and repair. In MMR-deficient cells, microsatellite sequences are highly susceptible to 
insertion and deletion mutations due to increased error rates of replicative DNA polymerases at 
these loci.(69) Hence, the microsatelite instability (MSI) phenotype represents a surrogate marker 
for the detection of MMR deficiency.(70) The National Cancer Institute recommend the testing of 
five microsatellite markers for determination of MSI, (BAT-25, BAT-26, D2S123, D5S346 and 
D17S250).(71) Two or more positive markers which demonstrate instability is classed as MSI-high 
and germline screening for HNPCC is indicated. Approximately 15% of sporadic cancers show high 
levels of MSI (MSI-H). Most of these tumours are MMR deficient due to epigenetic silencing of 
MLH1. It appears that BRAF mutations are associated with the sporadic form of MSI-H, but not the 
hereditary form, (HNPCC).(72) Epigenetic silencing occurs when the promoter region of genes are 
methylated, preventing them for being transcribed. CpG-islands are DNA sequences where 
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cytosine, (C) and guanine, (G) lie adjacent to each other. These islands are very susceptible to 
methylation and are often found in promoter regions. Patients who display this trait are referred to 
as having the CpG-island methylator phenotype, CIMP+.(73)  
Tumours have been described with low levels of MSI, termed MSI-L.(74) These tumours are thought 
to have a separate pathway of development to MSI-H tumours involving either (i) increased 
generation of methylG:T mismatches due to loss of expression of 0-6-Methylguanine DNA 
Methyltransferase (MGMT) that would stress the DNA mismatch repair machinery and (ii) partial 
methylation and loss of expression of the DNA mismatch repair gene MLH1. Tumours with MGMT 
methylation are often associated with K-ras mutation. Increasing interest in serrated adenomas as 
precursor lesions for these MSI-L tumours is developing.(37, 75)  
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Figure 1.5: Alternative pathways in colorectal cancer 
Figure 1.4: Putative pathways in the development of colorectal cancer. Multiple pathways of 
development are shown including germline mutation, chromosomal instability (CIMP-
negative) and microsatelite instability (CIMP-positive) pathways. Image adapted from Jass JR. 
Surg Oncol. 2007 Dec;16 Suppl 1:S7-9. Epub 2007 Nov 26. 
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1.6 DIAGNOSIS: POPULATION-BASED COLORECTAL CANCER SCREENING 
 
Diagnosis of colorectal cancer to date has relied on presentation of the patient to the general 
practitioner or local Accident and Emergency department with symptoms or signs suggestive of a 
colonic neoplasm. These features include, change in bowel habit (frequently to looser stool), blood 
in the stool, weight loss, iron deficiency anaemia or an abdominal mass.(76) The natural history of 
colorectal cancer makes it an ideal candidate for population-based screening. The disease is 
widespread in the population, readily detected at a pre-neoplastic stage, (adenomatous polyps) and 
is easily treated. Population-based screening for colorectal cancer commenced in June 2006 in the 
UK and is anticipated to reduce cancer-specific mortality by 15%. The current protocol in the UK 
uses the Faecal Occult Blood Test, FOBT, for those aged 60-69 years.  Several different modalities 
can be used for screening; the evidence-base for these is discussed below. Screening is set to have a 
major impact on the management of colorectal cancer.(77) The proportion of patients presenting 
with small and early colorectal cancers in the UK is predicted to double promoting a shift towards 
local excision and other minimally-invasive surgical techniques. The efficacy of the various methods 
used for screening will be vital for the early detection of flat and depressed tumours.(78) 
1.6.1 COLONOSCOPY 
Colonoscopy is recognized as the ‘gold-standard’ for detection of cancers and polyps. It is the only 
modality with the capacity to detect and remove adenomatous polyps from the whole colon in one 
session. Most alternative colorectal cancer screening modalities such as FOBT, flexible 
sigmoidoscopy and barium enema are utilised as a tool for the selection of patients for colonoscopy 
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and ultimately polypectomy and/or surgery.(77) It is perhaps surprising that there are no 
randomised controlled trials that demonstrate the effectiveness of colonoscopy in reducing 
mortality from colorectal cancer. One small, randomised trial from Norway showed a 75% 
reduction in the number of colorectal cancers that developed in the screened group after 10 years 
follow up but no survival information was available.(79) The efficacy of colonoscopy can be 
extrapolated from case-control studies of sigmoidoscopy; these demonstrated a risk reduction of 
80% for death from colorectal cancer in those with a history of flexible sigmoidoscopy 
examination.(80, 81) Evidence from the large cross-sectional study of the US National Polyp 
Database reported reductions in the expected number of colorectal cancers following colonoscopy 
and polypectomy of 76 – 90% compared to reference populations.(82, 83) There is evidence for 
relative risk reduction for colorectal cancer of 70% following negative colonoscopy; this reduces to 
55% at 5 years and 28% at ten years.(84) The detection rate for invasive cancer at colonoscopy in 
cross-sectional studies is reported as 0.5-1% with 6-12% having high-risk lesions (size ≥10mm, 
villous architecture, poorly differentiated histology or invasive cancer).(85) Almost 50% of patients 
with a proximal neoplasm have a sentinel lesion in the distal colon. In one such study 64% of all 
cancers and polyps ≥10mm were located within reach of a flexible sigmoidoscope and 53% were in 
the sigmoid colon or rectum.(86) In the younger age group, 40-49 years, the detection rate for 
significant polyps falls to 3.5% and screening below the age of 50 years is not recommended in the 
USA.(87) 
No perforations have been reported as a result of colonoscopy in the three large US trials although 
10 patients (0.3%) had post-polypectomy bleeding.(86)  In the UK FOBT trial the overall 
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complication rate following colonoscopy was 0.5%; 5 perforations, 1 major bleed and 1 snare 
entrapment in 1474 screened.(88) Missed lesions have been reported after colonoscopy. Miss-rates 
have been reported up to 6% for polyps <10mm after back-to-back colonoscopy. One such study 
found that 2% of asymptomatic patients undergoing screening had a missed polyp. Almost one-
quarter of these missed lesions were within 10cm of the anal verge, the majority of the remainder 
were located on a fold in the colon.(89) Ten-yearly colonoscopy for the over 50-year age group is 
the favoured colorectal cancer screening policy by the American College of Gastroenterologists.(3, 
90) There is not sufficient evidence at present to determine whether this a cost effective approach 
in the UK or other European countries.   
1.6.2 FLEXIBLE SIGMOIDOSCOPY 
Three large randomised trials of once-only flexible sigmoidoscopy have been performed in the 
UK(91), Italy(92) and Norway(93) and reported on neoplasia detection rates. The UK trial has now 
reported and found that 727 were died of certified colorectal cancer out of 170038 participants, 
(538/112939 in the control group versus 189/57099 in the flexible sigmoidoscopy group). In 
intention-to-treat analyses, colorectal cancer incidence in the intervention group was reduced by 
23% (hazard ratio 0.77, 95% CI 0.70-0.84) and mortality by 31% (0.69, 0.59-0.82).(94) Two case-
control studies from the US have shown a reduction in colorectal cancer mortality from a 
combination of flexible and rigid sigmoidoscopy of 60-80%.(80, 81) Cancer detection rates for 
flexible sigmoidoscopy have been reported as 0.3-0.7%. The incidence of distal cancers following 
sigmoidoscopy is decreased to 4% of expected in the first year of follow-up and remains 18% of 
expected after 4 years.(95) The removal of significant distal adenomas during the initial 
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examination is an attraction of the flexible sigmoidoscopy approach. In direct comparison with 
FOBT, flexible sigmoidoscopy has been shown to detect approximately three times as many of 
these lesions.(96, 97)  
There are disadvantages of using flexible sigmoidoscopy for screening. Referral rates for 
colonoscopy varied from 5-19% depending on the protocol used, but were higher than the 1.2-2.1% 
referral rates seen in FOBT trials, (unrehydrated tests). Two perforations after flexible 
sigmoidoscopy were seen in total during the three trials, a complication rate of 3 per 100,000 
examinations. Compliance with flexible sigmoidoscopy screening is lower than that for FOBT 
screening. In the UK 55% of the general population expressed an interest in flexible sigmoidoscopy 
after letter invitation, of these 71% attended for the examination, an overall compliance rate of 
39%.(91)  This is lower than the reported 54% compliance rate recorded in the first round of the UK 
FOBT trial.  
1.6.3 DOUBLE-CONTRAST BARIUM ENEMA, DCBE 
No randomised controlled trials are available on either single or double contrast barium enema for 
colorectal cancer screening of asymptomatic patients. The sensitivity of DCBE for cancers has been 
reported as 80-100%, whereas detection of polyps has been found to be poor.(98) Studies of DCBE 
in the average-risk population are rare. One study, of patients with a positive FOBT, compared 
DCBE to colonoscopy and found that barium enema detected 100% of cancers but only 27% of 
polyps ≥10mm. Polyps in the rectum were particularly poorly diagnosed with none of 7 polyps 
<10mm and 2 of 3 polyps ≥10mm detected.(99) One retrospective cross-sectional study of DCBE in 
the average-risk population had a detection rate of 0.7% for adenocarcinoma and 4.3% for polyps 
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≥10mm.(100) The low detection rate for polyps makes DCBE an unattractive option for screening 
and it is rapidly being superseded by CT colonography.  
1.6.4 CT COLONOGRAPHY 
CT colonography is a new diagnostic tool for lesions in the colon and very few studies have used 
this technology for screening of asymptomatic patients. The initial results of one cross-sectional 
study of 1110 asymptomatic adults found the rate of invasive cancer to be 0.3% and of large polyps 
(≥10mm) to be 3.9%.(101) Conventional colonoscopy was performed in 40 of these patients and the 
polyp was identified in 38 patients (95% concordance). The detection rate for polyps in this study 
was vastly improved compared to DCBE but not as high as optical colonoscopy (3.9% vs. 5.4%). No 
complications of CT colonography were reported and many authors in the US predict this 
examination becoming available via private health insurance schemes as a minimally invasive 
alternative to ten-yearly colonoscopy.   
1.6.5 GUAIAC FAECAL OCCULT BLOOD TESTING, G-FOBT 
The guaiac-based test for faecal blood was first developed in the 1970s as a screening test for 
colorectal cancer when endoscopic technology was in its infancy. G-FOBT makes use of the 
pseudoperoxidase activity of haemoglobin. Guaiac turns blue after oxidation by oxidants or 
peroxidases in the presence of an oxygen donor such as hydrogen peroxide. For the guaiac test to 
function, the haemoglobin must be degraded in the GI tract into haem and globin. As a result of the 
mechanism of action guaiac-based tests were initially thought to be more sensitive for causes of 
upper GI or proximal bleeding, however, they have been found to be better at detecting larger, 
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more distal lesions. The sensitivity of G-FOBT for distal (rectosigmoid) polyps has been reported as 
86% compared to 26% for proximal (ascending or transverse colon) polyps.(102)  
G-FOBT with follow-up colonoscopy is the only method of colorectal cancer screening which has 
been shown to reduce mortality from the disease in several randomised controlled trials. Three 
major randomised controlled trials from Minnesota, USA(103, 104), Nottingham, UK(105, 106) and 
Funen, Denmark(107) have shown a consistent reduction in colorectal cancer specific mortality of 
15-21%. The Minnesota trial had the longest follow up period of 18 years; they also rehydrated the 
FOB tests with a drop of distilled water prior to processing in order to increase the test sensitivity. 
These differences may explain the higher rate of colonoscopy compared to the Nottingham trial, 
38% versus 4%.(108) The detection rate for invasive cancer using G-FOBT with follow-up 
colonoscopy is reported as 0.2%, with a 1.8% chance of detecting any high-risk lesion. The main 
disadvantage of using G-FOBT is its relatively low sensitivity for polyps and cancer, (30% and 50% 
respectively). Unrehydrated G-FOBT detected half of colorectal cancers in the average-risk 
population. This may have been affected by compliance rates in the UK and Danish pilot studies, 
which, at 57-67% were lower than anticipated.(105-107) 
1.6.6 FAECAL DNA TESTING 
Faecal DNA testing relies on small amounts of altered DNA being exfoliated into the stool from 
colonic adenomas or carcinomas.(109) DNA is stable in stool and can be isolated and specific 
human DNA sequences extracted and amplified.(110) The main disadvantage of this technique is 
the relatively low frequency in which single genes are mutated in adenomas, (60% APC, 50% K-ras). 
This has been overcome by forming a panel of genes which may include APC, K-ras, p53 and BAT-
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26.  Faecal DNA screening in the average risk population has been shown to be more sensitive than 
G-FOBT with the same specificity.(111) The detection rate for advanced neoplasia, (carcinoma or 
adenoma≥10mm) was 18% for faecal DNA and 11% for G-FOBT which was disappointingly low in 
both cases. Currently, the cost of faecal DNA testing prohibits widespread use on a population 
basis.(112) Refinements to the marker panel which increase sensitivity and efforts to reduce costs 
may see faecal DNA testing ultimately supersede FOBT. 
 
1.7 MANAGEMENT OF COLORECTAL CANCER: THE RATIONALE FOR 
TREATMENT 
 
1.7.1 SURGERY 
The mainstay of treatment for colorectal cancer is complete surgical excision of the lesion including 
the arterial supply, venous drainage and lymph node group for the involved segment of bowel. 
Approximately 80% of patients who present with colorectal cancer undergo resection of the 
primary lesion. Adequate surgical resection is most vital in anterior resection or abdomino-peroneal 
resection for rectal cancer in which the aim is to preserve the mesorectal envelope and thus 
minimising the risk of a positive resection margin. The specimen is graded from 1-3 with 3 
corresponding to a completely intact specimen; a grade 3 resection is proven to be associated with 
lower recurrence rates. (113) Resection of the tumour is deemed to be complete on 
histopathological evaluation of the specimen if the tumour is >1mm from the surgical excision 
Protein expression in colorectal cancer                                     EM Tweedle 
 
  
34 
 
margins. The National Cancer Institute also recommends that 12 or more lymph nodes should be 
examined in each specimen in order to accurately stage and treat colorectal cancers.(114) 
1.7.2 ADJUVANT CHEMOTHERAPY 
Adjuvant chemotherapy has been recommended by the National institute for Clinical Excellence, 
NICE for all patients with lymph node metastases.(115) A number of large prospective randomised 
trials have now beyond doubt recognised the value of 5-fluorouracil (5FU) based chemotherapy in 
the adjuvant treatment of stage-III (Dukes C) colon cancer. (116-118) The mechanism of action of 
5FU is via incorporation in RNA as fluorouridine triphosphate and inhibition of thymidylate 
synthetase by fluorodeoxyuridine monophosphate, often in conjunction with reduced folates for 
maximum efficacy to interfere with DNA synthesis. Most studies have demonstrated a reduction of 
22-33% in risk of death for this group. There is a large body of evidence that suggests the first line 
use of a combination therapy of irinotecan and 5FU/folinic acid (FA) may provide a more efficacious 
treatment regime.(119) However, NICE guidelines, produced in 2002, suggest irinotecan be 
reserved for use as a single-agent, if 5FU treatment fails. The QUASAR trial reported a very small 
benefit of adjuvant treatment for stage-II patients overall, (4-5%).(120) Patients with poor 
prognostic indicators on histology, such as poor differentiation, T4 or perforated lesion, may be 
offered chemotherapy at the discretion of the treating clinician. In patients with unresectable 
disease, 5FU has been shown to improve survival over supportive care alone, (median survival 11.7 
versus 8 months and 1-year survival of 50 versus 34%).(121)  Oxaliplatin has been recommended as 
a first-line treatment in the very few cases where inoperable liver metastases could potentially be 
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made operable with chemotherapy. Potentially 13.5% of these patients could be rendered 
resectable with chemotherapy and those resected patients achieved a 39% 5-year survival.(122) 
1.7.3 ADJUVANT RADIOTHERAPY 
Cells exposed to ionizing radiation acquire multiple sites of bulky DNA lesions and double strand 
breaks. The accumulation of damage, specifically double strand breaks or adducts stalling the 
replication forks are stimulation signals for a global response to DNA damage. The common 
features of global response are induction of multiple genes, cell cycle arrest, and inhibition of cell 
division culminating in apoptosis. Radiotherapy is only used in the management of rectal cancer as 
the mobility of the colon within the abdomen makes consistent targeting of the lesion difficult.  
Small bowel is very sensitive to radiotherapy and irradiation of the abdomen can result in severe 
radiation enteritis.(123) Evidence from the CR07 trial suggests that recurrence rates for resectable 
rectal cancer are reduced by approximately 15% with the routine administration of short-course 
radiotherapy prior to surgery.(124) Some rectal tumours are bulky and appear to infiltrate the 
resection margin on pre-operative imaging. Pre-operative chemoradiation therapy for 6 weeks to 
‘down-stage’ the tumour doubles the rate of sphincter-sparing operations and lowers the rates of 
local recurrence, acute toxicity, and long-term toxicity. No difference in disease-free or overall 
survival was observed on comparison of pre or post-operative chemoradiotherapy.(125) 
1.7.4 NEW ADJUVANT TREATMENT MODALITIES 
Monoclonal antibodies directed against epidermal growth factor receptor, EGFR (cetuximab) and 
vascular endothelial growth factor, VEGF (bevacizumab) are new adjuvant therapies. In an initial 
Phase II study of 121 patients whose tumours expressed EGFR and were refractory to irinotecan, 
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treatment with the combination of cetuximab and irinotecan resulted in a response rate of 17%. 
(126) In a randomized, Phase III trial of 815 previously untreated patients with metastatic disease, 
the addition of bevacizumab to irinotecan plus fluorouracil/leucovorin (IFL) led to a statistically 
significant improvement in response rate (44.8% versus 34.8%, P = 0.004) and a 4.7-month 
prolongation in median overall survival (20.3 months versus 15.6 months,  p = 0.001).(127) Sub-
group analysis of metastastic colorectal cancer treated with cetuximab has revealed that response 
to the drug is poor in those patients with K-ras mutations in the tumour. Mutant K-ras activates the 
MARP/ras cell proliferation pathway downstream of the EGFR, which means that targeting the 
receptor with cetuximab is ineffective.(128) Tumour-specific adjuvant chemotherapy treatment is 
increasingly possible with the new generations of monoclonal antibodies.  
 
1.8 EARLY COLORECTAL CANCER: MANAGEMENT OPTIONS 
 
As more pre-cancerous adenomatous polyps and early cancers are detected with screening the 
scope for local resection of tumours will increase. The impact of tumour morphology on these 
treatment options is still controversial with some studies suggesting local resection should be 
avoided in depressed tumours, whereas other studies reporting safe and effective treatment in this 
group.(129)  The accurate staging of all tumours prior to local treatment is imperative and signs 
that predict which early tumours are likely to have infiltrated deep into the bowel wall, or have 
lymph node metastases are vital. Biomarkers which predict recurrence of tumour after local 
resection will be unvaluable in the management of early and small tumours. 
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1.8.1 TRANSANAL ENDOSCOPIC MICROSURGERY (TEM) 
TEM is a minimally invasive surgical technique originally designed by Buess et al. in the 1980s.(130) 
The anal sphincter is dilated with a large-diameter, (4cm) operating sigmoidoscope to 
accommodate optics, suction, and ports for dissecting instruments. Endoscopic surgical instruments 
are advanced into the rectum after insufflation. The magnified three-dimensional image allows an 
optimal view of the tumour and facilitates precise dissection. The plane of dissection extends 
through the muscularis propria into the surrounding adipose tissue; the remaining defect is 
typically closed using a continuous suture. TEM is most commonly used to resect large, benign 
rectal adenomas. In this group, microscopic involvement of the resection margin is significantly 
associated with recurrence; the overall recurrence rate is reported as 2 - 10.5% at 24 months.(131) 
No guidelines have been established for following up this patient group, common practise is rigid or 
flexible sigmoidoscopy at 4 months then 6-12 monthly thereafter. Three-monthly examinations are 
suggested for patients with positive margins. TEM has been used to resect rectal cancers, either 
with curative intent (for T1 tumours) or palliative intent in more advanced lesions. The recurrence 
rate in the UK has been reported as 20% pT1 (five-year survival of 77%), 25% pT2 (five-year survival 
74%) and 59% pT3 (five-year survival 35%).(132) No consensus on follow up for these patients has 
been established. Most authors have recommended salvage open surgery for patients with high-
risk lesions, (villous architecture, positive resection margins or poorly differentiated tumour on 
histology), initially treated with curative intent.  
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1.8.2 ENDOSCOPIC MUCOSAL RESECTION (EMR) AND SNARE-POLYPECTOMY 
EMR was first reported in 1988 by Tada et al. as a method of excising large, sessile polyps not 
amenable to conventional snare-polypectomy.(133) The technique describes the injection of fluid, 
(typically 1:40,000 adrenaline solution and methylene blue) into the submucosa around a polyp 
causing the lesion to ‘lift’ away from the muscularis propria. The lesion is then resected with a 
conventional polypectomy snare, piecemeal if necessary. Most authors advocate EMR for benign 
polyps. Lesions that are indurated, ulcerated, and/or exceedingly friable at endoscopy, as well as 
those that fail to ‘lift’ in response to a submucosal injection of fluid may contain invasive 
malignancy and should be avoided.(134) A recurrence rate of 17-21% with a median follow-up of 
12-24 months has been reported following resection of benign sessile polyps in the colon and 
rectum. The rate of invasive adenocarcinoma in these studies was reported as 12-18%.(134, 135) 
The guidelines issued by the British Society of Gastroenterologists for the follow-up of patients 
following conventional snare polypectomy are well established.(136) These polyps generally have a 
narrow stalk which, when snared, allows for easier, safer removal with a greater chance of 
complete excision. The British Gastroenterology Society recommends that those who have 
undergone removal of 5 adenomas or 3 adenomas (at least one of which is 10mm) are 
categorised as high-risk and should be offered follow-up colonoscopy in 12 months.(136) The 
cumulative risk, for these patients, of developing invasive cancer is estimated as 24% at 20 years 
without polypectomy.(137) Patients who have undergone removal of 1-2 small adenomas, 
(<10mm) are classed as low-risk and given the option of one surveillance colonoscopy in five years, 
or no follow up. Intermediate risk patients, 3-4 adenomas or one adenoma >10mm should be 
offered a further examination in three years.(136) 
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1.9 FLAT AND DEPRESSED-TYPE COLORECTAL CANCER  
 
Flat and depressed colorectal cancers have been reported in Japan since Muto in 1985.(138, 139) A 
series of case reports documented patients with lymph node or distant metastases from colorectal 
cancer in which the primary lesion was a diminutive depressed colorectal cancer, often 10-20mm in 
diameter. A common feature of these reported lesions was the small size, infiltrative growth 
pattern and the presence of early, aggressive metastases. These rare tumours were thought to be a 
phenomenon confined to the Japanese population; however colonoscopic studies began to identify 
depressed tumours in Western populations. The presence of flat and depressed cancers in 
European populations is now firmly established with a succession of papers from the UK, France, 
Germany and Sweden.(140-146)  
1.9.1 MORPHOLOGICAL CLASSIFICATION OF COLORECTAL LESIONS 
In 1997, Kudo devised the Japanese Research Society Classification (JRSC) for the morphology of 
colorectal adenomas which he based on the established classification of early gastric cancer. Four 
basic groups were described: Type I (polypoid) in which the adenoma protruded into the lumen of 
the colon with a height > 2x the depth of the mucosa: Type IIa, (flat), the lesion is elevated but the 
height is < 2x the depth of the surrounding mucosa, Type IIb (flat) the lesion lies flush with the 
mucosa and Type IIc, (depressed), the lesion is sunken in relation to the surrounding mucosa. The 
full classification is shown in Figure 1.5.(147)  
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Figure 1.5: JRSC classification of colorectal cancer morphology. Polypoid, flat and depressed 
cancer types are depicted in relation to level of normal colonic mucosa. Image adapted  from Kudo, 
S et al. World J Surg 21, 694-701 (1997). 
 
1.9.2 FLAT AND DEPRESSED LESIONS: INCIDENCE  
Flat and depressed tumours remain rare. Detection rates at routine colonoscopy are similar in 
Japanese and Western populations, shown in Table 1.5.(138, 142, 143, 146, 148-154) The most 
recent UK study from St Marks’ Hospital found that 71% of T1 lesions detected at colonoscopy were 
flat or depressed with 10% of all detected cancers of flat or depressed morphology.(153) 
Establishing the incidence of flat and depressed tumours in resected specimens retrospectively is 
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hampered by the difficulties in applying the JRSC classification to large cancers. Large cancers often 
show a mixed pattern of growth as they progress with areas of ulceration and distortion of 
surrounding tissue.(155) Ishihara (2000) and Nasir (2003) retrospectively compared a number of 
surgically resected polypoid and non-polypoid tumours of all sizes. In both papers there were 
difficulties in classifying tumours with mixed growth patterns or surface ulceration, leading to a 
number of exclusions. This may go some way to explain why a greater variation in incidence of flat 
cancers is reported in resected colorectal cancer. Small or diminutive tumours have been studied 
with more consistent results. Kubota (1996) reported an incidence of 1% diminutive, (10mm), flat 
or depressed colorectal cancer seen in resected colon which approaches that of colonoscopic 
studies.156 Ishihara (2000) analyzed small colorectal cancers, (20mm), and demonstrated an 
overall incidence of 1.3% with 15/23 (65%) of small cancers having flat or depressed 
morphology(156) (Table 1.6). In a retrospective study of small, flat and depressed colorectal 
cancers, (20mm) that I undertook with colleagues in the Royal Liverpool University Hospital, we 
reported an incidence of 2.2% (39/1763) which concurs well with the Japanese studies.(157) This 
suggests that the aetiology and natural history of these lesions is similar between East and West. 
The study is described in detail in section 1.9.4. 
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Table 1.5: Colonoscopically detected flat colorectal cancer/adenomas 
Main Author Year Country No of 
patients 
No of flat 
Carcinomas (%) 
Size 
(mm) 
Muto (138) 1985 Japan - 0 1-10 
Iiashi (158) 1991 Japan 3872 0 <5 
Mitooka (149) 1995 Japan 1152 5* (0.13%) 12-27 
 Kudo (150) 1995 Japan 17939 53 (0.30%) 5-21 
Smith (151) 1999 UK 2198 9 (0.41%) 9-30 
Fujii (140) 2000 UK 1000 4 (0.40%) 9** 
Tsuda (146) 2002 Sweden 1328 5 (0.43%) 16** 
Togashi (152)  2003 Japan 10939 34 (0.31%) < 20 
Diebold (142) 2004 France - 2 4-20 
 Suzuki (159) 
Gorgun(160) 
2004 
2009 
UK 
USA 
1026 
2003 
5 (0.49%) 
23(0.8%)† 
8-15 
- 
*depressed lesions only         **median size †adenomas only 
 
Table 1.6: Flat and depressed colorectal cancers in surgical resections 
Main Author Year Country No of 
specimens 
No flat carcinomas/ total 
specimens (%) 
Kubota (161) 1996 Japan 300 3/300 (1.0%) 
Ishihara (156) 2000 Japan 1140 15/1140(1.3%) 
Nasir A (162) 2003 USA 190 22/190 (11%)* 
Tweedle EM (157) 2005 UK 1763 39/1763 (2.2%) 
*All sized flat and depressed lesions included 
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1.9.3 FLAT AND DEPRESSED LESIONS: DETECTION  
The detection of flat and depressed tumours can be challenging. Magnified colonoscopy with the 
use of dye spraying has been recognized as the most sensitive method of detection.(163) 
Acceptance of the adenoma-carcinoma sequence as the main pathway of development for sporadic 
colorectal cancer has reinforced the need to identify and remove adenomas. Increasing awareness 
of flat and depressed morphologies has lead to a corresponding increase in detection and 
diagnosis.(164)  
1.9.4 FLAT AND DEPRESSED TUMOURS: LIVERPOOL EXPERIENCE  
 
1.9.4.1 MATERIALS AND METHODS 
From 1st January 1995 to 31st December 2004, 1763 colonic resections were performed for 
adenocarcinoma in the Department of Colorectal Surgery, Royal Liverpool and Broadgreen 
University Hospitals. I conducted a retrospective review of all the histology reports. Tumours were 
selected when their maximum diameter was reported to be 20mm or less, regardless of the 
accompanying macroscopic description. Tumours associated with Familial Adenomatous Polyposis, 
(FAP), Hereditary Nonpolyposis Colorectal Carcinoma, (HNPCC) or Inflammatory Bowel Disease, 
(IBD) were excluded. Patients treated with pre-operative radiotherapy were excluded.  
The original histology slides of all 61 patients were reviewed by the same experienced consultant 
histopathologist to avoid observer variation.(165) All lesions invaded the submucosa and were at 
least pT1 lesions classified according to the Vienna Classification.(166) The morphology of the 
tumours was classified according to the Japanese Research Society for Cancer of the Colon (JRSC). 
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Using these criteria, flat colorectal cancer was defined as a tumour in which the carcinomatous 
component is not more than twice the thickness of the surrounding non-neoplastic mucosa, all type 
II lesions. Fisher’s exact test was used for statistical analysis.  Values of p<0.05 were considered 
significant. 
1.9.4.2 RESULTS 
Sixty-one patients fulfilled the criteria. M: F 1:1. Age 69, (42 - 90 years). The lymph node yield, 
obtained from the original histology report, was 9 (0 -22). Sixty-four percent (39/61) of our cohort 
were flat and depressed tumours compared to thirty-three percent (20/61) polypoid tumours. Two 
tumours were unclassifiable due to a lack of preserved tissue. The site of the tumours was caecum 
8 (13.1%), ascending colon 6 (9.8%), transverse colon 5 (8.2%), sigmoid colon 23 (36.7%) and 
rectum 19 (31.2%). The ratio of tumours found in the right hemicolon compared to the left 
hemicolon is 7:13 (35%) for polypoid tumours and 11:28 (28%) for flat and depressed tumours. The 
number of tumours with residual adenomatous components on histology was 5/20 (25%) in the 
polypoid group and 1/39 (3%) in the flat and depressed group. Seven patients had ten synchronous 
adenomas, all of which were polypoid.  The low numbers of reported flat lesions in the background 
mucosa most likely reflects lack of awareness of this entity at the time of reporting.  
The prevalence of small, flat and depressed colorectal cancers in our population of resected 
tumours was 2.2% (39/1763), an incidence of 4 resectable cancers per year. Sixty-four percent 
(39/61) of our cohort were flat and depressed tumours compared to thirty-three percent (20/61) 
polypoid tumours. Two tumours were unclassifiable due to a lack of preserved tissue. Table 1.7 
shows the distribution of tumours according to the JRSC classification. All small cancers were staged 
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using both TNM and Dukes staging. The results are shown in Tables 1.8 and 1.9 respectively. The 
distribution of tumours according to T stage is shown in Figure 1.6. The proportion of flat versus 
polypoid tumours at each T stage was analyzed using Fisher’s exact test.  Statistical differences 
were found in the proportion of flat or depressed tumours presenting at T1, (P=0.033) and T3, 
(P=0.016). T1 lesions were most likely to be polypoid, T3 lesions were most likely to be flat or 
depressed. The rate of metastases was high in both groups, (30% polypoid versus 39% flat and 
depressed). Flat and depressed tumours showed a trend towards a greater proportion of distant 
metastases (0% polypoid v. 8% flat and depressed), this did not reach significance.  See published 
paper Tweedle et al.(157) 
 
Table 1.7:  Classification of lesions according to JRSC. Table shows proportion of small lesions 
which fell into each morphological group. 
JRSC classification Nos of small cancers(<20mm) Total 
Polypoid  20 
 Peduculated (Ip) 
 Subpedunculated (Ips) 
 sessile (Is) 
2  
4 
14 
Flat  17 
 Flat elevated (IIa) 
 Flat elevated with depression(IIa+IIc) 
 Flat (IIb) 
3  
10 
4 
Depressed  22 
 Depressed (IIc) 
 Depressed with rolled edge (IIc + IIa) 
9 
13 
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Table 1.8: Small cancers according to TNM staging. Proportion of polypoid versus flat and 
depressed tumours by depth of invasion (T-stage); shows a greater percentage of T1 lesions in 
polypoid group, and greater percentage of T3 lesion in flat/depressed group. For each T-stage, the 
percentage of tumours with nodal metastases (N-stage) and distant metastases (M-stage) is shown. 
* Fisher’s Exact Test 
Table 1.9: Small cancers according to Dukes Staging. Demonstrating fewer Duke’s A and more 
Duke’s D cancers in the flat/depressed group. *2 Dukes B tumours were not classifiable according to 
morphology due to lack of paraffin-embedded tissue. 
 
TMN Staging Polypoid Flat and 
 Depressed 
All small 
cancers 
p-value 
T1 6 (30%) 3 (8%) 9 (15%) 0.033* 
N+ 1 (17%) 1 (33%) 2 (22%)  
M+ 0 0 0  
T2 4 (20%) 6 (15%) 10 (17%) 0.457 
N+ 0 1 (17%) 1 (10%)  
M+ 0 0 0  
T3 4 (20%) 19 (49%) 23 (39%) 0.016* 
N+ 2 (50%) 7 (37%) 9 (39%)  
M+ 0 2 (11%) 2 (9%)  
T4 6 (30%) 11 (28%) 17 (29%) 0.676 
N+ 3 (50%) 6 (55%) 9 (53%)  
M+ 0 1 (9%) 1 (6%)  
Total 20 39 59  
 
 
A B C D Total 
All small cancers 15(25%) 23*(39%) 18 (31%) 3 (5%) 59 
Polypoid  9 (45%) 5 (25%) 6 (30%) 0 20 
Flat and Depressed  6 (15%) 18 (46%) 12 (31%) 3 (8%) 39 
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1.9.5 FLAT AND DEPRESSED LESIONS: MOLECULAR BIOLOGY 
The pathway of development of flat and depressed colorectal cancers is the subject of debate. A 
higher frequency of high grade dysplasia and submucosal invasion in flat adenomas compared to 
polypoid adenomas has been demonstrated in a number of papers. This may suggest that flat 
adenomas are the precursor lesions of flat and depressed carcinomas.(167, 168) An alternative 
theory proposes that these cancers arise de novo from the colonic mucosa. The low or absent rates 
of residual adenomatous component in flat and depressed cancers support this theory.(148, 169, 
170)  
= no metastases 
= nodal metasases (N+) 
= distant metastases (M+) 
0 
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40 
50 
Polyp Flat Polyp Flat Polyp Flat Polyp Flat 
T1               T2               T3                T4 
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Figure 1.6: T-stage of small colorectal cancers according to morphology.  Shows 
numbers of tumours in each group and proportion with nodal or distant metastases. 
3 
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Many key components of both the chromosomal instability and microsatellite instability pathways 
have been assessed in flat and depressed tumours. Reports are conflicting; however differences in 
the genetic and epigenetic events which influence carcinogenesis that have been consistently 
detected are as discussed below.  
There is some evidence that APC mutations occur less frequently in flat and depressed adenomas 
than polypoid adenomas with rates as low as 7% in some papers.(171) However, other studies have 
found higher rates of APC mutations which approach those seen in polypoid adenomas.(172) β-
catenin, of the Wnt pathway and has been reported to have a higher level of mutation (24%) in flat 
adenomas with a central depression compared to polypoid lesions.(173) The K-ras signalling 
pathway has been investigated in flat and depressed tumours since the 1990’s. Most studies have 
reported lower rates of mutation in early flat and depressed cancers than in polypoid cancers.(174-
176) One study reported a higher rate of K-ras mutation in flat adenomas.(176) Recent 
investigations into the BRAF gene, part of the K-ras signalling pathway has found higher rates of 
mutation of this gene in flat and depressed tumours.(177)  One study reported that BRAF mutations 
were only detected in lesions with a flat or depressed morphology.(178) Interestingly, mutations in 
the BRAF gene have been found to correlate closely with the presence of microsatellite instability, 
MSI. This contrasts with evidence from flat and depressed tumour studies which have reported low 
levels of MSI. p53 mutations are a late event in the chromosomal instability pathway and as such 
are very infrequently detected in adenomas and early cancers. No difference in rates of p53 
mutations have been reported in flat and depressed lesions compared to polypoid lesions.(179, 
180) 
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Methylation of CpG islands in the genome, epigenetic silencing, is one pathway by which genes can 
be functionally ‘switched-off’ without mutation of the genetic sequence. It is associated with the 
development of microsatellite instability, MSI as DNA repair genes are often affected. Two studies 
have assessed methylation of the promoter regions of MGMT, CDKN2A (p16) and MLH1 genes. 
Lower rates of methylation in flat and depressed adenomas and early cancers have been reported 
in both studies; this indicates that epigenetic alterations are not a feature of flat tumour 
development.(176, 177) In support of these findings, the panel of five microsatellite markers have 
been assessed in two separate studies of flat and depressed adenomas and found to occur very 
infrequently compared to polypoid tumours.(181, 182)  
The genetic findings lend credence to the theory that these morphologically different tumours have 
a separate pathway of development. No proteomic studies have yet been published in relation to 
flat and depressed tumours. My research, in part, has attempted to address whether protein 
expression between different morphological groups of tumour can be characterised. 
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1.10 OVERVIEW OF PROTEOMICS 
 
The genetic basis of many human cancers has been described and it is apparent that analysis of 
genetic material alone is insufficient to understand all of the complex cellular processes involved in 
tumorigenesis in many cases. Cellular proteins, (the proteome) are the expressed products of 
genes, (the genome), and are responsible for nearly all cellular functions. There are a number of 
levels at which the quantity and activity of a given protein can be regulated, including rates of gene 
transcription, translation into protein and post-translational modifications. The result of these 
complex levels of regulation means that the proteome can consists of several hundred thousand 
different proteins and may be a more sensitive indicator of disease. Analysis of cellular proteins, 
(proteomics) can offer a unique insight into the molecular mechanisms of cancer development and 
enable identification of tumours markers or novel therapeutic targets.(183) The advances in 
biotechnology mean that proteomic techniques can be used to quantify and identify proteins in cell 
culture, tissue and body fluids, (such as plasma or urine). Proteomics encompasses the study of 
proteins in health and disease, characterisation of post-translation modifications and protein-
protein interactions. Investigation of this intricate environment means that there are several 
essential steps which must be taken in order to produce a result. These include sample storage and 
preparation, purification, separation, visualisation and identification of proteins.(184)  
1.10.1 SAMPLE STORAGE 
The method of sample preparation used is very dependent on the subject under analysis. Cells in 
culture can be very simply prepared by lysing sufficient quantities of cells in lysis buffer. Analysis of 
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tissue is more complex as fresh tissue must be fixed quickly to avoid degradation. Formalin is a 
commonly-used fixative and DNA is relatively stable in formalin-fixed material. RNA and protein is 
subject to cross-linkage formation by formalin which reduces the quality of material which can be 
procured.(185, 186) Snap-freezing in liquid nitrogen is currently the preferred method of storage 
for fresh tissue. New alcohol-based fixative agents may prove useful if they are shown to preserve 
the quality of RNA and protein in the tissue.  
1.10.2 PURIFICATION  
The gold-standard of proteomics is the analysis of cells in the context of their native tissue.(187) 
The complexity of tissue means that the cells of interest only constitute a small proportion of the 
sample. Three main approaches have been taken to address the issue; cultured cell-lines, global 
survey and microdissection. The use of cell-lines cultured from fresh tissue is common; it is 
particularly useful for investigating the effects of interventions such as drugs on cells. The 
disadvantages in terms of cancer research are that the cells are removed from their 
microenvironment and this influences their behaviour and protein profile. The global survey 
approach utilises the assumption that RNA levels accurately reflect gene expression within a tissue. 
The disadvantages are that the cell population of interest is present in different proportions in 
whole tissue samples. Microdissection involves the separation of one or more specific cell 
populations directly from tissue for analysis. Various methods have been described; all involve 
sectioning of tissue and selection of the cells of interest under direct vision. Initial approaches 
involved manual dissection of tissue using a microscope and needle. More recently, two laser 
assisted techniques have emerged as the methods of choice.(188) Laser-beam microdissection 
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involves excising selected areas of tissue with a laser, then retrieving the material by pressure 
catapulting or needle transfer into extraction buffer. Laser-capture microdissection, LCM was 
developed at the National Institute of Health, USA. In this technique the tissue section is placed in 
contact with a cap coated with a heat-sensitive ethylene vinyl acetate film. On firing of the laser at 
the cells of interest, a small area of the film (7.5-30µm in diameter) melts and fuses the cells to the 
cap. The cap can then be lifted, removing the selected cells from the tissue. The cap is placed in 
extraction buffer which is used to lyse the cells and solubilise the protein or RNA for analysis, figure 
1.7.(188) The disadvantages of this technique are that staining and sectioning of the tissue to 
render it suitable for laser capture can degrade the protein or RNA content.(189) Strong H&E 
staining of sections in our laboratory was found to reduce the quality and quantity of protein 
extracted after laser capture. Other stains have been tried, such as methyl green which appear to 
have little effect on the extracted protein. One disadvantage of all microdissection techniques is 
that a level of expertise is required to examine the tissue and identify the cell population of 
interest. Moreover the process is labour intensive and time-consuming. Despite these problems, 
microdissection is the only utilised technique which enables comparisons of different cell 
population from the same tissue.   
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Figure 1.1: Schematic representation of laser-capture microdissection (from Mr Ali Shekouh) 
 
 
Fluorescence-activated cell sorting (FACS) is a type of flow cytometry devised and trademarked by 
Becton, Dickinson and Company. It provides a method for sorting a heterogeneous mixture of 
biological cells into two or more containers, one cell at a time, based upon the specific light 
scattering and fluorescent characteristics of each cell. A cellular suspension is generated from blood 
or tissue and the cells of interest labelled with an immunofluorescent antibody tag. In the flow 
cytometer the suspension is entrained in the center of a narrow, rapidly flowing stream of liquid. 
The flow is broken into individual droplets, each one containing a cell. A laser is used to measure 
the fluorescent character of each cell as it passes; simultaneously an electrical charge is applied to 
the droplet. The droplets then fall through an electrostatic deflection field that diverts them into 
containers based upon their charge.(190) Flow cytometry has been in use since the 1960’s, but the 
technology to capture in addition to quantifying populations of living cells have seen it recently 
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applied in the proteomic analysis of circulating human leukocytes.(191) It is likely that in the future 
this technology will be applied to effectively separate cancer cell populations from tissue for 
proteomic analysis.  
 
1.10.3 SEPARATION AND VISUALISATION 
There may be several hundred thousand different proteins in any given sample for proteomic 
analysis. None of the methods for fractionation and separation of proteins are sensitive enough to 
allow detection of the entire proteome. There are two main methods of protein separation, gel-
based and non gel-based techniques. 
1.10.3.1 GEL-BASED 
Separation of proteins in two dimensions on a SDS-polyacrylamide gel is a technique which was first 
described in the 1960’s.(192) Proteins are first separated by charge and pH in the first dimension, 
then by molecular weight in the second dimension. Commonly a gel strip with a fixed pH gradient is 
used to separate proteins in the first dimension. Once a voltage is applied the protein migrates 
along the strip towards the anode until it reaches a pH where the charge is lost (isoelectric point). 
Varying the pH gradient can allow different sets of proteins to be visualised. Common variations 
include non-linear gradients, with an expanded section from pH 7-9, or reduced pH range. 
Following protein separation, gels are stained so that the individual protein spots can be visualised. 
A relatively small quantity of protein, (100-200µg) can produce a good quality gel with up to 10,000 
spots visible. The most common protein visualization methods utilised are Coomassie blue staining, 
silver staining and increasingly, fluorescent staining.(193) Coomassie blue stains in a linear manner 
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and is easily reproducible, however, it is only sensitive for protein levels greater than 2mg per 2D 
gel (15x20cm). Silver staining is exponential, meaning that the rate of development of staining 
increases as more staining develops. Silver ions bind to protein within the gel and are reduced, 
(usually by formaldehyde or gluteraldehyde) to visible silver.(194) Deposits of non-ionic silver 
further catalyse the reduction of silver ions in the vicinity. This method is very sensitive (0.1ng per 
spot) however, it has a number of disadvantages. The dynamic range is only 10-20 fold and the 
complexity of the staining procedure makes reproducibility difficult. Some of the reduction agents, 
(such as gluteraldehyde) used for silver staining can cause structural changes in the proteins making 
subsequent identification with mass spectrometry impossible. Nevertheless, silver staining is a 
sensitive and reproducible method of gel staining, and despite its drawbacks, is frequently utilised.  
Difference gel electrophoresis (DIGE) is a staining method in which two protein samples are 
separately labelled with different fluorescent dyes and then co-electrophoresed on the same 2DE 
gel. There are two fluorescent dyes in common use, propyl-Cy3-NHS and methyl-Cy5-NHS; they 
have no net charge and have molecular masses which differ by only 2Da. Two labelling techiques 
are available (minimal and saturation labelling) depending on which amino acids residue is 
targeted; lysine (average of 30 residues per 50 kDa protein) or cysteine (average of 1-2 residues per 
50kDa protein). Minimal labelling targets 1%–2% of all lysines, which results in only a fraction of 
each protein species carrying a single dye molecule, while the rest are unlabelled. This creates spot 
shift in the lableled versus unlabelled protein population in the molecular mass dimension. This 
shift is negligible for proteins >30 kDa; however, proteins <30 kDa are generally shifted by up to one 
spot diameter. In practice, the minimal labelling dyes are used when one has >100 μg 
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protein/sample. Saturation labelling targets 100% of cysteine residues and labels the majority of 
protein in each sample, therefore this technique does not result in spot shift. It is typically used for 
low abundance, precious samples.(195)  
DIGE is sensitive, detecting <0.5 fmol protein per spot with minimal labelling and <25 amol per spot 
with saturation labelling. Fluorescent dyes have a detection range of about 30-fold under constant 
illumination, which is similar to silver staining.(196) This can be increased to 20,000-fold but 
requires the use of a scientific-grade, cooled charge-coupled device (CCD) camera. The main 
disadvantages with the use of DIGE are that a maximum of three samples can be compared per gel. 
In addition gels typical have a limited lifespan in storage, three months at -70 C for minimally-
labelled gels or one month at -70 C for those labelled with saturation dyes.(197) 
The advantages of the gel-based method are that a large amount of data can be generated from 
each gel as the isoelectric point and molecular weight of thousands of proteins can be calculated. 
Post-translational modifications of proteins can often be identified as horizontal or vertical clusters 
of proteins.(198) The disadvantage of gel-based techniques is that it is capable of demonstrating 
only 10-20% of the entire proteome. It has a particularly low sensitivity for certain types of protein 
including membrane-bound proteins, highly acidic or basic proteins, low molecular weight and low 
abundance proteins. Often the low abundance proteins are those of interest in terms of protein 
markers of disease.(199) Non-gel based protein separation techniques have been developed to 
attempt to address some of these problems.  
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1.10.3.2 NON-GEL BASED TECHNIQUES 
 There are two commonly used non-gel based techniques that allow relative quantification of 
proteins in samples; these are isotope-coded affinity tags (ICAT) and isobaric tags for relative and 
absolute quantification (iTRAQ). Both techniques use stable isotope labelling (SIL) to ‘tag’ peptides 
and allow identification and relative quantification of proteins. ICAT uses two isotope tags; one 
contains hydrogen (H), the other deuterium (L) with a mass difference of 8Da. The isotopes bind to 
the amino acid cysteine which is a component in an estimated 6 out of 7 of peptides. Two protein 
samples are separately labelled with H and L, the samples are then combined and subject to trypsin 
digestion.(200) The mixed, labelled peptides are eluted through a column containing a stationary 
phase which binds the peptides to the column matrix. The pH of the elution buffer, (mobile phase) 
is gradually increased so that the peptides are washed from the column individually in a process 
known as liquid chromatography (LC). Mass spectrometry is then used to identify ICAT pairs of 
peptides. A search of the database containing peptide fragmentation data results in the 
identification of the peptides and hence the original protein. 
iTRAQ is based upon tagging the N-terminus of peptides generated from protein digests.(201) Up to 
eight protein solutions are subject to trypsin digestion, each peptide solution is then labelled with a 
different tag. The tags are all neutral with the same molecular mass so they do not interfere with 
the liquid chromatography fractionation. Fragmentation of the tag attached to the peptides in the 
mass spectrometer generates a low molecular mass reporter ion that is unique to the tag used to 
label each of the digests. The relative intensity of these reporter ions enables relative quantification 
of the peptides in each digest and hence the original proteins.(202) iTRAQ is rapidly superseding 
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ICAT for proteomic analysis. It is more sensitive, allows eight samples to be compared and because 
the tags bind to the N-terminus rather than cysteine residues all proteins are potentially 
represented in the analysis.(203) 
1.10.4 PROTEIN IDENTIFICATION 
Peptide mass fingerprinting (PMF) is an analytical technique for protein identification that was 
developed by John Yates and colleagues.(204) In short, the unknown protein of interest is cleaved 
into peptides. Proteolysis using trypsin is most commonly used for this purpose as it has a high 
specificity and efficiency. The collection of peptides resulting from this cleavage comprises a unique 
identifier of the unknown protein. The absolute masses of the (still unknown) peptides are 
accurately measured with a mass spectrometer such as matrix-assisted laser absorption ionisation-
time of flight (MALDI-ToF) or electrospray ionization-time of flight (ESI-ToF). Many proteins can be 
identified simply by knowing the mass of each constituent peptide; however the best chance of 
identification comes by providing the amino acid sequence of one of the peptides.  
1.10.4.1 ION PRODUCTION, (MALDI AND ESI) 
MALDI is the most commonly used technique to ionise the peptide molecules within a sample. The 
sample is loaded onto and organic matrix and laser energy is transferred to the sample causing 
ionisation. ESI is a newer technique where the sample is pushed through a very small, charged and 
usually metal, capillary. The buffer in the sample is more volatile than the peptides dissolved in it. 
As the sample is forced out of the capillary it forms an aerosol, a mist of small droplets about 10μm 
across. As the buffer evaporates, the peptide molecules are forced closer together, repel each 
other and break up the droplets further. The process repeats until the peptide is free of buffer and 
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is a lone ion. These lone ions then move to the mass analyzer component of the mass 
spectrometer. As technology in the field of proteomics has advanced, liquid chromatography 
columns have been coupled directly to ESI mass spectrometers allowing the identification of 
peptides as they are eluted from the mixture, a process known as liquid chromatography-mass 
spectrometry (LC-MS).(205)  
1.10.4.2 ION SEPARATION AND ANALYSIS 
Once the peptides have been ionised using MALDI or ESI, they pass into the analyser which uses 
ToF to calculate the mass. Essentially, the peptides are accelerated in a vacuum tube towards a 
detector. The amount of time it takes for the ion to reach the detector is proportional to the mass 
of the peptide. Most analysers now include delayed extraction or reflection tubes which essentially 
‘focus’ the cloud of peptides in the field and have a longer flight-time. One method of detecting the 
mass of peptides is called the Fourier transform ion cyclotron, (FTICR). This relies on exciting the 
peptides in a magnetic field then detecting the sine wave signature released; this sine wave can 
then be converted into a mass. The advantages of this technique are that the peptides do not have 
to hit the detector, just pass close enough for the wave to be detected. Additionally, it is useful for 
complex mixtures of peptides as the specific resolution (narrow peak width) allows the signals of 
two ions of similar mass to charge ratio to be detected as distinct ions.(206) The ToF analyser is still 
the most commonly ion detection method used in MS.  
Tandem mass spectrometry (MS/MS) is the now the preferred technology for many applications in 
which mass spectrometry plays a part. Hybrid MS instruments consist of two ToF mass analyzers in 
series. After passing through the first detector the ions are subject to collision-induced 
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decomposition (CID) in a second chamber by subjecting them to energetic collisions with inert gas 
molecules. These collisions further fragment the peptides which are then passed through the 
second ToF detector. In this way fingerprints of component peptides can be produced to aid 
identification of the original protein.(207) 
 
1.11 PROTEIN MARKERS IN COLORECTAL CANCER 
 
Vast arrays of proteins have been identified as over-expressed or under-expressed in colorectal 
cancer tissue from proteomic analysis. Analyses of differential protein expression between normal 
colonic mucosa and colonic adenocarcinoma have identified a list of commonly identified 
proteins,(208, 209) listed in Table 1.10. Few of these markers have been verified as prognostic 
indicators of disease, and fewer yet are used clinically. A serum marker of colorectal cancer is the 
gold standard in terms of diagnosis and screening for the disease. Unfortunately, there is no protein 
marker which is sensitive enough for the task. Serum markers can be used to determine response 
to treatment and for surveillance. A number of promising serum and tissue biomarkers have been 
identified by the European Group on Tumour Markers (EGTM); however the only one currently 
recommended for clinical use is carcinoembryonic antigen (CEA).(210, 211) Tissue-based markers 
have been investigated for potential prognostic and predictive value. The potential prognostic and 
predictive value of the most widely studied tissue markers in colorectal cancer are discussed below. 
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Table 1.10: Proteins with altered regulation in colorectal cancer detected by proteomics (208, 
209) 
Up-regulated proteins Down-regulated proteins 
Annexin IV   NCF2 
MTA-1   PMM2  
SSX5 protein   Serpin 1  
Dynein heavy chain   CNRC  
Cytochrome P450   Annexin V  
CPT1   APC  
Keratin 10   VAV3 protein  
Keratin 8   RSP 4  
Keratin 19   SPARC like protein 1  
Vimentin   PDI  
β-actin   GN6ST  
REL1   Cathepsin D  
HSP60   Calreticulin  
Mortalin  SM31  
Cytochrome P450 enzymes  PDA6 ApoA1 precursor  
HSP70   ATP synthase b chain  
S100A9   Albumin  
S100A8   Liver fatty acid-binding protein  
S100A11   Actin-binding protein/smooth muscle  
S100A6   protein 22-a  
Adenosyl homocysteinase   Cyclooxygenase 2  
Leukocyte elastase inhibitor, 
claude B  
 
Puromycin-sensitive aminopeptidase  
Macrophage capping protein  Cathepsin fragment  NADH-ubiquinone oxidoreductase  
Biliverdin reductase A  Proteasome subunit α type 6  Succinate dehydrogenase subunit A  
Annexin 1 fragment  Triosephosphate isomerase  Aldehyde dehydrogenase, cytosolic,  
class I  α-tubulin  14-3-3 proteins  
Elongation factor 1-d  GST-P  Selenium-binding protein  
Tropomyosin α 1  P13693 translationally controlled 
tumour protein  
Creatin kinase B chain  
Tropomyosin α 4 chain  Nucleoside diphosphate kinase A  Placental thrombin inhibitor  
Actin fragment  Calgranulin B; S100 A9  Vimentin  
Annexin 3, 4 and 5   Desmin  
Microtuble-associated protein 
RP/EB  
 Tubulin β 5 chain  
Pyridoxal kinase   Carbonic anhydrase I  
  Myosin regulatory light chain 2  
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1.11.1 CARCINOEMBRYONIC ANTIGEN (CEA) 
The main use of serum CEA in colorectal cancer is in surveillance following curative resection for 
primary cancer. It is not recommended for screening or diagnosis because of its low sensitivity for 
cancer. A number of independent meta-analyses have compared outcome in patients undergoing 
intensive follow-up versus minimal or no follow-up. Although the frequency and modalities of 
screening used in the individual studies varied, all meta-analyses concluded that use of an intensive 
follow-up regime resulted in a modest but statistically significant improvement in outcome 
compared with a minimal follow-up strategy.(212-214) The Cochrane Review concluded that there 
was an overall survival benefit at five years of follow-up for patients undergoing more intensive 
surveillance (OR = 0.67, 95% confidence interval, 0.53–0.84).(215) Two of these meta-analyses 
investigated the specific contribution of CEA to the improved outcome. In the first of these, 
Bruinvels et al. concluded that intensive follow-up was associated with an improved outcome, but 
only if regular CEA determinations were carried out.(216) Similarly, Figueredo et al. (2003) found 
that trials using serial CEA measurements had a significant impact on survival, whereas those not 
using CEA failed to impact on outcome.(214) Recent reports suggest that a postchemoradiotherapy 
CEA level <5 ng/ml is a favorable prognostic factor for rectal cancer and is associated with increased 
rates of earlier disease staging and complete tumor regression.(217) Determination of CEA and 
carbohydrate antigen 19-9 (CA19-9) in peritoneal fluid at resection may also predict peritoneal 
recurrence in the absence of detectable tumour cells.(218) The EGTM Panel guidelines state that 
for stages II and III colorectal cancer patients, CEA should be measured every 2–3 months for at 
least 3 years, not only for patients who are suitable candidates for liver resection, but also for 
patients who are candidates for receiving systemic therapy.(210) 
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1.11.2 CARBOHYDRATE ANTIGEN 19-9 (CA19-9) 
The CA19-9 assay was devised to detect sulfated mucins isolated from normal human colonic 
mucosa. It is an antibody which recognizes the sialylated Lewis (a) antigen, fucopentaose II. CA19-9 
is the best serum marker for pancreatic adenocarcinoma; however it is less sensitive than CEA for 
the detection of colorectal cancer.(219) Elevated preoperative levels of CA19-9 have been found to 
correlate with adverse patient outcome.(220) The largest of these studies (n=495 patients), found 
the prognostic impact of CA19-9 to be independent of both Dukes’ stage and CEA 
concentration.(221) Filella and colleagues compared CEA and CA19-9 in the follow-up of 370 
patients with diagnosed colorectal cancer. While CEA was abnormal in 84% of patients with 
recurrence and provided a lead-time in 75%, CA19-9 levels were elevated in only 48% and gave a 
lead-time in only 25%.(222) Similarly, in monitoring the treatment of metastatic colorectal cancer, 
CA 19-9 results yielded no additional information to that provided by CEA. The use of CA19-9 for 
diagnosis and surveillance of colorectal cancer is not recommended by the EGTM panel.  
1.11.3 CARBOHYDRATE ANTIGEN 242 (CA242) 
As with CEA and CA19-9, serum CA242 cannot be used for the detection of early stage colorectal 
cancer. Carpelan-Holmstrom and colleagues have shown using multivariate analysis, that high 
preoperative levels of CA242 were a significant predictor of outcome when CEA was included in the 
analysis, but CEA only became an independent factor if CA242 was excluded.(223) Hall and 
colleagues compared CEA and CA242 in the surveillance of 149 patients who had undergone 
apparent curative resection for colorectal cancer. For the detection of recurrent disease, CEA alone 
had a sensitivity of 76% and a specificity of 86%. The corresponding sensitivity and specificity for 
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CA242 were 60% and 87%, respectively. Combination of the two markers increased the sensitivity 
to 88%, but reduced specificity to 78%.(224) The authors concluded that although CA242 alone is 
inferior to CEA, it may complement CEA in the follow-up after curative resection for colorectal 
cancer.  
1.11.4 TISSUE POLYPEPTIDE ANTIGEN (TPA) AND TISSUE POLYPEPTIDE SPECIFIC ANTIGEN (TPS) 
TPA is a complex of polypeptide fragments from cytokeratins 8, 18 and 19 and TPS is one epitope 
that contains fragments of cytokeratin 18. Both antigens have been subjected to limited evaluation 
in colorectal cancer. In a study of 202 newly diagnosed patients, Lindmark and colleagues found 
that high levels of CEA, C 19-9, CA242, TPA and TPS were all associated with aggressive 
disease.(225) In patients undergoing liver resection or radiofrequency ablation, TPA and TPS but 
not CEA, CA19-9 or thimidine kinase (TK), were important predictive markers of overall survival and 
disease-free survival.(226) 
1.11.5 TISSUE INHIBITORS OF METALLOPROTEINASES (TIMP-1) 
TIMP-1 is a multifunctional glycoprotein that inhibits metalloproteinase activity, stimulates cell 
growth and inhibits apoptosis.(227) Using a research enzyme-linked immunosorbent assay (ELISA), 
Holten-Andersen and colleagues reported that total serum levels of TIMP-1 were significantly 
higher in patients with both colonic (n=338) and rectal cancer (n=108) than in either healthy 
subjects (n=108) or patients with inflammatory bowel disease (n=50). At 95% specificity, TIMP-1 
detected colonic cancer with a sensitivity of 65% and rectal cancer with a sensitivity of 42%. 
Combining CEA with TIMP-1 increased sensitivity for colonic cancer from 65% to 75% and rectal 
cancer from 42% to 54% (at 95% specificity).(228)  
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1.11.6 THYMIDYLATE SYNTHASE (TS) 
TS is the rate limiting enzyme involved in the conversion of deoxyuridine monophosphate (dUMP) 
to deoxythymidine monophosphate (dTMP). This reaction provides the only de novo source of 
thymidylate which is essential for DNA synthesis.(229) TS expression has been widely investigated 
in colorectal cancer tissue as both a prognostic and a therapy predictive marker. The rationale for 
using TS as a therapy predictive marker in colorectal cancer is that it acts as the key target for 
several cytotoxic agents used to treat this disease such as the fluoropyrimidines, 5-fluorouracil (5-
FU) and 5-fluorodeoxyuridine and the antifolate agent, tomudex.(230)  Although widely used to 
treat colorectal cancer, only about 20% of patients with advanced disease respond to 5-FU. A 
retrospective clinical trial suggests that high TS levels in colorectal cancer tissue are associated with 
either relative resistance to 5-FU or poor outcome following treatment.(231)  Popat et al. 
performed a systematic review of the literature and meta-analysis. For patients with advanced 
colorectal cancer, 13 studies containing a total of 887 patients were identified. Of these, 12 were 
regarded as suitable for pooling of data. All of the patients in these trials were treated with TS 
inhibitors. Following a pooled-analysis, the overall hazard ratio (HR) associated with high levels of 
TS for overall survival was 1.74 (95% CI, 1.34–2.26). The HR improved if the assay was performed on 
the metastatic lesion to 2.39 (95% CI, 1.43–4.01).(232) The findings of this meta-analysis are 
promising in correlating high TS expression with poor outcome in patients with colorectal cancer, 
particularly metastatic disease. The disadvantages are that there was evidence of publication bias in 
the studies on patients with advanced disease and at present there is no standardised assay for the 
measurement of TS. The EGTM do not recommend the use of TS as a prognostic marker at present.  
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1.11.7 MICROSATELLITE INSTABILITY (MSI)  
Testing for MSI has a number of potential applications in colorectal cancer including; use as a 
surrogate marker for hereditary non-polyposis colorectal cancer (HNPCC), determining prognosis 
and predicting response to adjuvant chemotherapy in patients with sporadic colorectal cancer. 
Popat et al carried out a systematic review and pooled analysis of published studies relating MSI to 
prognosis in patients with colorectal cancer. Following a pooled analysis, patients with MSI had a 
15% better outcome compared to those without MSI.(233) The reason for the association between 
MSI and favourable prognosis may be related to a protective role provided by functionally active 
lymphocytes which infiltrate MSI-positive colorectal cancer.(234) The EGTM Panel recommended 
that MSI testing be validated in a clinical trial prior to its use as a general prognostic marker.(210) 
1.11.8 P53 
The p53 tumour suppressor gene encodes a transcription factor that regulates the expression of 
genes involved in apoptosis, angiogenesis, cell cycle and genome maintenance.(235) p53 has been 
widely investigated both as a prognostic and as a therapy predictive marker in colorectal 
cancer.(236) A multiplicity of methods was used to determine p53 abnormalities, including 
immunohistochemistry to detect p53 protein or DNA sequence analysis to detect gene mutations. 
Munro et al. carried out a systematic review of published studies that investigated the relationship 
between p53 abnormality and outcome in patients with colorectal cancer.(68) In total, 168 eligible 
studies comprising survival data on 18,766 patients were identified. The key findings were as 
follows: 
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• Patients with abnormal p53 whether detected by immunohistochemistry (IHC) or DNA sequence 
analysis had an increased risk of death. The relative risk (RR) with IHC was 1.32 (95% CI, 1.23–1.42) 
and with sequence analysis was 1.31 (95% CI, 1.19 1.90). 
• p53 had no impact on outcome in patients treated with chemotherapy. 
• Abnormal p53 correlated with failure of response to radiotherapy in patients with rectal cancer 
(RR, 1.49, 95% CI, 1.25–1.77). 
Due to the modest impact on survival described, routine determination of p53 status is not 
recommended in colorectal cancer by the EGTM panel. However, new data which combines 
estimation of p53 and its downstream activator p21 may be useful in predicting outcome and 
response to 5FU chemotherapy.(237) 
1.11.9 K-RAS  
 K-ras is one of the most frequently mutated c-oncogenes in human cancer. It functions as a 
guanine nucleotide binding protein involved in signal transduction.(41) Conflicting data exist on the 
relationship between the presence of mutant K-ras and prognosis in patients with colorectal 
cancer. A recent meta-analysis involving 4268 patients from 42 different institutions concluded that 
only a specific type of K-ras mutation predicted poor outcome (patients with a G–T transversion at 
codon 12). This specific mutation was detected in less than 10% of tumours and was prognostic in 
Duke’s C but not in Duke’s B patients.(238) The EGTM panel do not recommend determination of K-
ras mutation for prediction of prognosis in patients with colorectal cancer. However, recent studies 
revealed that the presence of K-ras mutation predicts lack of response to EGFR inhibition in the 
treatment of metastatic colorectal cancer.(128) 
Protein expression in colorectal cancer                                     EM Tweedle 
 
  
68 
 
 
Table 1.11: EGTM recommendations for the use of common protein markers. 
 Duffy et al. 2007 (210) 
 
 
Marker Use for test EGTM recommendations 
Serum   
CEA Determining prognosis  May be used in combination with standard prognostic factors  
Surveillance following curative 
resection 
Should be used for stages II and III patients who may be 
candidates for liver resection or systemic treatment, should 
recurrence develop  
Monitoring therapy in advanced 
disease 
Should be used, especially in patients with non-evaluable disease 
using standard criteria. Measure prior to start of treatment and at 
2–3 monthly intervals during therapy; use in combination with 
imaging.  
CA19-9 Determining prognosis  Not recommended  
Surveillance following curative 
resection 
Not recommended  
CA 242 Determining prognosis  Not recommended  
TIMP-1 Determining prognosis  Not recommended  
 
Tissue   
TS Determining prognosis  Not recommended  
Response to chemotherapy  Not recommended  
MSI Determining prognosis  Not recommended  
Response to chemotherapy  Not recommended  
DCC Determining prognosis  Not recommended  
K-ras Determining prognosis  
Predicting response to EGFR inhibition 
Not recommended  
Should perform Kras-gene testing before prescribing EGFR 
inhibitors 
p53 Determining prognosis  Not recommended  
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1.12 AIMS AND OBJECTIVES 
 
Proteomic analysis using 2D electrophoresis is well established for the identification of differentially 
expressed proteins in human cancers. The procurement of enough tissue from small colorectal 
tumours with low numbers of cancer cells in the specimen is a particular challenge which has been 
resolved with laser-capture microdissection. Prognostic markers in small colorectal cancers will be 
more crucial in coming years as the National Colorectal Cancer Screening Program detects a higher 
frequency of small and early cancers. We have demonstrated an association between increasing 
stage at presentation and flat and depressed morphology in small cancers.  
In this study I compared dissected adenocarcinoma tissue according to morphology in small cancers 
with a view to identifying differential protein expression related to prognosis. Benign matched 
epithelial tissue was also dissected for comparison.  The aims of the project were as follows; 
 
i. To compare protein profiles of small colorectal tumours with matched normal colonic 
epithelium  
ii. To compare protein expression profiles of small polypoid and depressed adenocarcinoma 
tissue 
iii. To identify differentially expressed protein markers between the groups 
iv. To verify the protein markers using immunohistochemistry in a large group of up to 404 
microarrayed colorectal cancers (199 colon cancer and 205 rectal cancers) 
 
Protein expression in colorectal cancer                                     EM Tweedle 
 
  
70 
 
2. MATERIAL AND METHODS 
 
 
The methods utilised in this project were devised following similar work on pancreatic ductal 
adenocarcinoma by A Shekouh et al. in 2003 in the Division and Surgery and Oncology, University of 
Liverpool.(239)   
 
2.1 TISSUE PREPARATION 
Specimens of colon and rectum were obtained following surgery, with full ethical consent, and 
examined by a specialist pathologist. Areas of tissue, considered upon macroscopic viewing to 
contain malignant or non-malignant colon or rectum were selected. The samples were cryofixed in 
liquid isopentane (-160°C), cooled by liquid nitrogen and stored at -160°C in the Liverpool Tissue 
Bank, School of Cancer Studies, University of Liverpool. Microscopic examination of the specimens 
to verify the presence of malignant tumour was undertaken by a consultant histopathologist after 
5µm frozen sections were cut onto slides and stained with haematoxylin and eosin (H&E). Each 
tissue sample was assigned an anonymised code on the Liverpool Tissue Bank, database. A 
microscopic description of the sample, details of the formal histopathology report of the specimen 
and clinical details of the patients were recorded under this code.  
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2.2 IDENTIFICATION OF SAMPLES 
Samples for this study were identified by searching the Liverpool Tissue Bank database for tumours 
with a maximum diameter of 20mm. Fourteen frozen tumours samples, resected between 1995 – 
2006 met the criteria. A consultant histopathologist reviewed the H&E slides of these tumours and 
classified them according to morphology using the Japanese Research Society Classification. 
Matched normal colonic tissue was available in all cases except one, 148-01T. The morphology and 
histopathological characteristics of the samples are documented in Table 2.1. H&E stained sections 
of each tumour are presented in Figure 2.1. 
Liverpool 
Tissue Bank No 
Morphology Matched 
normal colon 
T-
stage 
N-
stage 
Dukes’ 
stage 
Differentiation 
104-06T Depressed  3 1 C Moderate 
194-00T Depressed  3 1 C Moderate 
084-06T Depressed  3 0 B Moderate 
149-01T Depressed  4 0 B Moderate 
264-05T Depressed  3 0 B Well 
097-99T Depressed  1 0 A Moderate 
075-00T Polypoid  4 1 C Moderate/poor 
233-00T Polypoid  1 0 A Moderate 
292-99T Polypoid  1 0 A Moderate 
259-01T Polypoid  1 0 A Well 
148-01T Flat  3 1 C Moderate 
054-96T Flat  3 0 B Moderate 
108-03T Flat  2 0 A Moderate 
010-03T Flat  2 0 A Moderate 
Table 2.1: Characteristics of frozen Tissue samples12 
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Figure 2.1: H&E stained frozen sections from tumour tissue according to morphology2 
Depressed                        Flat                      Polypoid 
1 
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2.3 SECTIONING AND STAINING OF SAMPLES 
Sectioning of frozen tissue was performed using a Bright OTF 5000 cryostat, (Huntingdon, 
Cambridgeshire, UK), with the chamber temperature set to -20°C. Frozen sections 8µm thick were 
cut and immediately transferred to BDH frosted slides which had been pre-cleaned using detergent, 
washed with deionised water and oven-dried at 40°C. Sections were fixed immediately in 70% 
ethanol for 1 minute and rested in deionised water for no more than 10 minutes. Complete 
protease inhibitor cocktail tablets (Roche) were added to all the solutions used for fixing and 
staining, except xylene, (one tablet/80 mL solution). Two separate staining protocols were 
employed; H&E staining and Methyl green staining (see below). H&E stained sections were viewed 
using an inverting microscope (Leica CME microscope) and reference photographs taken with a 
Nixon Coolpix 4500. The reference slides and images were used to guide LCM, which was 
performed on methyl green stained sections only. 
H & E staining protocol 
Ehrlich’s haematoxylin (BDH)       30 seconds 
Deionised water         wash  
Acid alcohol 0.3%         5 seconds 
Deionised water         wash 
Scott’s tap water (2% ammonium hydroxide)    5 seconds 
Deionised water         wash 
100% ethanol          15 seconds 
Eosin (Shandon Inc.)        15 seconds 
100% ethanol         30 seconds x3 
Xylene          1 minute x2 
Coverslips applied using DPX mountant (VWR Ltd.)  
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Methyl green staining protocol 
Violet-free methyl green (2% in deionised water)     30 seconds  
Deionised water         wash x 2 
70% ethanol          30 seconds  
95% ethanol          30 seconds  
100% ethanol         30 seconds x2  
Xylene          5 minutes x 2 
Sections air-dried in fume hood for 30-60 minutes 
 
2.4 LASER CAPTURE MICRODISSECTION 
Air-dried methyl green stained sections were microdissected using an Arcturus Pixcell II system 
(Arcturus, Mountain View, CA, USA) with a 7.5 µm laser beam. Arcturus CapsureTM  Macro LCM 
Caps were applied to the slides so that the thermoplastic film was in direct contact with the section. 
Images of the section at 10x and 100x were viewed on the attached monitor (Sony Triniton) and the 
laser beam targeted at the cells of interest. Power and pulse duration were adjusted to generate 
melting of the film at the desired point on firing the laser. The conditions were typically 60-80 mW 
and 3–4 ms respectively. Two cell types were captured; 
 Malignant epithelial cells (n=12; 4 depressed, 4 polypoid and 3 flat type) 
 Normal columnar epithelial cells (n=11, matched to tumour) 
An estimated 80,000 cells from each specimen were laser captured using an average of 40,000 
pulses. Approximately 7-10 hours of LCM was required to obtain this quantity. Microdissection caps 
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were inserted into 0.5 mL eppendorf tubes containing 50 µL of lysis buffer (7 M urea, 2 M thiourea, 
4% CHAPS, 40 mM Tris base) and the cells solubilised by inversion of the tubes for 30 min on ice, 
followed by vortex-mixing for 30s and a brief pulse-centrifugation at 16,000 rcf. Five tubes, each 
containing 50 µL of lysis buffer were used for each specimen. The lysates from each tube were 
pooled once sufficient material had been collected and stored at -80ºC.  
Two specimens, 194-00 and 097-99 were sectioned and subjected to laser capture, but insufficient 
material was acquired to proceed to SDS-PAGE due to the small volume of tumour in the sample. A 
third specimen 292-99 was found to be adipose tissue only on sectioning. All other specimens (n=11 
tumours and n=10 normal colon) underwent successful accrual of material by laser capture, with a 
minimum of 40,000 pulses. One specimen, 233-00T, underwent laser capture of 70,000 pulses in 
order to produce enough material for a second 2D gel. The first 2D gel of the same specimen had 
inadequate separation in the first dimension and identification of protein spots on the right hand 
side of the gel was impaired. A summary of the results of laser capture and the corresponding SDS-
PAGE gel produced are presented in Table 2.2. An example of the laser capture results obtained 
from the dissection of one small colorectal cancer with matching normal colonic tissue from the 
same patient is shown in Figure 2.2. 
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Table 2.2: Summary of Laser Capture Microscopy procurement of material for proteomic 
analysis13 
 
Liverpool Tissue 
Bank No 
Gel no Gel batch Number of pulses at 
LCM 
Morphology 
104-06T A 1 40,000 Depressed tumour 
104-06N B 1 40,000 Normal colon 
075-00T C 1 40,000 Polypoid tumour 
075-00N D 1 40,000 Normal colon 
010-03T E 1 40,000 Flat tumour 
010-03N F 1 40,000 Normal colon 
084-06T G 2 40,000 Depressed tumour 
084-06N H 2 40,000 Normal colon 
233-00T I 2 and 3 70,000 Polypoid tumour 
233-00N J 2 and 3 40,000 Normal colon 
054-96T K 2 40,000 Flat tumour 
054-06N L 2 40,000 Normal colon 
148-01T M 2 40,000 Flat tumour 
264-05T N 3 40,000 Depressed tumour 
264-05N O 3 40,000 Normal colon 
259-01T P 3 40,000 Polypoid tumour 
259-01N Q 3 40,000 Normal colon 
108-03T R 3 40,000 Flat tumour 
108-03N S 3 40,000 Normal colon 
149-01T T 3 40,000 Depressed tumour 
149-01N U 3 40,000 Normal colon 
194-00T - Not run 15,000 (insufficient) Depressed tumour 
097-99T - Not run 10,000 (insufficient) Depressed tumour 
292-99T - Not run 0 (no tumour) Polypoid tumour 
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2.5 ESTIMATION OF SAMPLE PROTEIN CONCENTRATIONS 
 
Conventional protein assays, such as the Bradford assay were incompatible with the LCM-derived 
samples due to the low concentrations of protein present, the small volume of lysate and the 
reducing agents present in the lysis buffer. A relative quantification was performed using a 
reference sample for comparison in order to ensure good quality gels with equal loading.  
 
Figure 2.2: Laser capture microdissection of colonic tumour and normal colonic 
epithelium form the same patient3 
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2.5.1 REFERENCE SAMPLE PREPARATION 
A protein lysate was prepared from an undissected polypoid colorectal tumour specimen by the 
addition of 32 whole tumour sections to 2mL of lysis buffer.  Viscosity was reduced by repeated 
passage through a 21 gauge needle. The lysate was centrifuged at 16,100 rcf for 60 minutes at -4ºC 
and the resulting supernatant aliquoted into 100µL lots and stored at -80ºC. Serial dilutions of the 
lysate were prepared by diluting 100µL of sample with an equal volume of lysis buffer to produce a 
1:2 solution. This process was repeated until a range of concentrations from 1:2 to 1:16 was 
obtained. Five samples from undiluted to 1:16, each 100 µL in volume, were run on separate two-
dimensional SDS-PAGE gels, as described below. The concentration of reference solution required 
to produce a high quality silver-stained gel image with an appropriate number of protein features 
(≈800 spots) was determined.  
2.5.2 COMPARISON WITH LCM-DERIVED SAMPLES 
The concentration of lysate found to produce the best quality 2D SDS-PAGE gel was then used as a 
reference against which relative sample protein concentrations of LCM procured material were 
estimated. During the two-dimensional phase, 100µL of the reference sample was used in 
comparison to 250µL of LCM-procured material. The 2.5 fold difference in sample volume was 
maintained during the one-dimension gel phase in order to facilitate a direct comparison. Two-fold 
dilution series, from undiluted to a 1:16 dilution, of the LCM-procured samples were prepared to a 
volume of 10µL per lane. A similar two-fold dilution series was prepared for the reference sample 
to a volume of 4µL per lane. Three µL of sample loading buffer (0.48M Tris- HCl, pH 6.8, 50% w/v 
glycerol, 10% w/v SDS, 10% DTT, trace bromophenol blue) was added to each sample. All samples 
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were made up to 15µL per lane with lysis buffer and heated at 100ºC for 10 min. Protein samples 
were run on small format Tris-glycine SDS-PAGE gel consisting of a 10% separating gel (10% w/v 
acrylamide, 0.375M Tris pH 8.8, 0.1% w/v SDS, 0.1% w/v ammonium persulfate) and 5% stacking gel 
(5% w/v acrylamide, 0.125M Tris pH 6.8, 0.1% w/v SDS, 0.1% w/v ammonium persulfate) at 90V for 
15 minutes, then 150V until completion. Silver staining was carried out using the same protocol as 
the two-dimensional gels, (see silver staining section). The relative protein concentration of the 
LCM-procured samples was estimated by comparison to the reference samples. Dilution of the 
laser-captured samples was then performed where necessary in order to obtain the optimal 
concentration for two-dimensional electrophoresis.  
1D small format SDS-PAGE gels were produced for relative protein quantification of all laser 
captured samples, (n=21), an example is shown in figure 2.3. On comparison of the protein band 
intensity between the reference standard and the laser captured material, all but two laser 
captured samples showed a match with the 1 in 2 dilution. In these instances half of the total 
sample volume, (125µL) was used for 2D SDS-PAGE. In one case, 010-01T the undiluted sample 
showed a match with the reference and therefore the entire 250µL sample was utilised. In the 
second case, (sample 233-00T) the staining was too weak at the 1:2 dilution and too strong at the 
1:1 dilution to match the reference standard. In this case three-quarters of the sample volume was 
utilised, (188µL).  
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2.6 IEF AND SECOND DIMENSION SDS-PAGE 
 
2.6.1 IMMOBILISED PH GRADIENT (IPG) STRIP REHYDRATION 
IPG rehydration solution was prepared by adding 2% v/v IPG buffer (containing carrier ampholytes, 
pH range 3–10 non-linear; Amersham Biosciences, Uppsala, Sweden) and 2.8% w/v DTT to a stock 
solution containing 9 M urea, 2% CHAPS and a trace of bromophenol blue. Protein samples for 
analysis were made up to a volume of 350µL using IPG rehydration solution. Each 350µL sample mix 
was used to passively rehydrate one IPG focusing strip, (180mm, pH range 3–10, non-linear; 
Amersham Biosciences) in an IPG DryStrip reswelling tray at room temperature overnight. 
 
   1:2    1:4    1:8    1:16    1:1    1:2     1:4      1:8 
Figure 2.3:  Relative quantification of laser captured material. Lanes outlined in red represent reference 
standard. Lanes outlined in green correspond to matched dilution of LCM material4 
 
 
 
1:2    1:4     1:8    1:16      1:1     1:2      1:4      1:8 
  REFERENCE                 LCM NORMAL REFERENCE             LCM TUMOUR 
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2.6.2 ISO-ELECTRIC FOCUSING ( IEF)  
Rehydrated strips were transferred to the Multiphor II system (Amersham Biosciences) for focusing. 
A linear gradient of 0–500V was initially applied to the strips over 1 minute, followed by 500-3500V 
linearly over 90 minutes and finally 3500V over 5 hour 40 minutes. The total running time was 7 
hours 11 minutes, after which the strips were removed and stored in separate sealed tubes at -
80ºC. 
2.6.3 EQUILIBRATION AND SECOND DIMENSION SEPARATION 
12% acrylamide gels were cast and left to polymerise for at least 5 hours. Gels were then covered 
with cling film and refrigerated at 4ºC for no longer than 48 hours prior to use.   
Prior to the second dimension separation, strips were equilibrated in two successive buffers, each 
consisting of a stock solution comprising 1.5 M Tris-HCl (pH 8.8), 6 M urea, 34.5% v/v glycerol, 2% 
w/v SDS and a trace of bromophenol blue. To the first buffer was added 1% w/v DTT, while the 
second buffer incorporated 2.5% w/v iodoacetamide. Each rehydrated IPG strip was equilibrated 
for 15 minutes in 10mL of buffer 1, then a further 15 minutes in 10mL of buffer 2, with continuous 
agitation throughout. Strips were then rinsed in electrophoresis buffer (25mM Tris-base, 192mM 
glycine and 0.1% w/v SDS), applied to 12% acrylamide gels and sealed with melted agarose (0.5% 
w/v agarose in electrophoresis buffer containing a trace of bromophenol blue). Electrophoresis was 
carried out using an Ettan Dalt II apparatus (Amersham Biosciences) at 25ºC, with initial separation 
at a constant 5 W per gel for 30 min followed by 20 W per gel until the dye front had migrated 
approximately 18 cm. The total run time was typically 4 – 4.5 hours. Once electrophoresed, gels 
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were transferred to polypropylene containers and immersed in 250-300ml fixative solution (50% 
ethanol, 12% acetic acid) prior to staining.  
 
2.7 STAINING OF POLYACRYLAMIDE GELS 
 
2.7.1 COLLOIDAL COOMASSIE BLUE STAINING 
Coomassie blue staining was performed according to Neuhoff et al. Gels were incubated for three 
hours in a 4:1 mixture of staining solution (0.1% w/v Coomassie brilliant blue G250 dye, 2% 
orthophosphoric acid, 10% w/v ammonium sulphate, 25% methanol). Gels were washed to remove 
excess background staining in a wash solution containing 10% acetic acid and 25% methanol 
solution for 4 hours. Gels were scanned as described in scanning and analysis section and stored in 
25% methanol at 4°C. 
2.7.2 SILVER STAININ G  
Two silver-staining protocols were used in order to determine the most sensitive and consistent 
method for detecting protein. Protocol 1 was described by Yan et al.(240) and protocol 2 was 
described by Blum et al.(241) Both protocols used formaldehyde as the reducing agent and were 
compatible with the subsequent use of MALDI-ToF for protein identification. Gels were removed 
from fixative solution (50% ethanol, 12% acetic acid) and incubated in a series of staining solutions 
as outlined below. Gentle agitation of the gels on a rotary platform was used throughout.  
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Protocol 1 (Yan et al; 2000) 
SENSITIZATION SOLUTION        30 MINUTES  
(30% ethanol, 0.2% sodium thiosulfate, 0.83M sodium acetate) 
DISTILLED WATER          5 MINUTES X 3 
SILVER STAINING SOLUTION         20 MINUTES 
(0.25% w/v silver nitrate) 
DISTILLED WATER         20 SECONDSx2 
DEVELOPING SOLUTION         6-10 MINUTES  
(2.5% w/v sodium carbonate, 0.04% v/v formalin (37% formaldehyde).  
Development was carried out in glass containers until protein spots appeared. 
STOP SOLUTION           10 MINUTES 
50mL of fixative solution (50% ethanol, 12 % acetic acid) was added to terminate development once background 
started to darken. 
DISTILLED WATER          5 MINUTES X 3 
Protocol 2 (Blum et al; 1987) 
WASH            10 MINUTES x 3 
(30% ethanol)      
SENSITIZING SOLUTION          1 MINUTES 
(0.8 mM sodium thiosulfate) 
SILVER STAINING SOLUTION        40 MINUTES 
(11.8mM silver nitrate, 0.02% formaldehyde) 
DISTILLED WATER         20 SECONDSx2 
DEVELOPING SOLUTION         6-10 MINUTES 
(566 mM Na2CO3, 0.02% formaldehyde, 0.02 mM sodium thiosulfate). 
Development was carried out in glass containers until protein spots appeared. 
STOP SOLUTION           10 MINUTES 
50mL of fixative solution (50% ethanol, 12 % acetic acid) was added to terminate development once background 
started to darken. 
WASH (30% ethanol)         5 MINUTES x 3 
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2.7.3 GALLYAS PROTEIN STAINING OF SDS-PAGE GELS 
This protocol, described by Sorensen et al. was based on procedures used previously for 
histochemical intensification of silver staining.(194) The Gallyas staining solution was prepared by 
mixing two stock solutions, A (5% w/v sodium carbonate) and B (0.2% ammonium nitrate, 0.2% 
silver nitrate, 1% tungstosilicic acid and 0.5% v/v formalin (37% formaldehyde)), in a 1:1 ratio whilst 
stirring continuously. Silver-stained gels were washed in distilled water for 3x10 minutes, and then 
sensitized with 2% sodium acetate for 2 x15 minutes. Sensitized gels were incubated in freshly 
prepared Gallyas solution to intensify silver staining. Development was stopped with 10% acetic 
acid once the background began to darken, typically 3-6 minutes.  
 
2.8 SCANNING AND ANALYSIS OF GELS 
 
Gel images were obtained using a GS-800 scanner, at 400 dpi resolution using the green channel for 
silver-stained gels and the red channel for Coomassie blue stained gels (Bio-Rad, Hercules, CA, 
USA). Data were acquired using PDQuest software (Bio-Rad, V6.2). QuantityOne software was used 
to crop the raw gel images to the size 176 x 176mm. The cropped images were saved in TIFF format 
at 16 bit and imported into Progenesis SameSpot software (Nonlinear Dynamics, Newcastle, UK) for 
analysis.  Protein spot identification was performed by careful visual comparisons of the gels and by 
using SameSpot spot recognition software.  
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2.9 IDENTIFICATION OF PROTEINS BY LC-MS/MS 
 
Silver-stained gels were matched with well-loaded Coomassie-stained gels of undissected tumour 
and normal colonic tissue lysate. Protein spots of interest were identified and referenced to the 
correct spot on the Coomassie stained gels (Figure 2.8). Spots were excised and trypsin digested 
essentially according to the method of Courchesne and Patterson.(242) Briefly, the excised gel 
spots were washed in 50% v/v acetonitrile/ 25 mM w/v ammonium bicarbonate, pH 7.8, and dried 
in a SpeedVac. The dried gel spots were rehydrated with 4–10μL digestion buffer (10μg/mL 
modified sequencing grade trypsin in 25mM NH4HCO3) and incubated overnight at 37°C. The 
resulting peptides were extracted by the addition of 4μL water followed by 7μL 30% v/v 
acetonitrile/0.1% v/v TFA with mixing and brief centrifugation. The supernatants were recovered 
and liquid chromatography with tandem mass spectrometry, LC-MS/MS was used for analysis. The 
tryptic digest was delivered into a QSTAR® Pulsar i hybrid mass spectrometer (Applied Biosystems) 
by automated in-line RP-LC (integrated LCPackings System, 5mm C18 μ-precolumn cartridge and 
75μm x 15cm C18 column, Dionex, Camberley, UK) via a nano-electrospray source head and a 
10mm id PicoTip (New Objective, Woburn, USA). A gradient from 5% ACN/0.05% TFA v/v to 48% 
ACN/0.05% TFA v/v in 60 min was applied at a demanded flow rate of 200nL/ min, and MS and 
MS/MS spectra were acquired automatically in positive ion mode using information-dependent 
acquisition (Analyst® software, Applied Biosystems). Data were submitted to MASCOT and the NCBI 
database was searched with the MS tolerance set to 1.2Da and the MS/MS tolerance to 0.6Da, with 
carboxamidomethyl as a variable modification.  
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Figure 2.4: Matched laser-captured silver-stained 2D gel of tumour tissue lysate to undissected 
Coomassie stained 2D gel of same tumour tissue. Lines converge on protein spot of interest 
(circled) and were referenced to other protein spots  (arrowed) in order to accurately locate. 5 
 
2.10 CELL LINES AND WESTERN BLOTTING 
 
2.10.1 CELL LINES AND CELL CULTURE 
The human colonic adenocarcinoma cell line, SW480 and the human rectal adenocarcinoma cell 
line, SW837 were obtained from the European Collection of Cell Cultures (Salisbury, UK). Cells were 
maintained in L15 medium supplemented with 10% foetal calf serum, 2mM L-glutamine and 
5Ag/mL streptomycin (Sigma, Poole, United Kingdom) at 37°C in a humidified atmosphere of 5% 
CO2 (SW480) or 0% CO2 (SW837).  
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2.10.2  1D WESTERN BLOT 
Confluent cells were collected and resuspended in buffer containing 0.1M Tris-HCl (ph 6.8), 2% SDS 
supplemented with complete protease inhibitors (Roche Diagnostics, Indianapolis, USA) and 
sonicated on ice. Protein was quantified using the Bicinchoninic Acid (BCA) method, and an 
identical mass of protein was loaded in each lane of a small format SDS-Tris HCl gel (15% separating 
and 4% stacking gels) and subject to electrophoresis at a constant voltage of 150V (Pierce 
Biotechnology, Rockford, USA). Proteins were electrophoretically transferred to Hybond 
nitrocellulose membranes at 100V for 60 minutes (Amersham Biosciences, Buckinghamshire, UK), 
and membranes were blocked in 5% milk in PBS for 60 minutes before application of primary 
antibodies.  Membranes were washed thrice in PBS containing 0.1% Tween20 for 20 minutes 
followed by incubation with a horseradish peroxidase–conjugated secondary antibody. After 
extensive washing in PBS containing 0.1% Tween20, protein-antibody complexes conjugated with 
peroxidase were visualized with Western Lighting chemiluminescence reagent (Perkin-Elmer Life 
Sciences, Boston, MA). 
2.10.3  2D WESTERN BLOT 
Confluent cells were collected and resuspended in lysis buffer as for 1D western blot analysis. 
Whole tumour lysate was prepared as per section 2.5.1. Protein was quantified using the BCA 
method, and an identical mass (100µg) of protein was loaded onto each gel with two identical gels 
run for every sample. Gels were prepared for 2D electrophoresis with the exception that the 
second dimension run was stopped at 16cm. Proteins were electrophoretically transferred to 
Hybond nitrocellulose membranes at 400V for 2.5 hours (Amersham Biosciences, Buckinghamshire, 
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UK), then blocked in 5% milk in PBS for 60 minutes. Membranes were incubated with primary 
antibody for either 1 hour at room temperature or overnight at 4ºC. Protein transfer was verified 
using ponceau stain. Membranes were washed thrice in PBS containing 0.1% Tween20 for 20 
minutes followed by incubation with a horseradish peroxidase–conjugated secondary antibody. 
After extensive washing in PBS containing 0.1% Tween20, protein-antibody complexes conjugated 
with peroxidase were visualized with Western Lighting chemiluminescence reagent (Perkin-Elmer 
Life Sciences, Boston, MA). 
Antibody Indication Dilution Manufacturer 
Anti-SH3 binding glutamic acid rich 
protein like 3  
Western blotting 1:10 Gifted from Dr Q Zhang 
Anti-peroxiredoxin 6 Western blotting 1:2000 Santa Cruz Biotechnology 
Anti-peroxiredoxin 6-SO4  Western blotting 1:1000 Santa Cruz Biotechnology 
Cofilin1 Western blotting 1:10,000 Abcam (Cambridge Biosciences) 
Cofilin-phospho(ser3) Western blotting 1:50 Abcam (Cambridge Biosciences) 
Table 2.3: Primary antibodies used in Western blotting14 
 
2.11  VALIDATION OF DIFFERENTIALLY EXPRESSED PROTEINS  
 
2.11.1 GENERATION OF PARAFFIN-EMBEDDED FORMALIN-FIXED COLORECTAL CANCER TISSUE 
Six purpose-built colorectal cancer tissue microarrays (TMAs) were constructed, containing 2-6 
cores from 404 independent cases of adenocarcinoma in addition to 36 cores of normal colon and 
16 cores each of normal kidney, liver and testes, which served as control tissues. TMAs were 
constructed in the Liverpool Tissue Bank, University of Liverpool between 2005 and 2008. All 
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patients on the arrays had a signed consent form for the use of their tissue for research and ethical 
approval from the Knowsley and St Helens ethics committee had been given. Clinicopathological 
data including age, gender, site of tumour, stage (according to TNM and the American Joint 
Committee on Cancer, AJCC guidelines(243)) was obtained from hospital computer records. All data 
was recoded on the secure Liverpool Tissue Bank database and was provided courtesy of Mrs Ann 
Anderson. 
2.11.2 IMMUNOHISTOCHEMISTRY AND CO-IMMUNOFLUORESCENCE 
Staining of the colorectal microarray was undertaken as follows; briefly 5µ thick sections of the 
array were deparaffinised in xylene and rehydrated through alcohol to distilled water. Peroxidase 
block was performed by incubating with 15% methanol for 12 minutes. Antigen retrieval was 
perormed by pressure-cooking the slides in 10mmol EDTA solution, (pH 7.0), for 3 min. For 
immunohistochemical staining, slides were incubated for 60 min with primary antibodies in 
dilutent. These slides were then rinsed in TBS and visualisation achieved by incubating with a 
horseradish peroxidase conjugated secondary antibody for 30 min followed by diaminobenzidine 
for 10 min. Negative controls were incubated with conjugated secondary antibody only. Slides were 
counterstained with haematoxylin for 30s and coverslips mounted with DPX mountant, (BDH). 
Detailed protocol outlined in box (page 89) provided courtesy of Mr Andrew Dodson, 
Histopathology Department, Royal Liverpool University Hospital. 
Co-immunofluorescence was performed on duplicate whole formalin-fixed colorectal tumour 
sections. After antigen retrieval with heat treatment as described, the slides were incubated with 
primary antibodies overnight at 4°C. Visualisation was achieved using FITC-labelled donkey anti-
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mouse (30mg/mL; Santa Cruz Biotechnology) and TRITC labelled swine anti-rabbit (25mg/mL; 
DakoCytomation) secondary antibodies for 60 min at room temperature. DAPI was used as the 
counterstain.(244) 
 
 Immunohistochemistry protocol 
Slide preparation  
De-paraffinisation was carried out in xylene for 15-30 minutes. Rehydration with100% ethanol, 70% 
ethanol then distilled water was carried out for 5 minutes each. Peroxidase block was performed by 
incubating with 15% methanol for 12 minutes.  
Antigen retrieval 
Antigen retrieval was performed by pressure-cooking the slides in 10mM EDTA (pH 7.4) for 3 
minutes, followed by cooling in distilled water.  
Primary antibody  
The primary antibody was diluted in ChemoMate (DAKO) at volume of 500l per slide.  Slides were 
incubated overnight at 40 C then washed with Tris buffered saline x 3. 
Secondary Antibodies and Substrate 
Pre-diluted anti-mouse horse radish peroxidase conjugated secondary antibody from 
DakoCytomation kit K4010 was applied for 1 hour followed by 3 washes with Tris buffered saline. 
20µl of liquid DAB + Chromogen were mixed gently with 1ml of buffer provided in the 
DakoCytomation kit K4010 to produce the substrate diaminobenzidine in which the slides were 
incubated for 10 minutes.   
Haematoxylin staining  
Counterstaining was performed using Erlich’s haematoxylin for 30 seconds, followed by bluing 
agent (2% ammonium hydroxide solution) for 5s. Slides were dehydrated with 100% ethanol for 3 x 
1 minute and xylene for 2 x 1 minute. Coverslips were mounted with D.P.X. mountant (BDH).  
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Antibody Indication Dilution Manufacturer 
Polyclonal goat anti-S100A8 Immunohistochemistry 
Immunofluorescence 
1:2000 Santa Cruz Biotechnology 
Polyclonal rabbit anti-S100A9 Immunohistochemistry 
Immunofluorescence 
1:4000 Santa Cruz Biotechnology 
Monoclonal anti-SMAD4 antibody  Immunohistochemistry 1:50 Santa Cruz Biotechnology 
Monoclonal mouse anti-CD68  Immunofluorescence 1:200 Dako 
Monoclonal mouse anti-CD14 Immunofluorescence 1:100 Novocastra 
Monoclonal mouse anti-HSP27 Immunohistochemistry 1:50 Novocastra 
Cofilin1 Immunohistochemistry 1:40,000 Abcam 
Cofilin-phospho(ser3) Immunohistochemistry 1:75 Abcam 
Table 2.5: Primary antibodies in immunohistochemistry and co-immunofluorescence15 
 
2.11.3 MICROARRAY SCORING AND ANALYSIS  
All microarrays were scored by at least two independent scorers, one of whom was a consultant 
histopathologist (Dr B Azadeh or Dr M Terlizzo). A scoring system was agreed by both pathologists 
after scrutinizing images from the first colorectal cancer tissue microarray. Scores were then 
determined independently in separate locations. I compiled and compared the scores from myself 
and both pathologists; cores with discrepancies in HSP27 intensity and distribution (approximately 
10% of cores) were listed for review of the images and discussion. Dr Terlizzo and I viewed the 
slides on a dual-headed microscope linked directly to her computer; this allowed Dr Azadeh to view 
emailed images of the cores simultaneously on his office computer. A consensus score for the 
discrepent cores was allocated following discussion between Dr Terlizzo and Dr Azadeh by 
telephone. 
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Smad4 expression was graded using a 0-3 score for both cytoplasmic and nuclear intensity of 
staining. The extent of both S100A8 and S100A9-expressing cellular infiltrate in the stroma was 
graded using a similar 0-3 score. In addition, the number of positive S100A8 and S100A9 cells per 
field at 40x magnification was also determined in each tumour core. Mean S100A8 and S100A9 cell 
counts were obtained by averaging the number of positive stromal cells across all the tumour cores 
scored for each patient. HSP27 was scored using intensity of staining (using a 0-3 scale) and the 
extent of HSP27 staining (0-3 according to the percentage of positive tumour; 0: <5% positive cells, 
1: 5-30%, 2: 30-70% and 3: >70%). A combined score or 0-9 HSP27 index was calculated by 
multiplying the intensity by the extent of staining for every patient. 
2.11.4 STATISTICAL ANALYSIS  
Comparisons were made using the non-parametric Fisher’s exact test (2 groups), or chi-squared test 
(>2 groups). Life tables and Kaplan-Meier curves were used to evaluate cancer-specific survival; p-
values were calculated using the log rank test. Survival was measured from date of diagnosis to 
date of death, counting death from colorectal cancer as the end point; deaths from other causes 
were censored in the analysis. If no event occurred, the date of last follow up was used as the end 
point. Multivariate Cox regression analysis was conducted using stepwise forward selection starting 
with the most significant variable on univariate analysis and including variables with a P-value of 
<0.10. All analyses were performed using Statview Version 5.01 (SAS Institute Inc). A P -value of less 
than 0.05 was considered significant. 
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3. RESULTS 
 
3.1 SILVER-STAINING OF GELS 
 
3.1.1 COMPARISON OF SILVER-STAINING PROTOCOLS 
Small format Tris-glycine SDS-PAGE gels were prepared as described in section 2.5.2. Reference 
protein solution was loaded onto the gels in serial dilutions including undiluted, 1:2, 1:4, 1:8 and 
1:16, then repeated on the same gel to give a total of 10 lanes, and gels run as previously described. 
After fixing overnight in 50% ethanol and 12% acetic acid solution, the gels were transected to yield 
two identical sections each comprising 5 lanes. One gel half was silver-stained using protocol 1, the 
other side silver-stained with protocol 2 at the same time, Section 2.7.2. The experiment was 
repeated with the two other gels. The six gel-halves were scanned as described in section 2.8 and 
the quality and reproducibility of the images compared. Further comparison was made using the 
2D-SDS polyacrylamide gels.  Serial dilutions of the reference protein sample from 1:2 to 1:16 were 
run in duplicate, (as described in section 2.6) giving a total of eight gels.  Protocol 1 was used to 
stain one set of four gels and protocol 2 used to stain the duplicate set. The stained gels were 
scanned as described in section 2.8 and the images compared for sensitivity and reproducibility. 
Protocol 2 (Blum et al.) was found to give more consistent results with less background staining 
with 1D SDS-PAGE than protocol 1 (Yan et al.); figure 3.1. Following 2D SDS-PAGE, a greater number 
of protein spots were seen at each dilution using protocol 2 than protocol 1, figure 3.2. Blum et al. 
was judged to be more sensitive for the detection of protein and was the staining protocol adopted 
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for all further silver staining. The Gallyas technique (section 2.7.3) was applied to the previously 
silver-stained, small format 1D SDS gels described in the same section, see Figure 3.3. Further 
darkening of the protein bands was seen in all cases; however, a disproportionate darkening of the 
background rendered the gels difficult to interpret. Furthermore, successive incubations of the gels 
in the Gallyas solution caused them to become brittle and easily damaged. No further Gallyas 
staining was performed. 
3.1.2 DETERMINATION OF REFERENCE PROTEIN STANDARD 
The methodology for visualisation of protein spots was optimised by use of protocol 2, (Blum et al) 
for silver-staining without Gallyas enhancement. Reference protein gels were produced in serial 
dilutions from 1:2 to 1:16 concentration, as described. The reference standard was determined by 
the lowest concentration of reference protein solution which gave the optimal number of protein 
spots, (>800), without excessive darkening of the background. The 1:4 dilution was adopted as the 
reference standard (Figure 3.4). 
Protein expression in colorectal cancer                                     EM Tweedle 
 
  
95 
 
 
A B 
C D 
E F 
Figure 3.1: Reference protein solution produced from whole tumour lysate (section 2.5.1)  in 
serial dilutions on small format SDS gels. A, C, E stained with protocol 2, (Blum at el). B, D, F 
stained with protocol 1, (Yan et al). 6 
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Figure 3.2: Reference protein solution produced from whole tumour lysate (section 2.5.1) in 
serial dilutions on 2D SDS gels. 1:2 dilution; gels A&B, (A stained protocol 1, B stained protocol 
2). 1:4 dilution; gels C&D, (C stained protocol 1, D stained protocol 2). 1:8 dilution; gels E&F, (E 
stained protocol 1, F stained protocol 2). 1:16 dilution; gels G&H, (G stained protocol 1, H 
stained protocol 2). 7 
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Figure 3.3: Silver-stained 1D gels of reference protein solution in serial dilutions subject 
to further staining using Gallyas protocol. Gel A corresponds to gel E (Figure 3.1). (i) prior 
to Gallyas staining; (ii) following Gallyas staining. Gel B corresponds to gel F (Figure 3.1) (i) 
prior to Gallyas staining; (ii) following Gallyas staining. Gel C corresponds to gel C (Figure 
3.1). (i) prior to Gallyas staining; (ii) following Gallyas staining. Gel D corresponds to gel D 
(Figure 3.1) (i) prior to Gallyas staining; (ii) following Gallyas staining.  8 
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Figure 3.4: 2D SDS-PAGE of reference standard produced from whole tumour lysate (section 
2.5.1) at 1:4 dilution. Optimized staining protocol applied (Blum et al). Greater than 800 protein 
spots are visible without over-staining of the background gel indicating that this concentration of 
lysate is sufficient to produce a good quality 2D gel. 9 
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3.2 GEL ANALYSIS 
 
Twenty-one gels were produced from laser-captured frozen tissue, eleven samples of colorectal 
tumour and ten matched samples of normal colonic epithelium. One gel, sample 010-01T, (a 
morphologically flat, T1/N0 tumour), had insufficient protein loading to produce a good quality gel. 
This was in some part due to the small fragment of frozen material available for laser capture; not 
enough residual tissue remained for further microdissection. A total of 10 usable small tumours 
were compared with matched normal colonic epithelium in 9 cases. Gel images were analysed 
using proteomic software Progenesis SameSpots (Nonlinear Dynamics, Newcastle, UK). Samespots 
allows the manual mapping on gel images onto other gels thus facilitating comparison of spot 
patterns. A merged gel image constructed from the mapped images of each gel in the group was 
created; the software then identified differentially expressed spots between the groups of gels. Five 
merged images were created from this analysis; tumour (n=11 gels), normal (n=10 gels), depressed 
tumour (n=4 gels), flat tumour (n=3 gels), polypoid tumour (n=4 gels), (Figure 3.5). The software 
compared morphologically different tumours to produce a list of 30-40 variably-expressed spots 
(ringed in blue). Visual comparison of identified spots was performed by two independent 
observers (Dr Eithne Costello and myself). Approximately two thirds of spots were short-listed were 
excluded due to inaccurate mapping of spots between gels and artifact or background confounding 
the analysis. A final list of spots with genuine differential expression was drawn up with priority 
given to those proteins which shown variable expression in different morphology tumours and in 
tumour compared to normal tissue. Spots of interest after gel comparison are marked on the gel in 
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figure 3.6. Figures 3.7-3.12 illustrates each spot as expressed in individual gels, including 
comparison of spot volume determined by Samespots Progenesis software.  
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Figure 3.5: Merged images of silver-stained gels created for spot analysis by Samespot software. A: Tumour (n=10) B: Normal colon 
(n=9) C: Depressed tumours (n=4) D: Flat tumours (n=3) E: Polypoid tumours n=3 10
A B 
C D E 
TUMOUR NORMAL 
DEPRESSED FLAT POLYPOID 
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Figure 3.6: 2D gel of laser-captured tumour lysate (sample 233-00T) depicting nine spots found to 
be differentially expressed and selected for identification using tandem mass spectrometry. Spots 
were selected after analysis of all tumour gels using Samespots software and two observer visual 
comparison. Tumours with different morphologies were compared and the findings referenced 
against matched normal gels. Spots circled in dashed lines were also selected for identification as 
post-translational modifications of proteins already ringed on the gel. 11 
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Figure 3.7: Expression of differentially expressed 
proteins (spots 1 and 2); evaluation in individual 
samples. A: Tumour gel (233-00T). Box marks area 
of gel showing spots 1 and 2. B: Sections of 
individual tumour and matched normal gels (boxed 
area in A) showing expression of spot 1 (ringed in 
red) and spot 2 (ringed in blue) for visual 
comparison. Gel numbers correspond to the 
following samples; Tumours (T): Depressed-type 
(1=104-06T, 2=084-06T, 3=264-05T, 4=149-01T); 
flat-type (5=054-96T, 6=148-01T, 7=108-03T); 
polypoid-type (8=075-00T, 9=233-00T, 10=259-01T). 
Normal tissue (N) (11=104-06N, 13=084-06N, 
16=264-05N, 19=149-01N, 15=054-96N, 18=108-
03N, 12=075-00N, 14=233-00N, 17=259-01N). C and 
D: Volume of spot 1 (Chart C) and spot 2 (Chart D) 
quantified by Samespots software in each gel 
(numbered as in B). Additional bars (T, D, F and P) 
show mean spot volume across a number of gels, 
shown with corresponding error bars. T=mean spot 
volume all tumours (gels 1-10); D=mean spot 
volume in depressed tumour gels (gels 1-4), F=mean 
spot volume in flat tumours (gels 5-7), P= mean spot 
volume in polypoid tumours (gels 8-10). P values 
compare mean spot volume across gels D, F and P. 
The fold increase from lowest to highest mean spot 
volume is shown on each chart.12 
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Figure 3.8: Expression of differentially expressed 
proteins (spot 3); evaluation in individual 
samples. A: Tumour gel (233-00T). Box marks area 
of gel showing spot 3. B: Sections of individual 
tumour and matched normal gels (boxed area in 
A) showing expression of spot 3 (ringed in green) 
for visual comparison. Gel numbers correspond to 
the following samples; Tumours (T): Depressed-
type (1=104-06T, 2=084-06T, 3=264-05T, 4=149-
01T); flat-type (5=054-96T, 6=148-01T, 7=108-
03T); polypoid-type (8=075-00T, 9=233-00T, 
10=259-01T). Normal tissue (N) (11=104-06N, 
13=084-06N, 16=264-05N, 19=149-01N, 15=054-
96N, 18=108-03N, 12=075-00N, 14=233-00N, 
17=259-01N). C: Volume of spot 3 quantified by 
Samespots software in each gel (numbered as in 
B). Additional bars (T, D, F and P) show mean spot 
volume across a number of gels, shown with 
corresponding error bars. T=mean spot volume all 
tumours (gels 1-10); D=mean spot volume in 
depressed tumour gels (gels 1-4), F=mean spot 
volume in flat tumours (gels 5-7), P= mean spot 
volume in polypoid tumours (gels 8-10). P values 
compare mean spot volume across gels D, F and 
P. The fold increase from lowest to highest mean 
spot volume is shown on the chart.  13 
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Figure 3.9: Expression of differentially expressed 
proteins (spots 4A and 4B); evaluation in 
individual samples. A: Tumour gel (233-00T). Box 
marks area of gel showing spots 4A and 4B. B: 
Sections of individual tumour and matched normal 
gels (boxed area in A) showing expression of spot 
4A (ringed in blue) and spot 4B (ringed in dashed 
blue) for visual comparison. Gel numbers 
correspond to the following samples; Tumours (T): 
Depressed-type (1=104-06T, 2=084-06T, 3=264-
05T, 4=149-01T); flat-type (5=054-96T, 6=148-01T, 
7=108-03T); polypoid-type (8=075-00T, 9=233-00T, 
10=259-01T). Normal tissue (N) (11=104-06N, 
13=084-06N, 16=264-05N, 19=149-01N, 15=054-
96N, 18=108-03N, 12=075-00N, 14=233-00N, 
17=259-01N). C: Volume of spot 4A quantified by 
Samespots software in each gel (numbered as in 
B). Additional bars (T, D, F and P) show mean spot 
volume across a number of gels, shown with 
corresponding error bars. T=mean spot volume all 
tumours (gels 1-10); D=mean spot volume in 
depressed tumour gels (gels 1-4), F=mean spot 
volume in flat tumours (gels 5-7), P= mean spot 
volume in polypoid tumours (gels 8-10). P values 
compare mean spot volume across gels D, F and P. 
The fold increase from lowest to highest mean 
spot volume is shown on the chart.14 
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Figure 3.10: Expression of differentially expressed 
proteins (spots 5, 6 and 7); evaluation in individual 
samples. A: Tumour gel (233-00T). Box marks area 
of gel showing spots 5, 6 and 7. B: Sections of 
individual tumour and matched normal gels (boxed 
area in A) showing expression of spot 5 (ringed in 
pink) and spot 6 (ringed in dashed pink) and spot 7 
(ringed in purple) for visual comparison. Gel 
numbers correspond to the following samples; 
Tumours (T): Depressed-type (1=104-06T, 2=084-
06T, 3=264-05T, 4=149-01T); flat-type (5=054-96T, 
6=148-01T, 7=108-03T); polypoid-type (8=075-00T, 
9=233-00T, 10=259-01T). Normal tissue (N) 
(11=104-06N, 13=084-06N, 16=264-05N, 19=149-
01N, 15=054-96N, 18=108-03N, 12=075-00N, 
14=233-00N, 17=259-01N). C and D: Volume of spot 
5 (Chart C) and spot 7 (Chart D) quantified by 
Samespots software in each gel (numbered as in B). 
Additional bars (T, D, F and P) show mean spot 
volume across a number of gels, shown with 
corresponding error bars. T=mean spot volume all 
tumours (gels 1-10); D=mean spot volume in 
depressed tumour gels (gels 1-4), F=mean spot 
volume in flat tumours (gels 5-7), P= mean spot 
volume in polypoid tumours (gels 8-10). P values 
compare mean spot volume across gels D, F and P. 
The fold increase from lowest to highest mean spot 
volume is shown on each chart.  15 
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Figure 3.11: Expression of differentially expressed 
proteins (spots 8A and 8B); evaluation in 
individual samples. A: Tumour gel (233-00T). Box 
marks area of gel showing spots 8A and 8B. B: 
Sections of individual tumour and matched normal 
gels (boxed area in A) showing expression of spot 
8A (ringed in green) and spot 8B (ringed in dashed 
green) for visual comparison. Gel numbers 
correspond to the following samples; Tumours (T): 
Depressed-type (1=104-06T, 2=084-06T, 3=264-
05T, 4=149-01T); flat-type (5=054-96T, 6=148-01T, 
7=108-03T); polypoid-type (8=075-00T, 9=233-00T, 
10=259-01T). Normal tissue (N) (11=104-06N, 
13=084-06N, 16=264-05N, 19=149-01N, 15=054-
96N, 18=108-03N, 12=075-00N, 14=233-00N, 
17=259-01N). C: Volume of spot 8A quantified by 
Samespots software in each gel (numbered as in B). 
Additional bars (T, D, F and P) show mean spot 
volume across a number of gels, shown with 
corresponding error bars. T=mean spot volume all 
tumours (gels 1-10); D=mean spot volume in 
depressed tumour gels (gels 1-4), F=mean spot 
volume in flat tumours (gels 5-7), P= mean spot 
volume in polypoid tumours (gels 8-10). P values 
compare mean spot volume across gels D, F and P. 
The fold increase from lowest to highest mean spot 
volume is shown on the chart.16 
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Figure 3.12: Expression of differentially 
expressed proteins (spot 9); evaluation in 
individual samples. A: Tumour gel (233-00T). 
Box marks area of gel showing spot 9. B: 
Sections of individual tumour and matched 
normal gels (boxed area in A) showing 
expression of spot 9 (ringed in yellow) for visual 
comparison. Gel numbers correspond to the 
following samples; Tumours (T): Depressed-
type (1=104-06T, 2=084-06T, 3=264-05T, 
4=149-01T); flat-type (5=054-96T, 6=148-01T, 
7=108-03T); polypoid-type (8=075-00T, 9=233-
00T, 10=259-01T). Normal tissue (N) (11=104-
06N, 13=084-06N, 16=264-05N, 19=149-01N, 
15=054-96N, 18=108-03N, 12=075-00N, 
14=233-00N, 17=259-01N). C: Volume of spot 9 
quantified by Samespots software in each gel 
(numbered as in B). Additional bars (T, D, F and 
P) show mean spot volume across a number of 
gels, shown with corresponding error bars. 
T=mean spot volume all tumours (gels 1-10); 
D=mean spot volume in depressed tumour gels 
(gels 1-4), F=mean spot volume in flat tumours 
(gels 5-7), P= mean spot volume in polypoid 
tumours (gels 8-10). P values compare mean 
spot volume across gels D, F and P. The fold 
increase from lowest to highest mean spot 
volume is shown on the chart.17 
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3.2 IDENTIFICATION OF PROTEIN SPOTS 
Silver stained 2D gels were matched with well-loaded undissected Coomassie-stained gels of 
tumour and normal tissue lysate. Spots were cut out from gels and subject to tandem mass 
spectrometry analysis as described in Section 2.10. Three spots were not identified using this 
analysis. Spectra from the remaining spots are shown in Figure 3.13. Identities of each protein spot 
are shown in table 3.1 with corresponding average spot volumes calculated by SameSpots analysis 
according to tumour morphology. P-values were generated by comparing average spot volume. 
Table 3.1: Spots identified on 2D gel analysis16 
Spot 
no 
Spot volume Fold 
increase  
P-value Identity 
Depressed Flat Polypoid 
1 34,327 48,372 19,968 2.5x 0.02 No identity 
2 60,842 78,045 32,730 2.4x 0.007 No identity 
3 25,581 56,291 45,546 1.9x 0.039 SH3 domain-binding glutamic 
acid-rich-like protein 3 
4A 26,596 19,842 29,709 1.6x 0.545 Peroxiredoxin 2 (Oxidised) 
4B Analysed due to proximity to spot 4A  Peroxiredoxin 2 (Reduced) 
5 6,402 10,690 11,901 1.9x 0.479 Peroxiredoxin 6 
6 Analysed due to proximity to spot 5  Heat Shock Protein 27 
7 1,929 1,548 7,710 4.7x 0.005 No identity 
8A 9,269 19,286 19,419 1.7x 0.744 Cofilin (phosphorylated 
serine 3) 
8B Identified on western blotting  Cofilin 
9 22,768 29,968 102,292 3.8x 0.541 S100A8 
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Figure 3.13A-F: MS/MS spectra for identified protein spots. Complete sequences are shown on the 
right with peptide masses identified in the first chamber shown in colour. Spectra shown 
correspond to underlined peptide sequenced in second chamber. A: SH3BGRPL3 B: Peroxiredoxin 2 
C: Peroxiredoxin 6 D: HSP27 E: Cofilin1 F:S100A818 
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3.3 VALIDATION OF DIFFERENTIALLY-EXPRESSED PROTEINS 
 
Five identified differentially-expressed proteins were taken forward for validation. Commercial 
antibodies for heat shock protein 27 and S100A8 immunohistochemistry were in use in the 
Diagnostic Molecular Pathology Department in the Royal Liverpool University Hospital. Staining 
protocols for these two antibodies were kindly obtained from the Lead Biomedical Scientist in 
Pathology, Mr Andy Dodson. Validation of the expression of these proteins in colorectal 
adenocarcinoma is described in sections 3.6 and 3.8 respectively. Commercial antibodies for 
Peroxiredoxin 6 and Cofilin1 were purchased and protocols for use were developed as described in 
sections 3.5 and 3.7 respectively. No commercial antibody was available for SH3 domain-binding 
glutamic acid-rich like protein 3 (SH3BGRLP3). Dr Zhang (University of Sceince and Technology of 
China) was contacted and kindly agreed to donate a sample of mouse ascites for investigation, 
described in section 3.4.  Peroxiredoxin 2 was not selected for investigation as published results in 
other tumour types showed no correlation between total protein levels and prognosis or stage. No 
antibody was available for the for sulphide (hyperoxidised) form of the protein (section 3.5).  
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3.4 SH3 DOMAIN-BINDING GLUTAMIC ACID-RICH-LIKE PROTEIN 3 
 
3.4.1 INTRODUCTION 
The 10.5kDa protein SH3 binding glutamic acid-rich protein-like 3 has an isoelectric point of 5.0 
corresponding well with the position of the protein spot identified on 2D gel analysis (figure 3.8). 
SH3 binding glutamic acid-rich (SH3BGR) gene is located to human chromosome 21. Two 
homologous genes, SH3BGRL and SH3BGRL3 are located to chromosome Xq13.3 and 1p34.3-35, 
respectively and code for small proteins similar to the N-terminal region of the SH3BGR 
protein.(245) SH3BGRL3 protein shows a significant similarity to Glutaredoxin 1 of Escherichia coli, 
and all the three proteins are predicted to belong to Thioredoxin-like protein family. Glutaredoxins 
(GRXs) are ubiquitous oxidoreductases, which catalyze the reduction of many intra-cellular protein 
disulfides and play an important role in many redox pathways. However, the SH3BGRL3 protein 
lacks the enzymatic function of glutaredoxins and may have a role as a regulator of redox 
activity.(246) Proteins such as glutaredoxin and thioredoxin are reported as up-regulated in many 
cancers such as lung and pancreatic; they have been implicated in increased resistance of cancer 
cells to free-radicals. There is little current evidence which directly links SH3GRPL3 with survival in 
cancer cells, however the protein has recently been identified as up-regulated in glioblastoma 
multiform compared to normal cerebral tissue on proteomic analysis.(247) Studies of acute 
promyelocytic leukemia cell line NB4 have also reported up-regulation of the protein.(248) 
Conversely, the related protein SH3BGRL is reported to be downregulated in fibroblasts, lymphoid 
cells, and splenic tumor cells transformed by the viral oncogene v-Rel. Co-expression of SH3BGRL 
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with v-Rel in primary splenic lymphocytes reduced the number of colonies formed by 76%.(249)  Xu 
et al. reported SH3BGRPL3 protein as a post-translational modification of the 27kDa tumor necrosis 
factor alpha (TNF-α) inhibitory protein, TIP-B1. This protein is potentially involved in resistance of 
cells to the apoptosis-inducing affect of TNF-α.(248)  
 
3.4.2 VALIDATION OF SH3BGRPL3  
In order to validate both the identity of the protein spot thought to be SH3BGRPL3, and to 
determine the relationship of the protein to survival in colorectal cancer we sought an antibody 
which could be utilised for immunohistochemistry and western blotting. No antibody was available 
commercially; however a kind gift from Dr Q Zhang, University of Science and Technology of China 
of mouse ascites was investigated for antibody activity. Unfortunately, no antibody activity was 
detected on western blotting in colorectal cancer cell line or tissue lysate; or on direct spotting of 
the antibody onto nitrocellulose membrane (Figure 3.14).    
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Figure 3.14: Western blotting for SH3BGRPL3. A&B: Proteins from colorectal cancer cell lines HCT116, HT29, 
SW620 and whole tissue lysate from colorectal cancers 084-06 and 259-05 were separated by 1D SDS-PAGE, 
transferred to membrane and western analysis undertaken with anti-SH3BGRPL3 mouse ascites. Primary 
antibody concentration was 1:10 (A) and 1:100 (B) with exposure times of 2 and 40min. No specific protein 
band was detected. C: In order to ascertain whether the anti-SH3BGRPL3 mouse ascites contained active 
antibody the ascites was spotted directly onto nitrocellulose membrane with two commercial antibody 
solutions, (mouse anti-human β-actin and rabbit anti-human 1gG-HRP) in the positions marked. The 
membrane was incubated with anti-mouse secondary. No signal was seen from the donated anti-SH3BGRPL3 
mouse ascites at 20s or 2min exposure which confirmed that no antibody was present in the ascites.19 
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3.5 PEROXIREDOXINS II AND VI 
 
3.5.1 INTRODUCTION 
Peroxiredoxins, Prx are a highly conserved group of proteins in eukaryotes with six isoforms, I-VI. 
Peroxiredoxin II has a molecular weight of 21.8kDa and a theoretical PI of 5.7, whereas 
peroxiredoxin VI has a molecular weight of 24kDa and PI of 6.2; both correspond well to the spots 
identified following gel analysis (Figure 3.9 and 3.10 respectively). There are 3 forms of the 
peroxiredoxin protein, typical 2-Cys (I-IV), atypical 2-Cys (V) and 1-Cys (VI). Specific isoforms occupy 
discrete intra-cellular compartments; I and V are located in all compartments, II in cytoplasm and 
nucleus, III in mitochondria, IV in lysosomes and VI in cytoplasm.(250)  
Peroxiredoxins are responsible for reducing hydrogen peroxide within the cell (Figure 3.15). 
Cysteinyl residues in the protein are oxidised to form the short-lived and unstable form Prx-SOH. 
The protein can interact with another peroxiredoxin molecule to form a Prx-S-S-Prx disulfide bond. 
The disulphide bonded Prx dimers are reduced and recycled in a rapid reaction catalysed by 
thioredoxin. Alternatively, an over-oxidised form of peroxiredoxin can be generated at times of high 
peroxide concentrations by the formation of sulfenic acid residues, Prx-SO2H. This stable protein 
has a more acidic PI then the reduced form of the protein on 2D gel analysis and was thought to be 
irreversible. However, evidence suggests that it can be slowly recycled to the reduced form by the 
enzyme sulfiredoxin.(251)  
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Figure 3.15: Pathways of Peroxiredoxin metabolism. Reduced Peroxiredoxin (Prx-SH) 
binds hydrogen peroxide (H2O2) to form oxidized Peroxiredoxin (Prx-SOH). This 
unstable protein can interact with another Peroxiredoxin molecule to form a dimer 
(Prx-S-S-Prx) when it is reduced and recycled by thioredoxin. During periods of high 
hydrogen peroxide concentrations Prx-SOH can combine with another H2O2 to form a 
stable hyperoxidised peroxiredoxin (Prx-SO2H).  20 
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Peroxiredoxins scavenge low level hydrogen peroxide in the cytoplasm generated as by-products of 
metabolism. However, peroxiredoxins can be inactivated by hyper-oxidation during periods of high 
H2O2 exposure. Evidence is mounting that ROS (reactive oxygen species) such as H2O2 act as 
signalling molecules. Growth factors and cytokines applied to cells in vitro generate a pulse of ROS, 
and addition of oxidants to cells to induce ROS can activate growth factor signalling pathways. 
Hyperoxidation of peroxiredoxins can facilitate ROS-mediated cell signalling pathways by enabling 
transient pulses of H2O2 to occur.  
Two types of signalling pathways have been shown to utilise ROS such as H2O2: TNF-β1 induced 
apoptosis by generation of mitochondrial ROS, and cell growth and proliferation mediated by EGF 
and PDGF signalling.(252) Therefore, elevated peroxiredoxin expression may protect cells from 
apoptosis, whereas disproportionate elevation of the inactive Prx-sulfide form of peroxiredoxin 
could also indicate high levels of cell growth and proliferation.  
Total expression of Peroxiredoxin-II has been analysed using immunohistochemistry in many 
cancers including colon, lung, breast and renal. No association between stage or five-year survival 
has been demonstrated in lung(253) or breast cancer;(254, 255) correlation with good prognosis 
was reported in a small series of renal cell carcinoma patients.(256) In a small series of colon 
cancers (n=32), Prx II was found to be over-expressed in cancer tissue compared to normal tissue 
(n=23/32, 72%). A correlation was described between elevated tumour Prx II levels and incidence of 
nodal metastases (P=0.023).(257)  
Total PrxVI has been found to be up-regulated in the sera of individuals with both squamous cell 
carcinoma of the oesophagus(258) and lung cancer.(259) It is up-regulated in breast cancer cells 
Protein expression in colorectal cancer                                     EM Tweedle 
 
  
119 
 
and is associated with increased invasiveness and pulmonary metastases.(260) In colon cancer 
tissue (n=32 cases) Prx VI was over-expressed with a frequency of 18/32, (56%).  No association was 
seen in this study between expression of Prx VI and stage at presentation or prognosis in colon 
cancer.(257) 
Inability to distinguish between reduced and oxidised forms of peroxiredoxin using 
immunohistochemistry is a disadvantage when assessing their impact on cancer behavior as the 
ratio of reduced: oxidised isoforms may be more informative that total levels of the protein.  
We identified two isoforms of Peroxiredoxin II on 2D gel analysis. The form that was differentially 
expressed was more acidic, suggesting the oxidised Prx-II-sulfide protein.(261) No commercially 
available antibody has been generated which is specific for the sulphide form of Prx-II and therefore 
this supposition could not be confirmed. Given the lack of association between overall Prx-II levels 
in cancer tissue and prognosis, no further analysis of Prx-II was carried out in colorectal cancer 
tissue. One isoform of Peroxiredoxin-VI was differentially expressed in our cohort of colorectal 
cancer specimens, identified following 2D gel analysis and tandem mass spectrometry. It was not 
possible to determine which Prx-VI isoform (reduced or oxidised) was differentially expressed in 
silver-stained gels. Antibodies to both proteins were commercially available and were utilised in 1D 
and 2D western analysis of colorectal cancer cell lysate with a view to validating our findings on 
SDS-PAGE. Immunohistochemical analysis in colorectal cancer tissue could not be performed as the 
antibodies proved not to be sensitive or specific (section 3.5.2).  
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3.5.2 RESULTS OF PRX-VI ANALYSIS  
Lysate from cell lines HT-29, SW480, HCT116 and SW620 was quantified for protein and equal 
quantities loaded onto a series of 1D gels as previously described in section 2.10.2. Protein on 
electrophoresed gels was transferred onto nitrocellulose membrane and blots probed for both 
Peroxiredoxin-VI and Peroxiredoxin-VI-sulfide using primary antibodies at concentrations 
recommended by the manufacturer (see table 2.3). Adjustments were made to the protocol 
including alteration of blocking solutions, incubation time of the primary antibody and 
concentration of primary antibody utilised. Prx-VI antibody was found to detect a protein band at 
the appropriate molecular weight (24 kDa) which was equally expressed in all colorectal cancer cell 
lysate (Figure 3.16). However, cross reactivity was seen between the antibody and other proteins 
producing two bands at around 19kDa and 35kDa, figure 3.16A. Two-dimensional western blot 
analysis for Prx-VI was performed on colorectal cancer cell lysate to better determine the nature of 
the cross-reactivity seen on 1D western blot (results not shown). No convincing spot was 
highlighted at the expected located of Prx-VI on the 2D gel and cross-reactivity was seen with a 
multitude of different spots confirming that the reactivity seen on 1D western blotting was non-
specific in nature. Similarly, 1D analysis of Prx-VI-sulfide showed a faint band at the appropriate 
molecular weight (24kDa), but multiple additional bands and a high background reactivity (Figure 
3.16C). Alterations to the protocol used were made as outlined above, but cross-reactivity could 
not be eliminated and the decision was made that the antibodies were not suitable for further 
analysis in tissue.    
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Figure 3.16: Western blot of peroxiredoxin 6 and peroxiredoxin 6-SO4 expression. Protein lysate 
from colorectal cancer cell lines HCT116, HT29, SW480 and SW620 were separated by 1D SDS-
PAGE, transferred to membrane and western analysis undertaken with anti-PrxVI and anti-PrxVI-
SO3, β-actin was used as control. Primary antibody concentrations were Prx-VI 1:2000 (A), Prx-VI-
SO3 1:1000 (C) and β-actin 1:4000 (B&D). A: Blot probed for Prx-VI shows a band at the appropriate 
molecular weight (28kDa) but additional bands at 40kDa and 19kDa. B: B-actin control. 
Underloading HCT116. C: Blot probed for Prx-VI-SO3 shows multiple bands and heavy background 
despite blocking with both milk protein and goat serum. D: B-actin control. Underloading HCT116, 
overloading HT29. 21 
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3.6 HEAT SHOCK PROTEIN 27 
 
3.6.1 INTRODUCTION 
The HSP27 gene encodes a 27kDa mass, 199-amino acid polypeptide which, in unstressed cells 
exists predominantly as a single charged isoform (HSP27 A) with a PI of approximately 6.8.(262) 
After exposure to heat or chemical shock HSP27 synthesis increases, and the protein accumulates in 
the cytoplasm over 12-hours to levels that are approximately 10-fold higher than the basal level 
found in unstressed cells. Physiological transcription is mediated by Heat Shock Transcription Factor 
1 (HSF1) which translocates to the nucleus after heat shock and interacts with the heat shock 
element (HSE) in the promoter region of the HSP27 gene.(263) HSP27 is also subject to more rapid 
post-transcriptional modifications after cellular stress. Within minutes of exposure, two acidic 
isoforms of HSP27 are generated, (HSP27 B and C), which represent phosphorylation at the serine 
78 and 82 residues respectively by S6 kinase.(264) Additional agents which induce phosphorylation, 
but not transcription of HSP27 have been identified. These are predominantly mitogenic agents, 
such as serum, thrombin, fibroblast growth factor, TNF-α and TGF-β which exert their affect 
through p38 MAP kinase.(265)  
Up-regulation of HSP27 (and other HSP proteins) has been correlated with the acquisition of 
thermotolerance.(266) This state is induced by a spectrum of activity broadly categorised into 1. 
Direct inhibition of death pathways and 2. Repair of protein damage and resolution of protein 
aggregates. HSP27 inhibits at multiple levels both the intrinsic (mitochondrial death) pathway and 
the extrinsic (receptor-mediated) cell death pathways; both of which activate effector caspases to 
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execute cell death.(267) HSP27 prevents loss of mitochondrial membrane potential and release of 
mitochondrial proteins. It also prevents the interaction between cytochrome c and pro-caspase-9 
thus preventing apoptosome formation. HSP27 targets the extrinsic pathway through Daxx by 
inhibiting its binding to both the Fas cell death receptor and apoptosis signal regulating kinase, 
Ask1.(268) In conjunction with other members of the HSP family, HSP27 functions as a molecular 
chaperon. It forms complexes with damaged proteins preventing their non-specific aggregation, 
and then enables refolding in an ATP-dependant process mediated by HSP70.(269) F-actin is one 
such crucial protein stabilised by HSP27 during periods of cellular stress. HSP27 binds to denatured 
actin monomers dissociated from F-actin and protects them forming large insoluble aggregates 
under conditions of cellular stress. This has a potent anti-apoptotic affect by maintaining 
compartment integrity and supporting protein trafficking within the cell.(270) An overview of 
HSP27 regulation is shown in Figure 3.17. 
 
 
 
 
 
 
 
 
 
 
 
HSF-1 
HSP27 
Re-folds 
 proteins 
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cytoskeleton 
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apoptosis 
Stress 
Figure 3.17:  The regulation and actions of heat shock protein 27. HSF1 migrates into the nucleus 
following a stressor event. HSF1 interacts with the HSE on the promoter region of the HSP27 gene 
causing transcription of the HSP27 protein22 
Nucleus 
Cell membrane 
Cytoplasm 
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Given its inhibitory influence on programmed cell death, it is not surprising that HSP27 has been 
reported as elevated in a number of human cancers, principally prostate, breast and ovarian.(271) 
One putative mechanism for these observations has centred on micro-environmental stress 
imposed by tumour hypoxia; however evidence for this hypothesis is lacking. One model of 
prostate tumour spheroids cultured with embryoid bodies observed little HSP27 expression during 
tumour hypoxia, but an increase after neo-vascularisation and restoration of normal oxygen 
tension.(272) Indeed, tumours cells growing as xenografts exhibited inhibition rather than 
enhancement of HSP27 expression.(273) There is emerging evidence to suggest that genomic stress 
contributes to the up-regulation of HSP27 in cancer through direct activation of the HSE, removal of 
transcriptional repression and stabilisation of HSF1.(274) p53 reportedly attaches to the binding 
site for the transcription factor NF-Y in the promoter region of HSP genes causing repression of 
transcription. Proteomic analysis of p53-null cell lines documented increased expression of both 
HSP70 and HSP27 compared to cells with wild-type p53.(275) This is a potentially important 
mechanism of regulation in colorectal cancer which has a 50% rate of p53 mutation.(276) 
Stabilisation of HSF1, prolonging transcription of HSP27 has been reported following heregulinβ1 
activation of the c-erbB receptor,(277) a factor associated with poor survival in colorectal 
cancer.(278) In addition, direct transcription of HSP through the HSE can occur via the proto-
oncogene c-Myc, which is also induced by heregulin and HER2.(279)  
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3.6.2 HSP27 IS A PROMISING TARGET FOR VALIDATION IN COLORECTAL CANCER  
Spot 6 was picked for analysis due its proximity to spot 5, felt to be a potential isoform of the 
previously identified Peroxiredoxin-VI. The identification of the unrelated protein HSP27 was 
unexpected, yet interesting. Re-analysis of the gel images suggested that HSP27 was in fact 
differentially-expressed between different tumour samples, although not in relation to morphology 
(Figure 3.10). A protocol for use of a commercially available anti-HSP27 antibody was already 
employed for immunohistochemistry of prostate adenocarcinoma by the Lead Biomedical Scientist 
in Pathology, Mr Andy Dodson in the Diagnostic Molecular Pathology Department in the Royal 
Liverpool University Hospital. The antibody had previously been validated in our institute in a series 
of paraffin-embedded, formalin-fixed prostate cancers and was found to be specific for HSP27, 
easily scored and correlated with stage at presentation and prognosis of prostate cancer. Our group 
had also found HSP27 to be differentially expressed in a series of 2D gels of undissected Duke’s C 
colorectal cancers (work by Mr Ilyas Khattak). Initial staining of 98 cases of formalin-fixed colorectal 
cancers had identified an association between HSP27 expression and survival in node-positive 
colorectal cancer. Further validation of HSP27 expression in colorectal cancer was we felt merited 
by these early results and kind permission to utilise data from the first 98 cases was given by Mr 
Khattak and is included in the results discussed in this chapter.  
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3.6.3 PATIENT DEMOGRAPHICS  
Formalin-fixed, paraffin-embedded, primary colorectal adenocarcinomas, n=404 (199 colon, 205 
rectal) from fully-consented patients, who underwent surgery at the Royal Liverpool University 
Hospital, UK between 1993 and 2003, were obtained from the Liverpool Tissue Bank, University of 
Liverpool. The tissue was microarrayed in eight separate blocks utilizing between two and six cores 
per tumour in addition to normal control tissue from kidney, liver, testes, tonsil and colon. Patient 
demographic details are provided in Table 3.2. Thirty percent of patients (121/404) underwent 
chemotherapy. In the 103/121 (85%) patients in whom the chemotherapy agents were known, all 
received 5-fluorouracil; 4/103 (4%) received an additional agent, (irinotecan or oxaliplatin). Second-
line and third-line chemotherapy was given in 37/103 (36%) and 19/103 (18%) of patients 
respectively. Additional agents (irinotecan, oxaliplatin, mitomycin C or levamisole) were 
administered in 9/37 (24%) of second-round and 10/19 (53%) of third-round patients. Thirteen 
percent of rectal cancer patients underwent short-course radiotherapy as part of the CR07 
trial(280) (25 Gray in 5 fractions over 1 week; surgery within 1 week of treatment), while 15% 
underwent long-course radiotherapy (offered to patients with bulky tumours and consisting of 45  
Gray, administered in 25 daily fractions over 5 weeks followed by surgery after 6–10 weeks). The 
median follow-up was 49.5 months (IQR 19.6-74.6 months, range 0.23-146.5 months) and 284 
deaths from any cause were reported, including 176 deaths due to colorectal cancer. Seven 
patients died within 30 days of surgery and were censored in the survival analysis. Four additional 
patients were censored at the point of last follow up as no date of death was recorded.  
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Table 3.2: Clinicopathological data for n=404 patients on the microarrays17 
Clinical parameter All cases, n=404 (%) Colon cancer n=199 (%) Rectal cancer n=205 (%) 
Gender    
Female 153 (38) 95 (48) 58 (28) 
Male 251 (62) 104 (52) 147 (72) 
Age    
<70 years 209 (52) 90 (45) 119 (58) 
≥70 years 195 (48) 109 (55) 86 (42) 
Tumour size    
<40mm 98 (24) 42 (21) 56 (27) 
40-59mm 178 (44) 83 (42) 95 (46) 
≥60mm 128 (32) 74 (37) 54 (27) 
Resection margins    
Clear 356 (88) 181 (91) 175 (85) 
Involved 47 (12) 17 (9) 30 (15) 
Unrecorded 1 1 0 
Differentiation    
Well 10 (2) 4 (2) 6 (3) 
Moderate 359 (89) 181 (91) 181 (88) 
Poor 31 (8) 15 (7) 16 (8) 
Unrecorded 4 (1) 2 2 (1) 
Depth of invasion    
T1 20 (5) 12 (6) 8 (4) 
T2 60 (15) 19 (9) 41(20) 
T3 273 (67) 131 (66) 142 (69) 
T4 51 (13) 37 (19) 14 (7) 
Nodal status    
N0 225 (55) 117 (59) 108 (53) 
N1 99 (25) 43 (22) 56 (27) 
N2 80 (20) 39 (19) 41 (20) 
Adjuvant therapy    
None 279 (69) 152 (76) 127 (62) 
Chemotherapy 
Unrecorded 
121 (30) 
4 (1) 
46 (23) 
1 (1) 
75 (37) 
3 (1) 
Neoadjuvant therapy    
None - - 147 (72) 
Short course 
Long course 
- 
- 
- 
- 
27 (13) 
31 (15) 
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3.6.4 HSP27 INTENSITY MORE PREDICTIVE OF SURVIVAL THAN PERCENTAGE OF STAINED CELLS  
Scoring of HSP27 expression was performed using a protocol which included intensity of staining 
from 0-3 (based on staining of internal benign control tissue) and the percentage of cells staining 
grouped into 0: <5%, 1: 5-30%, 2: 30-70%, 3:>70%. The scoring system is illustrated in Figure 3.18 
using a selection of variably-staining colorectal adenocarcinomas. A composite value or 0-9 index 
was calculated by multiplying the intensity and percentage staining. The median score in each field 
was calculated and used to dichotomise the data for analysis; intensity (low≤1.5 versus high>1.5), 
percentage (low≤2 versus high>2) and index (low≤3 versus high>3). These factors were subject to 
univariate Cox regression to assess which aspects of HSP27 staining were most strongly correlated 
with overall survival, table 3.3. Intensity of staining, but not percentage staining was related to 
overall survival, P=0.0171 versus P=0.9261 respectively; however, index was most predictive of 
survival, P=0.0078 and was utilised in the further construction of Kaplan-Meier curves and life 
tables.  
 
Table 3.3: Univariate Cox regression of HSP27 intensity and percentage18 
Variable  Cases  Univariate analysis 
  n=404 (%) HR(95%CI) χ2 p-value 
HSP27 intensity (median score 1.5) ≤1.5 
>1.5 
232 (57) 
172 (43) 
- 
1.286 (0.957-1.730) 
 
2.780 
 
0.0955 
HSP27 percentage (median score 2.0) ≤2.0  
>2.0 
234 (58) 
170 (42) 
- 
0.944 (0.699-1.274) 
 
0.143 
 
0.7056 
HSP27 index (median score 3.0) ≤3.0 
>3.0 
228 (56) 
176 (44) 
 
1.382 (1.028-1.858) 
 
4.600 
 
0.0320 
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Figure 3.18: Immunohistochemistry for HSP27. (A) Benign control tissue showing absence of 
detectable HSP27 in normal colonic epithelium, weak staining in normal liver and intense staining 
of normal renal tubules. (B) Colorectal cancer tissue illustrating the range of intensities of HSP27 
immunostaining, from 0 to 3. (C) Colorectal cancer tissue depicting varying percentages of HSP27 
staining in different tumours. 23  
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3.6.5 HSP27 DOES NOT CORRELATE WITH STAGE AT PRESENTATION OR METASTASES 
We proceeded to assess the relationship between HSP27 index score and clinicopathological 
variables related to the 404 tumours on the tissue microarray. TNM and the American Joint 
Committee on Cancer, AJCC guidelines were used to stage tumours.(243) Associations were sought 
between HSP27 expression (combined index) and gender, age, anatomical location, size of tumour, 
resection margin status, differentiation grade, depth of invasion (T-stage), presence of nodal 
metastases (N-stage) and treatment (adjuvant chemotherapy and neoadjuvant radiotherapy). The 
entire cohort of 404 patients was examined, in addition to separate analyses of the subgroups of 
patients with colon cancer (n=199) and rectal cancer (n=205). No significant correlations were 
demonstrated between HSP27 index and these parameters in any of groups analysed, with one 
exception (Table 3.4). High HSP27 expression was associated with incomplete resection margins in 
rectal cancer patients (P=0.009; Table 3.4). 
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Table 3.4: Clinicopathological features associated with HSP27 expression19
 All cases Colon cancers Rectal cancers 
Clinical parameter Cases n=404 
(%) 
HSP27 –ve 
n=228(%) 
HSP27 +ve 
n=176(%) 
P 
value* 
Cases 
n=199 (%) 
HSP27 –ve 
n=115(%) 
HSP27 +ve 
n=84(%) 
P 
value* 
Cases 
n=205 (%) 
HSP27 –ve 
n=113(%) 
HSP27 +ve 
n=92(%) 
P 
value* 
Gender             
Female 153 (38) 83 (36) 70 (40) 0.489 95 (48) 51 (44) 44 (52) 0.262 58 (28) 32 (28) 26 (28) 0.993 
Male 251 (62) 145 (64) 106 (60)  104 (52) 64 (56) 40 (48)  147 (72) 81 (72) 66 (72)  
Age             
<70 years 209 (52) 113 (50) 96 (55) 0.320 90 (45) 51 (44) 39 (46) 0.771 119 (58) 62 (55) 57 (62) 0.306 
≥70 years 195 (48) 115 (50) 80 (45)  109 (55) 64 (56) 45 (54)  86 (42) 51 (45) 35 (38)  
Tumour size             
<40mm 98 (24) 52 (23) 46 (26) 0.439 42 (21) 25 (22) 17 (20) 0.683 56 (27) 27 (24) 29 (31) 0.391 
40-59mm 178 (44) 98(43) 80 (46)  83 (42) 45 (39) 38 (45)  95 (46) 53 (47) 42 (46)  
≥60mm 128 (32) 78 (34) 50 (28)  74 (37) 45 (39) 29 (35)  54 (27) 33 (29) 21 (23)  
Resection margins             
Clear 356 (88) 207 (91) 149 (84) 0.080 181 (91) 104 (90) 77 (91) 0.563 175 (85) 103 (91) 72 (78) 0.009 
Involved 47 (12) 21 (9) 26 (15)  17 (9) 11 (10) 6 (8)  30 (15) 10 (9) 20 (22)  
Unrecorded 1 0 1 (1)  1 0 1 (1)  0 0 0  
Differentiation             
Well 10 (2) 4 (2) 6 (4) 0.562 4 (2) 1 (1) 3 (4) 0.087 6 (3) 3 (3) 3 (3) 0.316 
Moderate 359 (89) 204 (89) 155 (88)  181 (91) 101 (88) 77 (91)  181 (88) 103 (91) 78 (85)  
Poor 31 (8) 18 (8) 13 (7)  15 (7) 12 (10) 3 (4)  16 (8) 6 (5) 10 (11)  
Unrecorded 4 (1) 2 (1) 2 (1)  2 1 (1) 1 (1)  2 (1) 1 (1) 1 (1)  
Depth of invasion             
T1 20 (5) 11 (5) 9 (5) 0.763 12 (6) 7 (6) 5 (6) 0.964 8 (4) 4 (3) 4 (4)  
T2 60 (15) 34 (15) 26 (15)  19 (9) 10 (9) 9 (11)  41(20) 24 (21) 17 (19)  
T3 273 (67) 157 (69) 116 (66)  131 (66) 77 (67) 54 (64)  142 (69) 80 (71) 62 (67)  
T4 51 (13) 26 (11) 25 (14)  37 (19) 21 (18) 16 (19)  14 (7) 5 (4) 9 (10)  
Nodal status             
N0 225 (55) 131 (57) 94 (53) 0.558 117 (59) 65 (56) 52 (62) 0.744 108 (53) 66 (58) 42 (46) 0.095 
N1 99 (25) 56 (25) 43 (25)  43 (22) 26 (23) 17 (20)  56 (27) 30 (27) 26 (28)  
N2 80 (20) 41 (18) 39 (22)  39 (19) 24 (21) 15 (18)  41 (20) 17 (15) 24 (26)  
Adjuvant therapy             
None 279 (69) 161 (71) 118 (67) 0.297 152 (76) 89 (77) 63 (75) 0.613 127 (62) 72 (64) 55 (60) 0.406 
Chemotherapy 
Unrecorded 
121 (30) 
4 (1) 
63 (27) 
4 (2) 
58 (33) 
0 
 46 (23) 
1 (1) 
25 (22) 
1 (1) 
21 (25) 
0 
 75 (37) 
3 (1) 
38 (33) 
3 (3) 
37 (40) 
0 
 
Neoadjuvant therapy             
None - - -  - - -  147 (72) 84 (74) 63 (68) 0.629 
Short course 
Long course 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
- 
 27 (13) 
31 (15) 
14 (12) 
15 (14) 
13 (14) 
16 (18) 
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3.6.6 HSP27 STATUS INDEPENDENTLY PREDICTS SURVIVAL IN RECTAL CANCE R 
Elevated HSP27 was associated with poor survival (P=0.0312) when the entire cohort of 404 
patients was examined (Fig. 3.19A). However, when the colon and rectal cancer patients were 
analysed separately, HSP27 expression was not associated with survival in the colon cancer group 
(P=0.7385; Figure 3.19B), but was significantly associated with poor survival in the rectal cancer 
group (P=0.0063; Figure 3.19C). At five-years, rectal cancer-specific survival of high HSP27-
expressers was 63% versus 73% for low HSP27-expressers. Survival was assessed across all stages at 
presentation in rectal and colon cancer. Elevated HSP27 predicted poor cancer-specific survival in 
rectal cancer patients with early stage I/II tumours (Figure 3.19D). HSP27 however, was not 
predictive of poor survival for rectal cancer patients with stage III (N+/M0) disease (P=0.2132, 
Figure 3.19E). Kaplan-Meier curves were constructed for stage I/II colon cancer (Figure 3.20A) and 
stage III colon cancer (Figure 3.20B). No difference in survival according to HSP27 expression was 
noted either group; P=0.8569 and P=0.4365 respectively (Figure 3.20A&B). The benefits of adjuvant 
therapy for patients with stage III disease are well established, whilst management of patients with 
stage II rectal tumours (T3-4/N0/M0) remains controversial.(281) We next determined whether 
high HSP27 expression might be useful in identifying a ‘high-risk’ group of patients with stage II 
rectal tumours (T3-4/N0/M0) who might benefit from adjuvant therapy. We found that the overall 
survival of patients with stage II (T3-4/N0/M0) disease who had elevated HSP27, n=29 was similar 
to that of patients with N1 disease, n=56 (P=0.6523, Fig. 3.19F). This was not observed in colon 
cancer, where the overall survival of patients with stage II (T3-4/N0/M0) disease who had elevated 
HSP27, n=41 was significantly better than that of patients with N1 disease, n=43 (P=0.0268, Figure 
3.20C). 
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Figure 3.19: Kaplan-Meier graphical analysis of 8-year survival in (A) all patients, (B) colon cancer 
patients, (C) rectal cancer patients, (D) Stage I/II rectal cancer patients, (E) Stage III rectal cancer 
patients. (F) Stage IIIA/B rectal cancer patients versus Stage II high HSP27 expressors.24 
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Figure 3.20: Kaplan-Meier curves of HSP27 index in colon cancer (A) Stge I/II colon cancer; high 
HSP27-expressors (n=52) showed similar survival to low expressors (n=65; log-rank, P=0.8569). (B) 
Stage III colon cancer; high HSP27-expressors (n=32) showed similar survival to low expressors 
(n=50; log-rank, P=0.4365). (C) Poor survival for stage IIIA/B colon cancer (all cases; n=43) versus 
Stage II high HSP27 expressors (n=41, log-rank, P=0.0268. 25 
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3.6.7 MULTIVARIATE ANALYSIS OF SURVIVAL 
Multivariate Cox proportional hazards regression analysis was performed to derive risk estimates 
related to survival for all clinicopathologic characteristics and HSP27 expression. Elements 
associated with cancer-specific survival on univariate analysis with a P-value<0.10 were included in 
the multivariate model. Univariate analysis of 205 rectal cancer patients revealed that resection 
margin status (P=0.0894), N-stage (P=0.0001) and HSP27 expression (P=0.0069) were significantly 
associated with survival (Table 3.5A). Only N-stage and HSP27 expression remained independently 
predictive of survival in rectal cancer with P-values of 0.0001 and 0.0233 respectively. Univariate 
analysis of 199 colon cancers revealed significant factors as differentiation grade (P=0.0278), T-
stage (P=0.0008), resection margin status (P=0.0001) and N-stage (P=0.0001), (Table 3.5B). HSP27 
was not associated with survival (P=0.7382). On multivariate analysis only resection margin status 
(P=0.0001) and N-stage (P=0.0001) remained independently significant for colon cancer (Table 
3.5B). 
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Table 3.5 A: Univariate and multivariate analysis of survival in rectal cancer20 
Table 3.5 B: Univariate and multivariate analysis of survival in colon cancer 21 
Variables Group Cases Univariate Multivariate 
  n=205 
(%) 
HR(95%CI) χ
2
 p-
value 
HR(95%CI) χ
2
 p-
value 
Age (years) 68yrs 
(60-74) 
- 1.000 (0.981-1.018) 0.001 0.973 - - - 
Size (mm) 45mm 
 (35–60) 
- 1.001 (0.998-1.004) 0.115 0.693 - - - 
Diff 
 grade 
Well-Mod 
Poor 
187 (91) 
16 (9) 
 
1.355 (0.682-2.693) 
 
0.753 
 
0.386 
 
- 
 
- 
 
- 
T-stage        T1 
T2 
T3 
8 (4) 
41 (20) 
156 (76) 
- 
1.154 (0.336-3.967) 
1.708 (0.539-5.416) 
2.686 
0.052 
0.827 
0.261 
0.820 
0.363 
- 
- 
- 
- 
- 
- 
- 
- 
- 
Resection 
margins              
Clear 
Involved 
175 (85) 
30 (15) 
 
1.563 (0.933-2.618) 
 
2.884 
 
0.089 
 
0.808 (0.450-1.453) 
 
0.506 
 
0.477 
N-stage          N0  
N1 
N2  
108 (53) 
56 (27) 
41 (20) 
- 
1.557 (0.962-2.521) 
3.259 (2.027-5.240) 
23.892 
3.250 
23.766 
0.001 
0.071 
0.001 
- 
1.539 (0.947-2.500) 
3.289 (1.956-5.532) 
20.227 
3.026 
20.150 
0.001 
0.082 
0.001 
HSP27 
expression     
Negative 
Positive 
113 (55) 
92 (45) 
 
1.720 (1.160-2.550) 
 
7.293 
 
0.007 
 
1.607 (1.066-2.422) 
 
5.143 
 
0.023 
Variable Group Cases  Univariate Multivariate 
  n=199 
(%) 
HR(95%CI) χ
2
 p-
value 
HR(95%CI) χ
2
 p-
value 
Age (years) 71 yrs 
(64 – 77) 
- 1.002 (0.982-1.022) 0.023 0.879 
 
- - - 
Size (mm) 50mm 
(40 - 60) 
- 1.001 (0.998-1.003) 0.246 0.620 - - - 
Diff 
grade 
Well-Mod 
Poor 
182 (91) 
15 (8) 
 
2.192 (1.089-4.412) 
 
4.838 
 
0.028 
 
1.315 (0.605-2.857) 
 
0.478 
 
0.489 
T-stage        T1 
T2 
T3 
T4 
12 (6) 
19 (10) 
131 (66) 
37 (18) 
- 
1.476 (0.134-16.29) 
4.818 (0.665-34.89) 
10.56 (1.425-78.29) 
16.738 
0.101 
2.423 
5.322 
0.001 
0.751 
0.120 
0.021 
- 
1.905 (0.172-21.15) 
3.257 (0.445-23.85) 
5.825 (0.771-43.99) 
7.181 
0.276 
1.352 
2.918 
0.066 
0.600 
0.245 
0.088 
Resection 
margins              
Clear 
Involved 
181 (91) 
17 (9) 
 
4.776 (2.532-9.008) 
 
23.326 
 
0.001 
 
4.002 (2.055-7.792) 
 
16.644 
 
0.001 
N-stage          N0 
N1 
N2 
 117 (59) 
43 (22) 
39 (19) 
- 
2.622 (1.510-4.555) 
4.671 (2.702-8.075) 
31.717 
11.712 
30.466 
0.001 
0.001 
0.001 
- 
2.021 (1.136-3.597) 
3.705 (2.062-6.658) 
19.423 
5.726 
19.191 
0.001 
0.017 
0.001 
HSP27 
expression     
Negative 
Positive 
 115 (58) 
84 (42) 
 
0.926 (0.588-1.456) 
 
0.111 
 
0.739 
 
1.354 (0.497-1.290) 
 
0.833 
 
0.361 
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3.6.8 RELATIONSHIP BETWEEN HSP27 EXPRESSION AND NEO-ADJUVANT TREATMENT 
The difference in survival observed in the rectal, but not the colon cancer patients, prompted us to 
question whether HSP27 expression was related to administration of neo-adjuvant radiotherapy. 
Our rectal cancer patients underwent two forms of treatment; long-course and short-course 
radiotherapy. Short-course pre-operative radiotherapy was offered as part of the CR07 trial which 
recruited patients with operable tumours and administered 25 Gray in five daily fractions over one 
week, with surgery within one week of treatment. Long-course radiotherapy was offered to 
patients with bulky tumours which, on pre-operative imaging, was felt to compromise the proposed 
mesorectal excision margin. The aim was to downsize the tumour rendering it operable, and 
45 Gray was administered in 25 daily fractions over five weeks followed by surgery after 6–10 
weeks. We analysed a cohort of rectal cancer patients in order to determine whether pre-operative 
radiotherapy was associated with a change in HSP27 expression. Data were obtained for 80 
patients; 49 (61%) had no neo-adjuvant therapy, 17 (21%) had short-course and 14 (18%) had long-
course radiotherapy. Matched diagnostic biopsy material was obtained for all 80 patients and 
analysed for HSP27 expression. In 65/80 (81%) of cases the HSP27 index was the same in the biopsy 
and the tumour. Four tumours (6%) showed up-regulation of HSP27 compared to the biopsy and 
9/67 (13%) down-regulated HSP27 in the tumour compared to the biopsy, (Figures 3.21A and B, 
Table 3.6). Expression of HSP27 in the primary tumour was not correlated with neo-adjuvant 
therapy received, P=0.802, neither was there an associated change in HSP27 expression between 
the biopsy and tumour specimens following pre-operative therapy, P=0.602, (Table 3.7).  
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3.6.9 NEO-ADJUVANT THERAPY IS NOT ASSOCIATED WITH OVERALL SURVIVAL 
Having demonstrated that neo-adjuvant radiotherapy did not influence HSP27 expression, we 
sought to determine whether the type of neo-adjuvant radiotherapy received contributed to the 
survival difference observed in the rectal cancer group. Survival analysis performed for the 147 
rectal cancer patients who did not receive radiotherapy treatment confirmed that high HSP27 
expression in this group was associated with poor survival (P=0.0078, Figure 3.21C). No difference 
in cancer-specific survival was seen in the rectal cancer group according to type of radiotherapy 
received (P=0.4317, Figure 3.21D). 
 
HSP27 expression in 
diagnostic biopsies  
No of cases, 
n=80 (%)  
Low HSP27 index, n=42 
(%)  
High HSP27 index, n=38 
(%)  
P-value  
Low HSP27 in biopsy 37 (46) 32 (76)  5 (14)  <0.0001  
High HSP27 in biopsy 43 (54) 10 (24)  33 (86)  
Table 3.6: Comparative HSP27 expression between diagnostic biopsy and tumour 22 
 
Levels of HSP27 in tumour 
compared to biopsy 
No of 
cases, 
n=80(%) 
Neo-adjuvant radiotherapy P-value 
None, 
n=49 
Short course, 
n=17 
Long-course, 
n=14 
Up-regulated in tumour 5 (6) 3 (6) 2 (12) 0 0.6423 
Equal expression 65 (81) 39 (80) 14 (82) 12 (86) 
Down-regulated in tumour 10 (13) 7 (14) 1 (6) 2 (14) 
Table 3.7: Change in HSP27 expression according to pre-operative radiotherapy 23 
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Figure 3.21: (A and B): HSP27 staining in diagnostic biopsy material (upper panel) compared to 
matched tumour cores (lower panel). (C) Kaplan-Meier survival curves demonstrating that the level 
of HSP27 remains predictive of cancer-specific survival in rectal cancer patients who have not 
received neoadjuvant radiotherapy and (D) that mode of neoadjuvant radiotherapy received did 
not correlate with cancer-specific survival. 26 
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3.7 COFILIN1 AND COFILIN-PHOSPHO(SER3) 
 
3.7.1 INTRODUCTION 
Cofilin is one of a group of universally-expressed actin-binding proteins which co-operate to control 
the structure of the cytoskeleton. The actin-binding region takes the form of a long α-helix which is 
highly conserved between isoforms. Cofilin-1 (non-muscle cofilin or n-cofilin) is an 18kDa protein 
consisting of 166 amino acids. It is the most abundant and ubiquitously expressed member of the 
cofilin family which also incorporates cofilin-2 (muscle cofilin or m-cofilin) and ADF (actin-
depolymerising factor or destrin). Expression of the different forms of the cofilin family varies 
according to tissue type; cofilin-1 and ADF are the predominant isoforms in most adult tissues 
whereas cofilin-2 is the chief isoform present in skeletal and cardiac muscle.(282) The protein is 
subject to a number of post-translational modifications including phosphorylation at residues 3, 25, 
41, 68, 140 and 156 and acetylation at 2 and 132. Phosphorylation at the serine 3 residue is the 
only known functional modification which prevents cofilin from binding to actin.(283) 
Actin filaments (F-actin) are formed by polymerization from actin monomers (G-actin); these helices 
intertwine generating actin microfilaments.(284) Filaments are polarised, with polymerisation 
taking place at the barbed-end and dissociation at the pointed-end of actin molecules. 
Polymerization in vivo is dependent on the formation of free barbed-ends that act as nuclei for 
elongation. Rapid nucleation is created by two complementary processes; uncapping or severing of 
existing filaments by cofilin and generation of novel nuclei on the body of filaments by the complex 
Arp 2/3 producing new branches.(285) Polymerisation proceeds once ATP-G-actin binds to the 
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nucleation point; the ATP is hydrolyzed to ADP releasing the inorganic phosphate. At the pointed-
end, ADP-F-actin dissociates slowly in a process which is catalysed by cofilin. Cofilin releases old 
ADP-F-actin into the cytoplasm to enable ADP-to-ATP exchange to take place, re-generating the 
cellular pool of ATP-G-actin. In the presence of plentiful G-actin, cofilin facilitates actin 
polymerization via its actin-severing activity; providing free barbed ends for further polymerization 
and nucleation. When the concentration of G-actin is limited, the net result of severing by cofilin is 
depolymerisation, not nucleation.(286)  
Cell motility is dependent on synchronised activity of the actin cytoskeleton. The cell initiates a 
protrusion at the front, which subsequently attaches to the substratum. This is followed by 
contraction of the cell body and tail detachment, resulting in movement in the direction of the 
protrusion. The initiating event in this cycle is appears to be activation of cell surface receptors by 
chemotactic factors, which establish a signalling cascade culminating in the polymerization of new 
actin at the leading edge.(287) The site of signal activation on the cell surface determines the 
direction of cell migration. Within 60 seconds of stimulation with a chemoattractant, Arp2/3 
complex and cofilin are recruited to the membrane. As described, both factors act synergistically to 
generate multiple dendritic actin filaments with free barbed ends. Function-blocking antibodies 
directed against either protein significantly decrease barbed-end generation and cell 
protrusion.(288) Polymerisation of the actin filaments is dependent on a high concentration of G-
actin to act as substrate. Cofilin depolymerises filaments at the base of membrane protrusions to 
replenish G-actin and facilitate polymerisation at the leading edge in a process called 
treadmilling.(289)  
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Cofilin activity can be regulated within a cell in a number of ways. Firstly, cofilin can be inactivated 
by phosphorylation of the serine 3 residue by the LIM family of kinases. LIM kinase 1 and 2 (LIMK1 
and LIMK 2) are regulated by Rho GTPases through their downstream effectors Rho-associated 
protein kinase (ROCK) and p21-activated kinases 1 and 4 (PAK1 and PAK4). These activate LIMK1 
and LIMK2 by phosphorylation at residues Thr508 and Thr505, respectively. Active cofilin can be 
sequestered by phosphatidylinositol (4,5)-bisphosphate, PIP2 forming a pool of the protein close to 
the cell membrane unavailable for actin binding. Cofilin is also regulated by pH; the actin binding 
efficiency is markedly reduced when the pH drops below 7.0.(290, 291)  Activation of cofilin can 
take place through increasing pH, dephosphorylation by various phosphatases including Slingshot 
(SSH) and chronophin or hydrolysis of PIP2 due to increasing phospholipase C (PLC) activity which 
releases cofilin from sequestration.(292) An overview of cofilin regulation is shown in Figure 3.22. 
The central position of cofilin in co-ordinating membrane protrusion and directional motility has led 
many to investigate its role in cancer cell invasion.  Expression of cofilin has been reported as up-
regulated in tumour tissue including oral squamous cell,(293) ovarian(294) and renal cell 
carcinoma;(295) and in human cancer cell lines for example breast (MDA-MB435S),(296) pancreatic 
(EPP85-181RDB)(297) and lung adenocarcinoma (A549).(298) Phospho(ser3)-cofilin has been 
quantified and found at reduced levels in various human cancer cell lines including T-cell lymphoma 
(Jurkat), cervical (HeLa), colon (KM12), liver (HepG2) and kidney (COS1). A study of 13 different 
colorectal cancer cell lines confirmed universally high levels of cofilin-1 and ADF on Western blot. 
SiRNA induced knock-down of both cofilin and ADF was associated with enhanced adhesion to 
laminin I and collagen I/IV. Migration of cells through Matrigel was reduced in colorectal cancer cell 
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lines HCT116 and LS174T, but not the Isrecol cell line following reduction of cofilin-1 expression; 
whereas Isrecol cell migration was reduced by ADF depletion.(299) However, several studies have 
found cofilin to be down-regulated in cancer, specifically hepatocellular carcinoma cell line 
(MCHCC97-H),(300) and increasing cofilin expression in H1299 human lung cancer cells reduces 
invasion by disrupting the actin cytoskeleton at the leading edge.(301) In breast cancer cells, EGFR 
activation results in PLC-mediated hydrolysis of PIP2, releasing cofilin; simultaneously LIM kinase 
and phosphorylated cofilin levels are seen to increase.(302) This points to formation of an 
equilibrium between active cofilin1 and inactive cofilin-phospho(ser3) within a cell mediated by a 
number of different factors including LIM kinase and PLC. Following stimulation of the cell by 
chemotactic factors a new equilibrium may be reached.(303)  
Cofilin has been linked to cell invasion and an increase in malignant phenotype of breast cancer 
cells.(303) Little is known about the expression of cofilin in actual tumours. Only one study 
evaluated immunohistochemical levels of cofilin1 in paraffin-embedded cancer tissue. The paper 
reports an increase in depth of invasion in neuroendocrine gastrointestinal tumours with increasing 
expression of cofilin1, although the number of cases involved was small (n=34).(304) We have 
made preliminary investigations of commercially available antibodies to cofilin and cofilin-
phospho(ser3) with a view to conducting the first large scale study of cofilin expression in colorectal 
cancer tissue. 
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Figure 3.22: Regulation of cofilin27 
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3.7.2 COFILIN AND COFILIN-PHOSPHO(SER3) EXPRESSED IN COLORECTAL CANCER CELL  LYSATE 
Colorectal cancer cell lines HCT116, HT29, SW480 and SW620 cell lines were cultivated in L15 in 5% 
CO2 to confluence. Cell lysate was prepared as described in Section 2.5.1 from each cell line and 
protein quantified using the BCA method. An equal quantity of protein (30µg) was loaded onto 
each lane of a small format 1D gel and run as described in section 2.5.1. Anti-cofilin antibody and 
anti-cofilin-phospho(ser3) antibodies were used as primaries in concentration 1:10,000 and 1:50 
respectively. The secondary antibody was horseradish-conjugated rabbit anti-mouse at 1:4000 
concentration. Development of blots revealed a band at the appropriate molecular weight (17kDa) 
in all cell lines probed for cofilin. Loading was variable in actin control films with underloading in 
HCT116 lane and overloading in SW480 lane. When probed for cofilin-phospho(ser3) only HT-29 
(non-metastastic) colorectal cancer cell line showed a band at the appropriate molecular weight at 
2 minutes with weaker bands visible at 15 minutes in SW480 and SW620 samples. Anti-cofilin and 
cofilin-phospho(ser3) antibodies are capable of detecting protein bands of the relevant size in 
tumour cell lysate and show little cross-reactivity with other proteins. Inconsistent gel loading, 
evidenced by variable expression of β–actin control, indicated that relative expression of cofilin 
between cell lines could not be commented upon (Figure 3.23A&B).  Despite inconsistent gel 
loading in evidence on β–actin control blot, the expression of cofilin-phospho(ser3) was felt to be 
more variable, with highest expression in cell line HT29, followed by SW620 and SW480; lowest 
expression was seen in the cell line HCT116 (Figure 3.23C&D).   
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Figure 3.23: 1D Western blots of colorectal cancer cell lysate probed for cofilin and cofilin-
phospho(ser3). Protein lysate from colorectal cancer cell lines HCT116, HT29, SW480 and SW620 
were separated by 1D SDS-PAGE, transferred to membrane and western analysis undertaken with 
anti-cofilin1 and anti-phosphylated cofilin. β-actin was used as control. Primary antibody 
concentrations were cofilin1 1:10000 (A), cofilin-P 1:50 (C) and β-actin 1:20000 (B&D). A/B: Blot 
probed for cofilin1 and β-actin showing greater expression of the protein in HCT116 cells. C/D: Blot 
probed for cofilin-phospho(ser3) and β-actin showing greatest expression in HT29 and lowest 
expression in HCT116 cells28 
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3.7.3 CONFIRMATION OF SPOT IDENTITY USING 2D WESTERN BLOTTING IN CELL LINES AND TISSUE  
In order to confirm the identity of cofilin1 on tandem mass spectrometry I sought to validate the 
findings on 2D Western blot. Western blot analysis could give a more accurate impression of post-
translational modifications in the protein of interest.  Two samples from each of four lysates were 
subject to 2D electrophoresis as described in section 2.3; cell lines SW480 and HT29 in addition to 
undissected material from patient 264-05 (tumour and normal colon). One gel from each pair was 
fixed and stained with coomassie blue as control: proteins on the second gel were electro-
phorectically transferred onto nitrocellulose membrane in preparation for Western blotting as 
described in section 2.5. Membranes were stained with Ponceau stain to check adequate transfer 
prior to being probed with anti-cofilin-phospho(ser3) at 1:50 overnight at 4°C. Following 
development of the blots, membranes were stripped with stripping buffer (20ml SDS 10%, 12.5 ml 
0.5 M Tris HCl (pH 6.8), 0.8 ml ß-mercaptoethanol, 67.5 ml ultra pure water) and re-probed with 
anti-cofilin1 at 1:10,000 for 1hr at room temperature.   
Colorectal cancer cell lysate, undissected tumour and undissected normal colon showed similar 
pattern of cofilin1 staining. A string of proteins of similar molecular weight (17kDa) was seen 
extending from PI 6.5-8.0. Little non-specific cross-reactivity was seen with other proteins on the 
blot. Cofilin-phospho(ser3) showed activity in a single spot at 17kDa, PI 6.5 which corresponded 
well with the spot picked as variably-expressed on the silver-stained gels. Staining was more 
variable across samples with the metastatic cancer cell line SW480 showing heaviest staining, 
frozen tumour tissue and non-metastatic cell line HT29 showing moderate staining and normal 
colon showing minimal staining; (Figures 3.24 and 3.25). 
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Figure 3.24: 2D Western blot of cofilin and cofilin-phospho(ser3) in colorectal cancer cell lines. 
A&B. Coomassie-stained gels C&D: Ponceau-stained membrane E&F: Cofilin1 blot showing string of 
proteins at 17kDa, PI 6.5-8.0. Ringed in green. G&H: cofilin-phospho(ser3) blot showing one spot 
corresponding top the most acidic form of cofilin1 with variable expression. Ringed in green. 29 
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Figure 3.25: 2D Western blot of cofilin and cofilin-phospho(ser3) in frozen tumour and normal 
colon. A&B. Coomassie-stained gels C&D: Ponceau-stained membrane E&F: Cofilin1 blot showing 
string of proteins at 17kDa, PI 6.5-8.0. Ringed in green. G&H: cofilin-phospho(ser3) blot showing 
one spot corresponding top the most acidic form of cofilin1 with variable expression. Ringed in 
green. 30 
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3.7.4 DETECTION OF COFILIN1 AND IN PARAFFIN-EMBEDDED COLORECTAL TISSUE 
Sections of paraffin-embedded colorectal cancer tissue were stained using the protocol outlined in 
methods (Section 2.1). Primary antibody was monoclonal rabbit anti-cofilin1 at a concentration 
1:40,000. Staining of whole tumour and benign tissue sections was undertaken in order to compare 
immunohistochemistry levels with expression in laser-captured 2D gels. Initial results on whole 
tumour staining were promising with variable expression seen in tumour cytoplasm; no staining in 
tumour nucleus or membranes was identified. In benign tissue strong staining was seen in muscle; 
no or light staining at the base and stronger staining at the neck of normal colonic epithelial crypts, 
(Figure 3.26). 
The second stage of immunohistochemical evaluation was staining of the colorectal cancer tissue 
microarray using the same antibody conditions. Unfortunately, staining of a larger number (n=313) 
of specimens demonstrated that the antibody utilised was not sensitive enough to detect the small 
differences in expression levels between the majority of tumours, images not shown. 
Approximately 80-90% of the arrayed specimens had scores of 2 or 3 in the cytoplasm. The array 
was assessed by a consultant histopathologist, Dr Bahram Azadeh who felt that the pattern of 
staining given by this antibody was not sensitive or specific enough to define different groups of 
colorectal adenocarcinomas. Further evaluation of the cofilin pathway is planned using anti-cofilin-
phospho(ser3) antibody in paraffin-embedded tissue.  
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                      Tumour                         Normal 
 
    Tissue section                     2D gel                Tissue section                    2D gel 
Figure 3.26A: Immunohisto-chemistry (IHC) of cofilin1 in 
normal colon and depressed-type tumour tissue with 
corresponding 2D gel images.  
A: Whole tumour gel with area of gel shown in B marked with 
box. B: Immunohistochemistry for cofilin1 in normal colon and 
colorectal cancer tissue matched with 2D gel analysis of the 
same tissue (samples 104-06, 084-06, 264-05, 149-01). Good 
concordance demonstrated between expression of cofilin1 in 
tumour or epithelial cells on IHC (brown staining) and silver-
staining of spots on 2D gel analysis. 31 
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                   Tumour                        Normal 
 
 Tissue section               2D gel                    Tissue section            2D gel 
Figure 3.26B: Immunohistochemistry (IHC) of cofilin1 in 
normal colon and polypoid and flat-type tumour tissue with 
corresponding 2D gels images.  
A: Whole tumour gel with area of gel shown in B marked with 
box. B: Immunohistochemistry for cofilin1 in normal colon and 
colorectal cancer tissue matched with 2D gel analysis of the 
same tissue (samples 054-96, 148-01, 108-03, 075-00, 233-00, 
259-01). Good concordance demonstrated between expression 
of cofilin1 in tumour or epithelial cells on IHC (brown staining) 
and silver-staining of spots on 2D gel analysis. 32 
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3.8 S100A8 
 
3.8.1 INTRODUCTION 
The calcium-binding proteins S100A8 and S100A9 are expressed on the surface of myeloid cells and 
are secreted at the site of inflammation as stable heterodimeric complexes.(305, 306) Monocytes 
are found predominantly in the circulation, but can be recruited to areas of inflammation or 
tumour whereon they differentiate into macrophages.(307) The factors that promote monocyte 
recruitment and differentiation, and the affect this may have on the composition of the tumour-
associated stroma are not yet clear. There is some evidence to suggest that certain subsets of 
circulating monocytes can be recruited to the tumour by hypoxia and ligand expression on the 
surface of cancer cells; and that they are capable of promoting angiogenesis in the stroma.(308) 
S100A8 and S100A9, which are secreted by infiltrating monocytes have demonstrable cytokine-like 
properties, acting as a chemotactic factor for other inflammatory cells.(309) More recently, both 
proteins have been shown to activate signalling cascades through cell-surface receptors and 
promote motility of various cancer cell types in vitro. This affect has been reported to occur 
through activation of the multi-ligand receptor RAGE, (receptor for advanced glycation end-
products).(310)  
Colorectal cancers show varying degrees of desmoplastic stroma response. The cellular content of 
the surrounding stroma principally comprises myofibroblasts, myeloid cells, lymphocytes and 
macrophages. The composition of the tumour-associated stroma can affect tumour growth, 
metastasis and patient survival.(311, 312) One type of stromal response is characterised by a strong 
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‘cytotoxic’ (CD8+) lymphocytic infiltrate around the tumour margin which is closely associated with 
dendritic cells and macrophages. This type of response has been linked to tumour regression, 
inhibition of metastases and good prognosis, and is frequently associated with MSI tumours.(313) 
Other forms of stromal response have been reported in which myofibroblasts and large numbers of 
infiltrating macrophages are associated with nodal metastases and poor prognosis.(314, 315) These 
observations have been partially explained by the macrophage balance hypothesis, which proposes 
two different macrophage populations; M1 type characterised by potent cytotoxic activity, and M2 
type characterised by angiogenesis and matrix remodeling.(316) The role of the cancer cell in 
recruitment, differentiation and maintenance of the stroma is not yet fully understood. 
In 1990, Fearon and Vogelstein proposed multistage genetic alterations in colorectal carcinogenesis 
which underpin the transformation of a benign adenoma to a malignant lesion.(33) The genes 
associated with various stages of transformation were identified as the APC (5q), the K-ras gene, 
p53 gene (17p) and a gene located on 18q21. In the 18q21 region Smad4 was one of the proposed 
candidate genes. Smad4 forms a cytoplasmic complex with other Smad proteins following TGF-β 
signalling, causing them to migrate into the nucleus initiating gene transcription. Loss of expression 
of the Smad4 protein in colorectal cancers occurs in 10-15% of cases overall,(317) but is reported to 
increase in frequency in to 30-35% in those tumours with distant or nodal metastases.(318) The 
largest study of prognosis for those with 18q deletions in colorectal cancer noted a reduction in 
long-term survival predominantly in node-negative (stage II) tumours.(46) Chromosomal instability, 
CIN is the most common abnormality in colorectal cancer, however approximately 15% of sporadic 
colorectal cancers show microsatellite instability, MSI as a result of a functional mis-match repair 
Protein expression in colorectal cancer                                     EM Tweedle 
 
  
155 
 
defect (commonly as a result of promoter methylation of the hMSH2, hMLH1, hPMS1 or hPMS2 
genes).(71) These tumours generally have a characteristic pattern of increased stromal 
inflammatory response and better prognosis than similar tumours displaying chromosomal 
instability.(233, 234)  
My results in laser-captured colorectal cancer tissue suggest there is low level over-expression of 
S100A8 in colorectal cancer tissue compared to normal colonic epithelium in all tumours analysed, 
however, over-expression was more pronounced in the polypoid tumour group (Figure 3.11). Our 
group has previously identified the proteins S100A8 and S100A9 as abundant in tumour-associated 
stroma of pancreatic ductal adenocarcinoma on 2D gel analysis. Immunohistochemical validation of 
the findings revealed that the numbers of S100A8 and S100A9-expressing cells in the tumour 
stroma were related to the Smad4 status of the tumour. Comparison was made between my n=11 
2D gels of laser-captured colorectal tumours and n=12 gels of undissected Duke’s C colorectal 
cancer produced in the Division of Surgery and Oncology (work by Mr I Khattack) in which S100A8 
was also identified as differentially expressed. S100A8 was more strongly and variably expressed in 
the n=12 gels containing tumour plus associated stroma; we postulated therefore that the majority 
of S100A8 was expressed in the stroma. We undertook immunohistochemical staining for S100A8, 
S100A9 and Smad4 using our pre-existing protocol in n=313 paraffin-embedded colorectal cancer 
cases in order to assess expression of these proteins in both tumour and stromal tissue. 
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3.8.2 DISTRIBUTION OF S100A8 AND S100A9 AT IMMUNOHISTOCHEMISTRY 
As expected, normal colonic epithelium did not stain positive for either S100A8 or S100A9. There 
was universal expression of S100A8 in the cytoplasm of colorectal cancer cells which show low to 
moderate staining in all cases (intensity score 1-2). Differences in the S100A8 levels detected in 
laser-captured tumour tissue may have been due to the variable presence of inflammatory infiltrate 
within tumour glands (rather than stroma) in these cases. S100A9 was not expressed at a 
detectable level in cancer cells which corresponds with the pattern of protein expression seen on 
2D gel analysis. Similar stroma staining was seen in both colorectal and pancreatic ductal 
adenocarcinomas with cells strongly positive for S100A8 and S100A9 scattered throughout the 
tumour stroma (Figure 3.27A-D). Co-immunofluorescence was undertaken in colorectal cancer 
sections to delineate the nature of these positive stromal cells.  Co-immunofluorescence indicated 
extensive co-localization of S100A8 and S100A9 in stromal cells (Figure 3.28A). Furthermore, co-
localization of S100A9 was observed in some cells with the monocyte marker CD14 (Figure 3.28B) 
but not the macrophage marker CD68 (Figure 3.28C).These images suggest that a population of 
tumour-associated monocytes co-express S100A8 and S100A9, but these proteins are not 
expressed in tissue-associated macrophages.   
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Figure 3.27: Immunohistochemistry in paraffin-embedded colorectal cancer tissue. T=tumour, S=stroma. A: 
Tumour stained for S100A8 showing low expression in tumour cytoplasm but no S100A8 positive stroma 
cells. B: Tumour showing higher numbers of S100A8-positive stromal cells in addition to several intra-tumour 
inflammatory cells (arrowed). C: S100A9 staining confirming no expression in tumour cells and low numbers 
of positive stromal cells. D: High numbers of S100A9 positive stromal cells. E: Tumour stained for Smad4 
showing loss of expression. F: Tumour showing Smad4 expression in cytoplasm. 33 
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Figure 3.28  Co-immunofluorescence. S100A9 labelled with red fluorescence, DAPI used as nuclear 
counterstain (blue). (i) Co-localisation between red/green fluorescence plus blue nuclear 
counterstaining. (ii) Red fluorescence alone in same tissue section. (iii) Green fluorescence alone in 
same tissue section. A(i-iii): S100A8 labelled with green fluorescence and shows co-expression in 
the same S100A9-positive stromal cells. B(i-iii): CD68 labelled with green fluorescence showing no 
co-localization between CD68+ macrophages and S100A9+ cells. C(i-iii): CD14 labelled with green 
fluorescence showing co-expression of S100A9 in CD14+ monocytes.34 
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3.8.3 QUANTIFICATION OF S100A8, S100A9 AND SMAD4 EXPRESSION 
The S100A8 and S100A9 positive cells present in each tumour on the colorectal microarray were 
quantified by counting the number of stained cells in a field at 40x magnification. Tumour cores on 
the microarrays were visualized in entirety in one field at 40x magnification making the cell count 
per field equivalent to the cell count per core. The mean number of positively stained S100A8 and 
S100A9 cells was calculated by averaging the number of positive stromal cells across all the tumour 
cores scored for each patient. The number of S100A8-positive or S100A9-positive cells in each of 
313 patient tumors (mean of at least 2 TMA cores per tumor case) was determined. Numbers 
ranged from 0 (4.5% of cases) to 288, and from 0 (0.65% of cases) to 882 for S100A8 and S100A9 
respectively. The median number of stromal S100A8-expressing cells was 23 (IQR 6-70), while the 
median number of stromal S100A9-expressing cells was 65 (IQR 27-126) with 284/308 (92%) 
tumors showing more S100A9 than S100A8-expressing cells in the stroma. Although tumors 
generally contained fewer S100A8-positive than S100A9-positive cells (P<0.0001, Wilcoxon Signed 
Rank Test), there was a strong positive relationship between S100A8 and S100A9 counts (n=302 
independent tumor cases; R2=0.76, P<0.0001). This is entirely consistent with our observation that 
S100A8 co-localized with S100A9. The median S100A9/S100A8 ratio was 2.2 (IQR 1.3-4.4). To 
examine whether a relationship existed between the numbers of stromal S100A8-positive or 
S100A9-positive cells and the Smad4 tumor status, the expression of Smad4 protein was 
determined by immunohistochemistry (Figure 3.27E-F). Forty-two of 304 patients (14%) were 
categorized as Smad4-negative based on mean cytoplasmic intensity scores of ≤ 0.5. The remaining 
262/304 (86%) were categorized as Smad4 positive.  
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3.8.4  LOSS OF SMAD4 EXPRESSION IS RELATED TO STROMAL LEVELS OF S100A8  
We found that loss of Smad4 expression in the primary tumour was associated with significantly 
lower median counts of S100A8-positive monocytes in the stroma; 14 (IQR 5-37) in Smad4-negative 
group compared to 25 (IQR 6-76) in the Smad4-positive group, P=0.036, Mann-Whitney U Test, 
(figure 3.29C).  A Receiver Operating Characteristic, ROC curve was constructed to establish 
whether stromal S100A8 counts were predictive of Smad4 expression in the tumour, and was found 
to be conclusive with a threshold of <42 S100A8+ cells, (Area Under the Curve, AUC=0.602, 
P=0.024), figure 3.29D. There was no difference in the S100A9-positive count between Smad4 
negative and positive tumours, 48 (IQR 23-96) versus 65 (IQR 27-129), P=0.266, Mann-Whitney U 
Test, figure 3.29E. The ROC curve constructed to establish whether stromal S100A9 counts were 
predictive of Smad4 expression in the tumour showed no significant relationship between the two 
factors, (AUC=0.554, P=0.250), figure 3.29F. The S100A8 and S100A9-positive cell counts were 
divided into two groups; S100A8 was divided by the predicted threshold for prediction of Smad4 
status (<42 cells versus ≥42 cells) and S100A9 was divided by the median count (≤65 cells versus 
>65 cells) as the ROC curve did not predict a significant threshold point. Low numbers of S100A8-
positive cells, but not S100A9-positive cells are linked to loss of Smad4 expression in the primary 
tumour, P=0.015, Fisher’s exact test, (Table 3.8). 
 
SMAD4 
staining 
Cases with 
S100A8 scoring, 
n=300 (%) 
No of S100A8 +ve cells p-value Cases with 
S100A9 scoring, 
n=298 (%) 
No of S100A9 +ve cells p-
value Low <42 (%), 
n=190 
High ≥42 
(%), n=110 
Low <52 
(%), n=127 
High ≥52 
(%), n=171 
    
 
0.015 
    
 
 
 
0.094 Negative , n=42 41 (14) 33 (17) 8 (7) 42 (14) 23 (18) 19 (11) 
        
 
       
Positive, n=262 259 (86) 157 (83) 102 (93)  256 (86) 104 (82) 152 (89)  
       
Table 3.8: Correlation between Smad4 expression in the tumour and S100A8 and S100A9+ cells in the 
stroma24 
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Figure 3.29: correlation between stromal S100A8 and S100A9 and Smad4 in the tumour. A: Correlation 
between number of stromal S100A8 and S100A9+ cells in the same tumour, B: comparison of S100A8 and 
S100A9+ stromal cells, C: numbers of S100A8+ cells in relation to Smad4 status of tumour, D: Roc curves to 
predict Smad4 expression using S100A8+ cell counts, E: numbers of S100A9+ cells in relation to Smad4 status 
of tumour, D: Roc curves to predict Smad4 expression using S100A9+ cell counts 35 
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3.8.5 RELATIONSHIP OF SMAD4 TUMOUR EXPRESSION AND S100A8 AND S100A9 STROMAL 
EXPRESSION WITH CLINICOPATHOLOGICAL PARAMETERS 
We aimed to establish whether a relationship existed between the various tumour and stromal 
proteins identified on the tissue microarray and the clinical and histological parameters of those 
tumours, Table 3.9. Patients were categorized as having mean S100A8-positive cell counts that 
were low (≤median of 23), n=156 or high (>23), n=153. Similarly, for S100A9, patients were 
categorized as having low (≤median of 65), n=159 or high (>65), n=147 cell counts. Smad4 
expression was categorised as negative (≤0.5 mean score, n=42) and positive (>0.5 mean score, 
n=262). No correlation was demonstrated between degree of stromal S100A8 and S100A9 
infiltration with age at surgery, gender, site of tumour, depth of tumour invasion or nodal 
metastases (Table 3.9). However, high cell S100A8 and S100A9 counts were associated with larger 
tumour size (P=0.01 and 0.0006 respectively; chi-squared test). High S100A9 counts were 
associated with poor differentiation grade, P=0.036, (Table 3.9, chi-squared test). Smad4-negative 
tumours were significantly associated with greater depth of tumour infiltration than Smad4 positive 
tumours; P=0.022, (Table 3.10, Chi-squared test). Loss of Smad4 expression was more frequent in 
rectal tumours compared to colonic tumours, 55% versus 37%, P=0.027, (Table 3.10, Chi-squared 
test). No relationship between Smad4 expression and differentiation grade, size of tumour or 
presence of nodal metastases was established in our patient cohort (Table 3.10).  
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Table 3.9: Clinicopathological characteristics and correlation with S100A8+ and S100A9+ cell 
infiltrates in the stroma. S100A8 and S100A9 cell counts were dichotomized by median counts and 
analysed according to clinical and pathological variables. Statistical analysis was performed using 
chi-squared test.  25 
Clinicopathological 
parameter 
All cases, 
n=313 (%) 
S100A8 +ve cells, n=309 p 
value* 
S100A9 +ve cells, n=306 p 
value* 
Low ≤23 cells 
(%), n=156 
High >23 cells 
(%), n=153 
Low ≤65 cells 
(%), n=159 
High >65 cells 
(%), n=147 
Age 70 (IQR 62-76 
years) 
 
 
      
Young (<median) 155 (49) 75 (48) 80 (52) 0.459 75 (47) 78 (53) 0.303 
Old (> median) 158 (51) 81 (52) 73 (48)  84 (53) 69 (47)  
Gender        
Male 188 (60) 93 (60) 92 (60) 0.926 97 (61) 85 (58) 0.570 
Female 125 (40) 63 (40) 61 (40)  62 (39) 62 (42)  
Site of tumour        
Colon 188 (60) 89 (57) 96 (63) 0.307 94 (59) 90 (61) 0.707 
Rectum 125 (40) 67 (43) 57 (47)  65 (41) 57 (39)  
Size 50 (IQR 38-60mm)        
Small-Medium (<60mm) 214 (69) 116 (74) 94 (61) 0.014 123 (77) 87 (59) 0.0006 
Large (≥60mm) 99 (31) 40 (26) 59 (39)  36 (23) 60 (41)  
Differentiation grade        
Well 5 (2) 2 (1) 2 (1) 0.819 2 (1) 3 (2) 0.036 
Moderate 283 (90) 140 (90) 140 (92)  150 (94) 127 (86)  
Poor 21 (7) 12 (8) 9 (6)  5 (4) 15 (11)  
Uncategorised 4 (1) 2 (1) 2 (1)  2 (1) 2 (1)  
Excision Margin        
Clear 270 (86) 130 (83) 138 (90) 0.055 134 (84) 130 (88) 0.199 
Involved 39 (13) 25 (16) 12 (8)  24 (15) 14 (10)  
Uncategorised 4 (1) 1 (1) 3 (2)  1 (1) 3 (2)  
T-stage        
T1 13 (4) 8 (5) 5 (3) 0.766 8 (5) 5 (3) 0.356 
T2 47 (15) 22 (14) 25 (16)  21 (13) 24 (16)  
T3 206 (66) 104 (67) 101 (66)  110 (69) 92 (63)  
T4 44 (14) 19 (12) 22 (15)  18 (12) 25 (17)  
Uncategorised 3 (1) 3 (2) 0  2 (1) 1 (1)  
N-stage        
N0 177 (56) 82 (53) 93 (61) 0.446  90 (57) 82 (56) 0.332 
N1 71 (23) 38 (24) 32 (21)   40 (25) 30 (20)  
N2 62 (20) 33 (21) 28 (18)    27 (17) 34 (23)  
Uncategorised 3 (1) 3 (2) 0  2 (1) 1 (1)  
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Table 3.10: Association between Smad4 status and clinicopathological parameters. Tumours were 
dichotomized by Smad4 expression into negative and positive tumours and compared to clinical and 
pathological tumour features.  Chi-squared test used for statistical analysis.  26 
Clinicopathological 
parameter 
All cases,  
n = 303 (%) 
SMAD4 status p value 
Negative (%), n=42 Positive (%), n=261 
Age (median 70, ranged 33-
93) 
    
Young (<median) 148 (49) 23 (55) 125 (48) 0.409 
Old (≥ median) 155 (51) 19 (45) 136 (52)  
Gender     
Male 183 (60) 26 (62) 157 (60) 0.829 
Female 120 (40) 16 (38) 104 (40)  
Site of tumor     
Colon 184 (61) 19 (45) 165 (63) 0.027 
Rectum 119 (39) 23 (55) 96 (37)  
Size 50 (IQR 38-60mm)     
Small (<38mm) 72 (24) 9 (21) 63 (24) 0.863 
Medium (38-59mm) 133 (44) 20 (48) 113 (43)  
Large (≥60mm) 98 (32) 13 (31) 85 (33)  
Differentiation grade     
Well 5 (2) 1 (3) 4 (1) 0.848 
Moderate 273 (90) 38 (90) 235 (90)  
Poor 21 (7) 3 (7) 18 (8)  
Uncategorized 4 (1) 0 4 (1)  
Excision Margin     
Clear 262 (87) 36 (86) 226 (86) 0.848 
Involved 37 (12) 5 (12) 32 (13)  
Uncategorized 4 (1) 1 (2) 3 (1)  
pT     
T1 13 (4) 1 (2) 12 (5) 0.022 
T2 43 (14) 4 (10) 39 (15)  
T3 203 (67) 25 (59) 178 (68)  
T4 41 (14) 12 (29) 29 (11)  
Uncategorized 3 (1) 0 3 (1)  
pN     
N0 171 (56) 22 (52) 149 (57) 0.547 
N1 70 (23) 13 (31) 57 (22)  
N2 59 (20) 7 (17) 52 (20)  
Uncategorized 3 (1) 0 3 (1)  
Stage (AJCC)     
I 37 (12) 4 (9.5) 33 (13) 0.697 
II 133 (44) 18 (42.9) 115 (44)  
III 128 (42) 20 (47.6)  108 (41)  
Uncategorized  5 (2) 0 5 (2)  
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3.8.6  ASSOCIATION BETWEEN NUMBERS OF STROMAL S100A8 AND S100A9-POSITIVE CELLS AND 
CANCER-SPECIFIC SURVIVAL  
Following the confirmation of an association between stromal S100A8 and S100A9 and tumour size, 
we endeavored to determine whether a relationship existed between these proteins and overall 
patient survival. Kaplan-Meier curves were constructed of overall 96-month survival for n=302 
patients according to stromal S100A8 expression and n=299 according to stromal S100A9 
expression. For the purpose of analysis, patients were catagorised as having high or low S100A8 
and S100A9 counts based on the median cell count (≤23 versus >23 cells S100A8, ≤65 versus >65 
cells S100A9). No survival difference was observed for either protein (Figure 3.30A(i/ii). On analysis 
of patients with loss of Smad4 expression in the primary tumour (n=38), high S100A8 counts were 
associated with poorer survival at 36 months, (76% versus 39%, p=0.02 Mantel-Cox), but not at 96 
months (P=0.29, Mantel-Cox), figure 3.30B(i). A similar pattern was seen for S100A9 counts, high 
S100A9 in the stroma corresponded with poor early survival (73% versus 41% P=0.02, Mantel-Cox) 
but no difference was seen in the long term (P=0.36, Mantel-Cox), Figure 3.30B(ii). In patients with 
Smad4 positive tumours, neither S100A8 nor S100A9 counts in the stroma appeared to predict 
overall short, or long-term survival, (P=0.37 and P=0.80 respectively), Figure 3.30C(i/ii).  
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Figure 3.30: Cancer specific survival according to stromal S100A8 and S100A9+ cells. Kaplan-Meier curves 
with p-values (Mantel-Cox). A: Survival according to stromal S100A8+ cells (i) and S100A9+ cells (ii). B: Smad4 
negative tumours; survival according to S1008+ cells (i) and S100A9+ cells (ii), C:  Smad4 positive tumours; 
survival according to S1008+ cells (i) and S100A9+ cells (ii). 36 
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3.8.7 LOSS OF SMAD4 EXPRESSION PREDICTS FOR POOR SURVIVAL IN SOME PATIENT GROUPS 
Loss of Smad4 expression has been mooted as a poor prognostic marker in colorectal cancer, we 
planned to establish whether this was the case in our cohort of patients. Kaplan-Meier curves were 
constructed to assess the impact of Smad4 on overall survival in colorectal cancer. Survival analyses 
were performed on 259 patients after excluding 37 patients with non-curative tumor resections 
(positive tumor resection margins) and 7 patients who died within 30 days of surgery. Patients with 
node-negative tumors had significantly better survival compared to those with node-positive 
tumors (P<0.0001, Figure 3.31A). Smad4 loss was not associated with survival (P=0.09) when the 
entire cohort of 259 patients was examined (Figure 3.31B). However, when the node-negative 
(Stage I and Stage II) and node-positive (Stage III) cancer patients were analyzed separately, it was 
observed that patients in the node-negative cancer group who had lost Smad4 expression had 
poorer survival compared to patients in that group who had retained Smad4 expression (n=156; 
P=0.019, Figure 3.31C). In fact, the survival of patients with node-negative tumors who had lost 
Smad4 expression was similar to that of patients with nodal metastases (P=0.542, Figure 3.31D). 
There was no association between Smad4 expression and survival in the node-positive cancer 
group (n=103; P=0.925, Figure 3.31E). 
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Figure 3.31: Association between Smad4 status and cancer-specific survival. Kaplan-Meier curves 
with p-values (Mantel-Cox). A: Nodal status, B: Smad4 expression, C: N0 tumours; survival 
according to Smad4 status, D: N+ tumours; survival according to Smad4 status, E: N0, Smad4 
negative tumors versus all N+ tumours 37 
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4. DISCUSSION 
 
The key findings of this MD are summarized as follows: 
1. Laser-capture microdissection of frozen colorectal tissue was successfully performed and 
sufficient material generated to produce 19 good quality (10 tumour and 9 normal epithelium), 
silver-stained 2D gels using SDS-PAGE. 
2. 2D gels were analysed for variations in protein spot pattern between tumours of different 
morphologies; depressed-type, flat-type and polypoid-type. Six proteins were successfully 
identified using in-gel trypsin digestion and tandem mass spectrometry; these were redox 
proteins peroxiredoxin 2, peroxiredoxin 6 and SH3 binding glutamic acid-rich protein-like 3; and 
cytoskeletal protein cofilin1. Also identified were the anti-apoptotic protein heat shock protein 
27 and inflammatory protein S100A8, which had been previously identified in 2D gel analysis of 
undissected colorectal cancer in our Institution (n=12 gels). 
3. Heat shock protein 27 expression was evaluated in a large cohort of n=404 paraffin-embedded 
colorectal cancer tissue, including n=98 samples previously validated in a small cohort of 
paraffin-embedded colorectal cancers in our Institution. High HSP27 levels were strongly 
associated with poor cancer-specific survival in rectal cancer (n=205, P=0.0063) but not colon 
cancer; (n=199, P=0.7385). Multivariate Cox regression confirmed nodal metastases (P=0.0001) 
and HSP27 expression (P=0.0233) as independent markers of survival in rectal cancer. 
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4. S100A8 and related proteins S100A9 and Smad4 were similarly evaluated in a large cohort 
(n=313).  S100A8 expression co-localised with a subset of S100A9-positive monocytes. S100A9 
was co-expressed with CD14 in tumour-associated monocytes, but not with CD68 in tissue 
macrophages. Smad4 was expressed in the tumour cytoplasm of 262/304 (14%) tumours. Loss 
of Smad4 expression correlated with a reduction in the stromal S100A8-positive, but not 
S100A9-positive cell count, (P=0.034, Mann-Whitney U test) and  was associated with a poorer 
overall survival in patients with stage I-II disease, but not stage III disease.  
5. Antibodies to cofilin1 and cofilin-phospho(ser3) were assessed in colorectal cancer cell and 
tissue lysate and found to be specific on 1D and 2D western blot. Cofilin antibody did not show 
sufficient variability of staining when used for immunohistochemistry in colorectal cancer tissue 
to be useful for accurately assessing and scoring expression of the cofilin protein.  
Further discussion of these findings is detailed in the following sections. 
 
4.1 PROTEINS IDENTIFIED USING LASER CAPTURE AND 2D GEL ANALYSIS 
 
Laser-capture microdissection and 2D gel electrophoresis for proteomic analysis was first described 
in 1999.(319) Numerous groups have successfully combined laser capture with 2D SDS-PAGE,(239, 
320-324) DNA analysis,(325-329) and mRNA analysis.(330, 331) The advantage of this methodology 
is that it allows specific selection of cell populations from human colorectal cancers in situ, without 
resorting to cell line culture. Normal colonic epithelium, not amenable to culture as a cell line, can 
be also analysed using this technique.(188, 332) Our results confirm that laser capture 
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microdissection and 2D gel proteomic analysis is feasible in frozen colorectal adenocarcinoma and 
benign colonic epithelium. The gels produced are readily amenable to interpretation visually and 
electronically to highlight differentially-expressed protein spots, and in this study the technique led 
to the identification of proteins that appear to be variably expressed both between different 
morphologies of colorectal cancer and between cancer tissue and benign epithelial tissue.  A recent 
meta-analysis of proteomic analysis in colorectal cancer tissue found 98 proteins reported as 
variably regulated in more than one study. They included high abundance proteins (serum albumin, 
HLA class I and kerritin type II cytoskeletal 8); cytoskeletal proteins (annexin A5, A4, A3 and A1, 
tropomyosin beta chain, actin, coronin 1C, ezrin, vimentin and gelsolin); inflammatory proteins 
(S100A9, macrophage capping protein, leukocyte elastase inhibitor); redox proteins 
(peroxiredoxin1, glyceraldehydes-3-phosphate dehydrogenase, glutathione s-transferase P, 
thiosulfate sulfurtransferase); cellular stress proteins (heat shock protein beta1, heat shock protein 
75, endoplasmin, heat shock protein 90); synthesis/degradation proteins (elongation factor 2, 
apolipoprotein A1, UDP-glucose dehydrogenase, serpin B6, eukaryotic initiation factor 4A); cell to 
cell interaction proteins (thrombospondin 1, lamin-B1).(332)  
 
4.2 HEAT SHOCK PROTEIN 27 
 
We report the identification of the low molecular weight heat shock protein, HSP27 as differentially 
expressed in colorectal cancer using proteomic techniques. It is interesting to note that HSP27 has 
been reported as over-expressed in approximately 30% of 2DE proteomic studies.(333) It is 
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consistently identified in investigative proteomic studies of colorectal cancer, both tissue and cell 
lines.(334, 335) Despite promising initial reports, this study was the first to undertake validation of 
the expression of this protein on a large scale in adenocarcinoma of the colon and rectum.  
Tissue microarrays are a powerful tool for high-throughput evaluation of putative biomarkers, 
although concerns have been raised that lack of tumour heterogeneity could cause misleading 
results. Several studies have addressed this issue and reported the concordance between TMA and 
tumour sections when assessing one core is in the region of 80% and this increases to 95% when 
two cores are included.(336) Our TMAs were constructed using 2-6 cores per tumour and care was 
taken to include benign liver, kidney and colon tissue as internal control. Immunohistochemistry 
detection of HSP27 has been previously reported in formalin-fixed colorectal cancer using a variety 
of antibodies and scoring protocols. The findings have thus far been inconclusive; one group 
reported a strong relationship between HSP27 expression in the primary tumour and nodal status 
in n=40 patients,(334) whilst a second group found no such association in n=68 patients.(337) We 
devised a reproducible method of grading intensity of HSP27 staining by direct comparison to 
internal TMA control tissue (colon, liver and kidney); in addition to scoring the percentage 
expression in each core. In our cohort of n=404 patients we observed no correlation between any 
aspect of HSP27 staining in the primary tumour, (intensity, percentage or combined score) with 
histopathological features including nodal status. As we proceeded to analyse the association 
between aspects of HSP27 expression and overall survival we found the intensity rather than 
percentage staining to be prognostic, however an index which combined both the intensity and 
percentage scores was most strongly associated with survival.  
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We report the novel finding that high HSP27 expression is an independent marker of poor 
prognosis in patients with rectal cancer, but not colon cancer. This adds to accumulating evidence 
that rectal and colon tumours are distinct biologically entities and have a different pattern of 
genetic mutations.(338) The link between HSP27 expression and survival has been investigated in a 
multitude of human cancers.(271) Poor overall- and cancer-specific survival has been linked to 
elevated HSP27 expression in prostate cancer; it also correlates with various histological 
parameters including Gleason score and lymph node metastases.(244, 339, 340) Despite initial 
promising reports in breast cancer,(341) larger studies of node-positive and negative patients failed 
to demonstrate a difference in overall or cancer specific survival according to HSP27 
expression.(342, 343) Numerous other small studies have identified high HSP27 as poorly-
prognostic in ovarian cancer,(344) gastric cancer(345) and hepatocellular cancer.(346) We observed 
elevated HSP27 as predictive of lower five-year cancer-specific survival across all stages of rectal 
cancer, however there was a stronger association with stage III compared to stage I/II disease. 
However, utilising elevated HSP27 as a biomarker, we defined a poor prognostic group of stage II 
patients with a similar survival to that of stage III patients. This may be an area in which further 
work could aid clinical decision making in the management of this patient group.  HSP27 expression 
was independently associated with survival in rectal cancer patients on multivariate analysis. We 
were interested to note that age and resection margin status, approached, but did not reach 
significance which was contrary to our expectations. We felt this reflects the lack of standardised 
pathological reporting of rectal cancer in our institution. The introduction of standard surgery in the 
form of total mesorectal excision (TME) and guidelines on the minimum pathological dataset were 
introduced in 1999.  
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We report the novel findings that radiotherapy treatment does not alter the expression of HSP27 
between diagnosis and surgical resection of a rectal tumour. Variation, both up and down 
regulation, was observed in 19% of diagnostic biopsies compared to the primary tumour. This may 
reflect the small, superficial nature of some of the biopsy material or could be indicative of tumour 
biology. Our findings concord with the only published prospective study of HSP27 expression in 
relation to radiotherapy treatment of rectal cancer, which reported no consistent change in HSP27 
expression identified after radiotherapy was administered.(347) We conclude that there is no 
evidence to suggest that radiotherapy treatment induces HSP27 expression in rectal cancer. 
The mechanism by which HSP27 exerts its effects on survival in cancer is not fully understood. 
HSP27 may confer a gain of function for the tumour cell in terms of motility and invasion or 
increase tumour cell survival by inhibition of apoptosis and resistance to anti-cancer treatments. 
There is emerging in vitro evidence that HSP27 can promote motility and increase cancer cell 
invasion, in part by promoting secretion of metalloproteinase MMP2.(348) This is mediated by the 
TGFβ/p38 mitogen-activated protein kinase pathway, implying a role for the phosphorylated 
isoform of HSP27 in this phenomenon.(349) HSP27 has been associated with inhibition of NF 
kappaB in hepatocellular carcinoma cells. Knockdown of HSP27 in these cells resulted in increased 
concentrations of NF kappaB in the nucleus, suppressed cell migration and invasion and induced 
apoptosis.(350) Reducing the expression of HSP27 by siRNA interference has demonstrated an 
increase in apoptosis and cell death via capase-3 in prostate cancer cell lines.(351) A similar study 
conducted using human bladder cancer cells in murine models demonstrated that HSP27 
knockdown resulted in reduced tumour growth and enhanced sensitivity to chemotherapy.(352) 
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The role of HSP27 in chemoresistance has been intensely studied and the protein has been 
implicated in 5-fluorouracil and irinotecan resistance in colorectal cancer(353-355) and more 
recently, pancreatic cancer.(321) Of particular interest in rectal cancer, as with prostate and 
bladder cancer is the role that HSP27 plays in resistance to radiotherapy; indeed there is in vitro 
evidence that HSP27 confers resistance to gamma-radiation in human cancer cell lines.(356) 
Combined treatment using anti-sense oligonucleotides against HSP27 and radiotherapy in mice 
with SQ20B radioresistant head and neck squamous cell carcinomas resulted in tumour shrinkage, 
reduced angiogenesis and increased survival.(357) Further work is required to establish a link 
between HSP27 expression, resistance to radiotherapy treatment and prognosis in rectal 
adenocarcinoma.  
To conclude, elevated HSP27 is an independent marker of poor prognosis in rectal cancer. 
Expression of the protein is not altered by neo-adjuvant radiotherapy and further work is necessary 
to determine whether HSP27 has a role to play in resistance to adjuvant radiotherapy and 
chemotherapy in vivo. 
 
4.3 COFILIN1 
 
In this study an isoform of cofilin1 was identified as potentially differentially expressed on 2D gel 
analysis of laser-captured frozen colorectal cancer tissue and benign colonic epithelium. The 
colorectal cancers formed three distinct morphological groups, flat, depressed and polypoid types. 
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The protein spot identified appeared to be maximally expressed in polypoid tumours, with 
correspondingly lower levels in the matched benign tissue. In the flat and depressed tumours the 
level of the protein was lower than polypoid tumours, with correspondingly higher expression in 
the matched benign tissue. The small numbers of tumours utilised in this stage of the analysis led 
us to investigate the protein expression further using colorectal cancer cell lines and tissue. We 
undertook preliminary investigations of two commercially available antibodies to cofilin1 and its 
physiologically inactive isoform cofilin-phospho(ser3) in protein lysate and paraffin-embedded 
tissue in order to confirm the identity of the protein spot and assess specificity prior to validation. 
Using 1D western blotting we established both anti-cofilin1 and anti-cofilin-phospho(ser3) 
antibodies to be specific for a protein band of the appropriate molecular weight in colorectal cancer 
cell lysate and whole cancer tissue lysate. Cofilin-phospho(ser3) was variably expressed whereas 
cofilin1 had a similar expression levels between cell lines. 2D western blot analysis in whole tumour 
lysate and colorectal cancer cell lysate confirmed the protein spot of interest to be cofilin-
phospho(ser3).   
Immunohistochemistry for cofilin1 was performed using the same antibody in paraffin-embedded 
benign and malignant colorectal tissue to assess distribution of staining. We found cofilin1 to be 
expressed strongly in smooth muscle and endothelium in addition to normal colonic epithelium 
(particularly cells at the neck of crypts). Variation could be detected in the level of staining between 
tumours after staining of n=10 tumour sections and n=9 benign sections from the same tumour 
material subject to 2D analysis. This is consistent with data from the only paper reporting cofilin1 
immunohistochemistry in tumour tissue which found variable expression in n=34 gastrointestinal 
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endocrine tumours.(304) Unfortunately, on increasing the numbers of colorectal adenocarcinomas 
stained to n=313, the results showed poor consistency of staining between cores from the same 
tumour and insufficient variation in staining between tumours for cofilin1 to be of value as a 
prognostic marker. Further cofilin1 staining was therefore abandoned in favour of the more 
variably-expressed cofilin-phospho(ser3), although evaluation is not yet complete. Accurate 
assessment of phosphorylated proteins is notoriously difficult due to 1. Lack of antibody affinity and 
2. Degradation of phosphorylated proteins during tissue fixation. One paper reported that levels of 
phospho-proteins were unreliable in formalin-fixed tissue specimens larger than 2cm3 due to time-
dependent de-phosphorylation of proteins following devascularization.(358, 359) Assessment of a 
large number of tumours is vital in order to obtain reproducible results. 
 
4.4 S100A8 
 
We have previously demonstrated that the calcium-binding proteins S100A8 and S100A9 are 
expressed in tumour-associated monocytes in pancreatic cancer stroma in differing quantities.(59) 
A number of other studies have used similar proteomic techniques to detect the differential 
expression of the S100 group of proteins in cancer material, including pancreas,(59, 360)  
breast,(361) prostate,(362) bladder (363) and colorectal.(364) In this study S100A8 was found 
expressed at higher levels in colorectal cancer tissue compared to benign epithelial tissue on 2DE 
gel analysis. Verification of our findings using immunohistochemistry demonstrated low-level 
expression of S100A8, but not S100A9 in all colorectal cancer tissue. The tumour stroma was found 
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to contain variable numbers of S100A8 and S100A9-positive infiltrating cells. Co-
immunofluorescence indicated that S100A8 is expressed in a subset of S100A9 positive cells which 
is consistent with our finding that tumours contained greater numbers of S100A9- than S100A8-
positive cells. S100A8 and S100A9 are reported to be expressed in circulating granulocytes and pro-
inflammatory monocytes but not in tissue resident macrophages.(365, 366) They promote 
phagocyte migration by enhancing the polymerisation of microtubules and S100A8/S100A9 
heterodimers (also known as calprotectin) are believed to recruit further monocytes to sites of 
inflammation. The expression and secretion of these proteins in the tumour microenvironment is 
likely to contribute to the host inflammatory response to the tumour.(367) Given that S100A9 
positive cells did not co-express CD68, a marker of mature macrophages, but did co-localise with 
CD14, a monocyte marker, the cells we have observed are likely to represent tumour-associated 
monocytes or immature macrophages, which are characterised by a lack of or low expression of 
differentiation-associated macrophage antigens (reviewed in Lewis et al.(316)).  
There has been a great deal of work on the influence of tumour-associated macrophages, (TAMs) in 
the stroma of colorectal cancer patients. Evidence suggests there is a spectrum of macrophage 
phenotypes in the tumour environment ranging from M1, which co-operate with T-cell and 
dendritic cells and have potent anti-tumour cytotoxic capacity; to M2, which promote stromal 
remodelling, angiogenesis and have immumnosuppressive capabilities.(368) Certainly, a dense 
CD86+ macrophage infiltrate around the tumour margin is associated with a good prognosis in 
colorectal cancer,(369, 370) conversely high intra-tumoural macrophages, (TAMs) have been found 
shown to predict for poor survival.(314) Less is known about the recruitment of monocytes from 
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the circulation into the tumour-associated stroma, the differentiation of these cells or the 
prognostic significance of such infiltrates. One recent report centred on the discovery of a subset of 
Tie2+ monocytes in the circulation which were attracted to the tumour both by hypoxia, and the 
expression of the receptor Angiopoietin-2 of the surface of the cancer cells.(371) These monocytes, 
on recruitment, were associated with areas of angiogenesis and high TAM infiltration within the 
stroma. We found that in this study, large colorectal tumours (≥60mm) were coupled with a 
profound increase in the S100A8 and particularly S100A9-positive cell counts in the stroma. This 
may indicate a role for these cells in supporting stromal vascularisation and tumour growth. In 
common with other studies and our own findings in pancreatic adenocarcinoma,(59, 372) we did 
not observe any differences in overall survival associated with the numbers of infiltrating S100A8 or 
S100A9-positive monocytes in the stroma in colorectal cancer patients .                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Loss of Smad4 expression is observed in 10-15% of colorectal cancers and is reported to be a 
relatively late event in cancer development. We have ascertained the loss of Smad4 expression in 
42/304 (14%) cases overall, which is consistent with previous reports.(58, 373) In our patient group 
we found no difference in the Smad4 expression according to the presence of lymph node 
metastases, but there was a relationship between loss of Smad4 and depth of tumour invasion. This 
is in contrast to a number of other studies which have observed that loss of Smad4 expression 
occurs with increasing frequency in tumours which have metastased to nodes or distant 
organs.(374-376) There is also conflicting evidence for the use of Smad4 as a prognostic marker in 
colorectal cancer, however most papers report poor prognosis in association with loss of Smad4 
expression or deletion of 18q.(58, 373, 377) There has been recognition that loss of Smad4 
Protein expression in colorectal cancer                                     EM Tweedle 
 
  
180 
 
expression is poorly-prognostic in earlier stage colorectal tumours in some studies.(60, 378) We 
found that loss of cytoplasmic Smad4 expression does predict poor survival in those patients with 
node-negative disease, whereas in those with node-positive disease there was no detectable 
difference.  
Smad4 is an intracellular mediator of TGF- signalling. While TGF- functions as a tumour 
suppressor in early stages of carcinogenesis by potently inhibiting cell growth, cancer cells 
characteristically acquire resistance to this growth inhibition and frequently secrete high levels of 
TGF- at later stages.(52) There is mounting evidence to suggest that loss of Smad4 expression and 
resistance to TGF- are separate and unrelated events in carcinogenesis.(379) Re-introduction of 
Smad4 expression into Smad4-negative colorectal cancer cells did not restore TGF- mediated 
growth inhibition, or impede proliferation of tumour cells in vitro. However, these clones showed a 
marked restriction of tumour growth in vivo in nude mice which was related to a reduction in 
angiogenesis. Smad4-negative clones were found to produce 2-3 fold more of the cytokine Vascular 
Endothelial Growth Factor, VEGF than clones which re-expressed Smad4.(380) A recent study has 
shown that knock-down of Smad4 rendered cancer cells resistant to TGF- induced cell cycle arrest 
and migration but not to TGF- induced epithelial-mesenchymal transition.(381) This indicates that 
cancers cells which have lost Smad4 expression respond differently to stimulation from exogenous 
cytokines such as TGF- and this may be associated with a fundamental change in the behaviour 
and secretion profile of these cells.  
Consistent with a recent report in primary pancreatic adenocarcinoma; in this study we observe the 
same association in colorectal cancer.(59) There are few reports to date of direct relationships 
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between the genetic status of tumour cells and the expression patterns of surrounding host cells. 
Our data thus provide important evidence of a direct relationship between cancer cells and host 
stromal response. The Smad4 status of cancer cells has been shown to directly influence the 
protein composition of the surrounding stroma; Smad4-negative clones have been shown to 
differentially secrete high levels of the matrix proteins SPARC (secreted protein, acidic and rich in 
cysteines) compared to clones which re-express Smad4.(382) SPARC has previously been 
characterized as an anti-adhesive and invasion-promoting protein which may have a role in 
facilitating tumour invasion.(383) Evidence suggests that loss of Smad4 also induces changes in the 
cytokine expression profile of the primary tumour which, in turn, changes the stromal 
environment.(384) We have postulated that these changes to the tumour microenvironment may 
promote recruitment of distinct sets of monocytes from the circulation or influence the rate or 
direction of differentiation of these cells. Support for this theory comes from a murine model of 
wound healing in which S100A8 expression was induced in fibroblasts by fibroblast growth factor-2 
(FGF-2) and reduced by TGF-.(385) More research is required into this area to fully understand the 
mechanisms behind this phenomenon. 
We found that high levels of infiltrating S100A8 positive cells in the stroma of Smad4-negative 
colorectal cancer patients demonstrated poorer short-term survival than those with low levels of 
infiltrate, although there was no difference in survival in the longer term. This may indicate that 
Smad4-negative tumours have a decreased time to recurrence or distant metastases in the 
presence of high numbers of S100A8-positive monocytes. It is possible that Smad4-negative 
tumours with high S100A8 infiltrate develop early metastases and are not candidates for curative 
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resection of the primary tumour, which may explain the lower frequency of this phenotype in our 
cohort. This is supported by evidence from a murine model in which VEGF and other soluble 
chemokines released by the tumour induced production of S100A8 and S100A9 from recruited 
myeloid cells in the lung, promoting the subsequent development of metastases at the site, 
endorsing the theory that S100A8 and S100A9 are key to priming the pre-metastatic niche for 
tumour cells.(386)   
Both S100A8 and S100A9 have been reported to have cytotoxic effects at high levels,(387) however 
recent reports using a number of human cancer cell lines suggests that S100A8/A9 may trigger 
intracellular signalling pathways in cancer cells by activating the multiligand receptor RAGE 
(receptor advanced glycation end-products).(310, 388) RAGE signalling induces an inflammatory 
signalling cascade inside the cell which activates Nuclear Factor-Kappa-Beta, NF-κ. Several NF-κ-
regulated genes encode adhesion molecules, matrix metalloproteinases (MMP), serine proteases 
and chemokines (such as IL-6) which are known to be implicated in tumour invasion and 
metastasis.(389) It is clear that interaction between the cancer cell and its environment is one 
important factor in determining metastatic behavior.(390, 391) Changes to the tumour 
environment induced by loss of Smad4 may allow cancer cells to take advantage of S100A8/A9-
induced signalling in vivo. This may explain the difference in survival observed in Smad4-negative, 
but not Smad4-positive tumours in response to high stromal S100A8 positive monocytic infiltrate.  
To conclude, we have demonstrated that expression of S100A8 and S100A9 can be detected on 
infiltrating CD14+/CD68- monocytes or undifferentiated macrophages in the stroma. Smad4-
negative colorectal cancers are associated with a change in composition of the surrounding stroma 
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demonstrating lower levels of S100A8-positive infiltrating monocytes. Loss of Smad4 expression is 
not predictive of overall survival except in those patients with node-negative disease, and those 
with high levels of infiltrating S100A8-positive stromal cells. Our findings underpin the importance 
of the interaction between cancer cells and their microenvironment to the malignant potential of 
colorectal tumours.  
 
4.5 FINAL CONCLUSION 
 
 
In conclusion, laser-capture microdissection combined with 2D gel analysis and tandem mass 
spectrometry allowed me to successfully compare protein-expression between colorectal cancer 
and normal tissue, and between different morphologies of colorectal cancer. In this small study it 
was not possible to identify all differentially-expressed proteins on the gels; however the most 
promising candidate spots according to Samespot software analysis and intra-observer visual 
analysis were identified. Validation of five candidate proteins was attempted and succeeded two 
proteins, owing to available antibodies with specific and reproducible staining on tissue 
immunohistochemistry. At the conclusion of this study, HSP27 as a prognostic marker in rectal 
cancer and S100A8 expression in the stroma of colorectal cancer tissue have been characterised 
and published. The aims of this study at the outset have not been met in entirety as there remain 
other differentially-expressed spots to identify and more proteins to validate; however a sound 
platform for further work in the area has been achieved.  
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4.6  AREAS OF FUTURE RESEARCH 
 
Further areas of investigation are outlined as follows: 
1. A second cohort of paraffin-embedded specimens was utilized (with kind permission from Dr 
Heike Grabsch) to futher validate expression of the HSP27 protein in rectal cancer patients using 
the immunohistochemistry protocol described in this thesis. The results were reported in the 
following publication; Low Molecular Weight Heat Shock Protein, HSP27 is a prognostic 
indicator in rectal cancer, but not colon cancer. Elizabeth Tweedle, Ilyas Khattak, Chin Wee Ang, 
Taoufik Nedjadi, Rosalind Jenkins, B. Kevin Park, Helen Kalirai, Andy Dodson, Bahram Azadeh, 
Monica Terlizzo, Heike Grabsch, Wolfram Mueller, Arthur Sun Myint, Peter Clark, Helen Wong, 
William Greenhalf, John P Neoptolemos, Paul S Rooney, Eithne Costello. Gut. 2010 
Nov;59(11):1501-10. 
2. The cellular response of colorectal cancer cell lines to S100A8/S100A9 was further investigated 
in our Institution on the basis of immunohistochemistry findings included in this thesis. The 
findings were reported in the following publication; Smad4 loss is associated with fewer 
S100A8-positive monocytes in colorectal tumors and attenuated cellular response to S100A8 in 
colorectal and pancreatic cancer cells. Chin W. Ang, Adnan A. Sheikh, Elizabeth M. Tweedle, 
Sarah Tonack, Taoufik Nedjadi, Rosalind E. Jenkins, Kevin Park, Irmgard Schwarte-Waldhoff, 
Ilyas Khattak, Bahram Azadeh, Andrew Dodson, Helen Kalirai, John P Neoptolemos, Paul S 
Rooney, Eithne Costello.  Carcinogenesis. 2010 Sep;31(9):1541-51. Epub 2010 Jul 9. 
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3. Elevated HSP27 expression is postulated as a predictive marker for response to chemo-
radiotherapy in rectal cancer patients. Tissue from patients recruited to phase II trials of 
chemoradiotherapy in Clatterbridge Centre for Oncology will be collated on a tissue microarray 
and HSP27 levels determined using the immunohistochemistry scoring protocol outlined in this 
work. Comparison will be made in histopathology features, tumour regression grade and 
patient survival. 
4. HSP27 has been found at elevated levels in the tumour microenvironment of breast cancers, 
where it has been shown to influence phenotypic differentiation and activity of tumour 
associated macrophages. Future work will seek to investigate the association between HSP27 
levels in the microenvironment of rectal cancers and the numbers and phenotypes of tumour-
associated macrophages in the stroma. 
5. Evaluation of oxidized peroxiredoxin 2 and SH3BGRPL3 expression in colorectal cancer tissue is 
planned when commercially available antibodies are available for use in immunohistochemistry. 
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